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BIOTECHNOLOGY
New medicines are an important part of innovation in medical care. Advances in
genomics, biotechnology and other innovative areas in the biopharmaceutical
sciences fuel the surge in new active compounds for unmet medical needs [1,2]. It
has been predicted that the combination of genomics, bioinformatics and structural
genomics will generate unprecedented results in the new century, which will
revolutionise medicine [3-6].
In 1978, researchers first reported that they had been able to express the human
insulin gene in E. Coli [7]. In the late 1970s and early 1980s high expectations have
been placed on the young biotechnology industry. A 1984 cover of The Economist
read: ‘The genetics gold rush’ [8]. Some, but not all of the dreams of that time have
come true. The first recombinant molecules to be developed, human insulin and
growth hormone, have been successfully introduced to the market. Interferon,
however, did not come through as the magic cure for cancer that it was supposed to
be, and several biotech compounds, such as for example nebacumab, have failed as a
treatment for sepsis [9,10]. During the late 1980s and the early 1990s the initial
enthusiasm for the biotechnology industry faded [11]. On a 1994 cover of
BusinessWeek the question was even raised: ‘Biotech, why it hasn’t paid off’ [12].
Nevertheless, in 2000, more than 50 biopharmaceuticals were commercially
available on the Dutch market (see Table 1). By now biopharmaceuticals are fully
integrated in everyday’s medical practice. In the top 10 drugs most prescribed
by specialists in 1999, 3 biotech were present (Table 2) [13]. During the past few
years the biotech hype has even revived again, not in the least due to the Human
Genome Project which was completed in 2000 [14,15]. The number of innovative
biopharmaceuticals on the market will probably continue to rise, and, in addition,
high hopes are set on gene therapy, medication adapted to one’s gene profile
(pharmacogenetics), and improved diagnostic possibilities [16-19]. The genetics
gold rush is re-opened again, and while the internet and information technology
funds experience bad times, new biotech funds continue to appear on the stock
markets [20,21].
DIFFUSION AND TECHNOLOGY ASSESSMENT
On the one hand, these medical developments are greeted by society with great
enthusiasm, as they give hope for future cures for diseases like cancer and HIV.
Advances in medical research and technology are often the last straw for people
suffering from serious disease. However, there is also fear for the continuous advance
of science and technology. In the public opinion genetic engineering is sometimes
associated with the danger of its usage to eliminate displeasing races and create
‘super humans’ [22,23].
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Table 1 Biotechnology drugs approved in the Netherlands until May 2001
Brandname Chemical name Brandname Chemical name
Actilyse Alteplase Pulmozyme Dornase alfa
Avonex Interferon beta-1a Puregon Follitropin beta
BeneFix Factor IX Rapilysin Reteplase
Beromun Tasonermin Rebif Interferon beta-1a
Betaferon Interferon beta-1b Recombinate Factor VIII
Bioclate Factor VIII ReFacto Moroctocog alfa
Cea-Scan Te-99m-arcitumomab Refludan Lepirudine
Cerezyme Imiglucerase Regranex Becaplermin
Enbrel Etanercept Remicade Infliximab
Eprex (alfa) Epoetine alfa Reopro Abciximab
Forcaltonin Calcitonin, salmon Roferon-A Interferon alfa-2a
Genotropin Somatropin Simulect Basiliximab
Glucagen Glucagon Synagis Palivizumab
Gonal-F Follitropin alfa Thyrogen Thyrotropin alfa
Granocyte Lenograstirn Viraferon Interferon alfa-2b
Helixate Factor VIII ViraferonPeg Peginterferon alfa-2b
Herceptin Trastuzumab Zenapax Daclizumab
Humaspect Votumumab Zomacton Somatropin
Humatrope Somatropin Insulins:
Immukine Interferon gamma-1b Actrapid Insulin, normal
Infergen Interferon alfacon-2 Humaject Insulin, normal
Intron A Interferon alfa-2b Humalog Insulin lispro
Kogenate Factor VIII Humuline Insulin, normal
Leucomax Molgramostim Insulatard Insulin isophane
LeukoScan Sulesmab Insuman Insulin, normal
Mab Thera Rituximab Isuhuman Insulin, normal
Metalyse Tenecteplase Lantus Insulin glargine
NeoRecormon Epoetine beta Mixtard Insulin, normal
Neupogen Filgrastim Monotard Zinc insulin, amorph
Norditropin Somatropin Novomix Insulin aspart
Novoseven Factor Vlla Novorapid Insulin aspart
Orthoclone OKT 3 Muromonab-CD3 Optisulin Insulin glargine
PEGintron Peginterferon alfa-2b Ultratard Zinc insulin, cristaline
Proleukin Interleukin-2
Source: Nefarma
In Europe there is considerable resistance against genetically modified food [24-26].
Although high tech developments strike the imagination, there is also a movement
visible towards more attention for essential and intrinsic values, and for
‘caring for’ and ‘standing by’ patients. Natural and holistic remedies enjoy large
popularity [27,28].
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Table 2 Top 10 prescriptions by specialists in Dutch community pharmacies
in 1999
Costs (million Euros)
1 Omeprasol 30.9
2 Simvastatin 20.0
3 Atorvastatin 16.3
4 Somatropin 12.3
5 Human insulin 11.8
6 Mesalasin 10.9
7 Goserelin 9.5
8 Budesonide 9.1
9 Ciclosporin 8.6
10 Interferon beta-1a 8.6
Source: Stichting Farmaceutische Kengetallen
Not all that is possible is desirable. We do not want science and technology to evolve
autonomously, without society having say in it [29,30]. The average citizen or
politician, however, is not well enough informed to sensibly weigh the possible
benefits and risks of scientific advancements. That’s where Technology Assessment
(TA) came in. In 1972, the United States installed the Office of Technology
Assessment (OTA), in order to provide the senators with systematic and structured
overviews of advantages and disadvantages as an input to decision making [31]. The
‘Health Programme’ was one of the first and most extensive programs of the OTA.
The start of this programme in 1975 has been marked as the birth of Medical
Technology Assessment (MTA) [31-33].
The emergence of MTA coincides with a development towards the rationalisation of
medical practice. In the early postwar period medical practice was seen foremost as
an art, and not so much as a science. During the past decades, however, the scientific
character of medical practice was more and more emphasised. For the first time, this
made it possible to judge and scrutinise medical practice (increased accountability)
[34]. Movements such as MTA, creating protocols and guidelines, and evidence based
medicine stem from the desire to render medical practice more scientific.
However, as Rogers [35] describes in his book on the diffusion of innovations, the
perceived medical advantage is not the only variable determining the rate of
adoption of a new drug. Other variables such as the nature of the social system and
the extent of promotion efforts have an influence as well. The assessment of
biotechnology drugs takes place at different levels. Politicians, regulators and health
care insurers have to decide about the licensing and reimbursement of
pharmaceuticals. Specialist organisations and formulary committees develop good
Chapter 1
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practice guidelines. On the lowest level, physicians, often together with their
patients, choose individual treatment strategies. Since these decision-makers operate
in different social systems and act from different perspectives, their interests may
also differ. Together, the different stakeholders shape the diffusion pattern of a new
biotechnology drug.
COST CONTAINMENT
While the medical possibilities continue to advance, the health care costs have
increased during the past decades and cost containment has been an important goal
for policy makers [36-38]. Especially medicines have received a lot of attention, as
they represent a relatively easy target to take on [39-41].
Measures taken to control extramural expenditures include for example the
reimbursement cluster system (GVS, 1991) and the reference pricing system (Wet
Geneesmiddelenprijzen, 1996) [41,42]. Within hospitals drug expenditures are
covered by the general budgeting systems. Notwithstanding these measures, the
costs have continued to grow, and recently 3 separate groups of investigators in their
advice to the Minister each concluded that these measures are not sufficient anymore
[43-45]. This led to a paradigm shift from a supply driven to a demand driven
orientation. The current trend is towards regulated competition among insures (and
among providers), in which health care insurers should be the critical buyers of high
quality and efficient care for their insured [46]. Doubts remain whether the insurers
have the knowledge and the expertise to fulfil this task. In addition, measures have to
be taken in order to maintain solidarity and to prevent risk selection by the insurers.
Biotechnology drugs are generally expensive drugs, which are prescribed for serious
diseases and are often used inside the hospital. A high price per treatment or per
patient attracts the attention and also it worries payers, since it means that a small
increase in volume can cause a large increase in costs [47-49]. The Health Insurance
Fund Council (CVZ) advocates including a pharmacoeconomic evaluation in the
assessment of new and expensive drugs [50]. Politicians, however, operating from a
budget oriented environment, find themselves in a difficult position when they have
to explain that not everything that can be done should be done, while at the same
time they are confronted with patients whose individual sorrows are hardly
proportionate to strict budget keeping. In the health care sector, a politician can
hardly afford himself to be a ‘bookkeeper’. While the Minister of Health is trying to
contain the use of expensive (biotech) pharmaceuticals, the Minister of Economics is
investing €50 million to stimulate the establishment of young biotech start-ups in
the Netherlands [51].
Introduction
13
AIMS AND OUTLINE OF THE THESIS
The general aim of this thesis is to explore the broad field of the assessment and the
diffusion of biotechnology drugs (Table 3). The research was conducted by means of
case studies of particular biotechnology drugs, except for one study that concerned
the general attitude of decision-makers towards economic evaluations (Chapter 3).
Case studies provide an appropriate mean to generate insights, and to explore a
broad and relatively new field.
The next paragraphs discuss the specific aims of the different chapters.
Medical Technology Assessment
To investigate the factors that are important in the process of the assessment of
biotechnology drugs, in Chapter 2 we collected data on three biotechnology drugs
that were chosen to cover a broad range of potentially relevant issues: nebacumab,
filgrastim and recombinant human growth hormone (rhGH). Nebacumab
(Centoxin®), a drug for the treatment of Gram-negative sepsis, could be considered a
failure, since it had only been on the European market for 2 years. In the United
States it had never received marketing approval. In contrast, filgrastim (Neupogen®),
a granulocyte colony-stimulating factor, was a very successful product that was
generating a lot of profit [52]. Although filgrastim is fairly expensive, its value did not
seem to be questioned. Recombinant hGH has been a successful drug as well, but it
encountered much more concern about unwarranted use and a lack of long-term
utility. Moreover, this biotechnology drug had substituted the previously used
pituitary derived compound.
The data for analysis were collected from scientific papers and government reports.
They were analysed in a standardised way covering: 1) safety, 2) efficacy/effective-
ness, 3) economic evaluation, and 4) ethical, legal and social factors [32].
Economic evaluation and abciximab
The objective of Chapter 3 was to investigate differences in attitudes, knowledge and
actual use of economic evaluations in four different groups of decision-makers: 1)
politicians, 2) regulators, 3) hospital pharmacists and 4) physicians. The methods
used were individual interviews with decision-makers and a postal questionnaire.
This study was conducted within the framework of the European Network on
Methodology and Application of Economic Evaluation Techniques (EUROMET)
project. The Dutch results were compared with the overall results from all countries
participating in the EUROMET project.
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Table 3 Content of the thesis
Subject matter
General Expensive new
biotech drug
- abciximab
Biotech substitute
for existing
compound
- factor VIII
- follitropins
G
e
n
e
ra
l
Chapter 2
Structured
description of 3
biotech cases
(nebacumab,
filgrastim and
recombinant human
growth hormone)
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e
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n
Chapter 3
Decision makers’
opinions on health
economics
Chapter 4
CEA of abciximab
alongside a clinical
trial
Chapter 5
CEA of stenting
combined with
abciximab in real
practice
F
o
cu
s 
o
f 
st
u
d
y
D
iff
u
si
o
n
Chapter 6
Abciximab usage in
different Dutch
hospitals
Chapters 7 & 8
Plasma Factor
VIII →
recombinant
Factor VIII
Chapter 9
Urinary
gonadotropins →
recombinant
follitropins
CEA=cost-effectiveness analysis
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Abciximab (ReoPro®), a glycoprotein IIb/IIIa receptor blocker, has been shown to be
effective in reducing the rate of myocardial infarction and the necessity for urgent
revascularisation in patients undergoing percutaneous transluminal coronary
angioplasty (PTCA) [53-56]. Intracoronary stents have been shown to reduce the need
for repeat revascularisations by 20-50% [57-63]. In the ‘Evaluation of Platelet
IIb/IIIa Inhibitor For Stenting Trial (EPISTENT)’ study the combined use of stents
and abciximab was studied and turned out to be superior to either stenting or
abciximab administration alone [64,65]. In Chapter 4 the question was addressed on
the balance between the costs and effects of combined use of abciximab and stenting,
using the efficacy data from the EPISTENT study in combination with Dutch
estimates of unit costs. Assessed were both the cost-efficacy of adding a stent to a
procedure where the use of abciximab is planned, and the cost-efficacy of adding
abciximab to a procedure where the use of a stent is planned. Special attention was
given to the uncertainties surrounding the estimates, especially when breaking down
the results between diabetics and non-diabetics.
The clinical and economic findings in clinical trials are not necessarily generalisable
to a general population setting. Therefore, in Chapter 5, a study was conducted in
daily clinical practice comparing stented and non-stented patients undergoing
coronary angioplasty with abciximab administration. The results were compared
with the findings of the EPISTENT trial.
In the Dutch health care system all hospitals are budgeted. In the media cardiologists
have expressed their concern that their budgets do not allow them to give abciximab
to all eligible patients. Public exposure of this issue has been high. In Chapter 6, the
patterns of prescribing of abciximab were studied and factors that determine the
level of usage were identified. All thirteen PTCA centers in the Netherlands
participated in the study.
Diffusion of biotech substitutes
Starting in 1982 with the introduction of recombinant human insulin, several
biotechnology drugs have been launched as an alternative to similar, already existing
compounds purified from organic materials such as pituitaries, urine and blood
(Table 4). These biotechnology substitutions constitute well-defined cases to
investigate the diffusion of biotechnology drugs.
The first case presented in this thesis is the case of recombinant Factor VIII (rFVIII),
which was introduced in the Netherlands in 1995 for the treatment of hemophilia A.
Until then, hemophilia patients had been treated with plasma derived Factor VIII
(pdFVIII), the main provider of which was the Central Laboratory of the Netherlands
Red Cross Blood Transfusion Service. Seventeen percent of all Dutch patients with
severe hemophilia who were treated with clotting factor products before 1985
became infected with the human immunodeficiency virus (HIV) [66,67]. In addition,
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the large majority (about 80%) of patients have been infected with hepatitis C virus
[68,69]. Because of this history of infectivity with pdFVIII one may have expected
that rFVIII would receive a warm welcome and would be quickly adopted by the
market. This, however, has not been the case.
Table 4 Overview of biotech substitutions
Recombinant compound year of introduction* substitute for
human insulin 1982 porcine and bovine insulin
human growth hormone 1985 pituitary derived growth hormone
alteplase (tPA) and
reteplase
1988 and 1999 streptokinase and urokinase
Factor VIII 1995 plasma derived Factor VIII
follitropins 1996 urinary gonadotropins
Factor IX 1997 plasma derived Factor IX
* Year of introduction to the Dutch market, tPA= tissue plasminogen activator
We sent a postal questionnaire to both patients (Chapter 7) and hemophilia treating
physicians (Chapter 8) to investigate their opinions on rFVIII as compared
to pdFVIII, and to determine which factors predict whether someone uses pdFVIII
or rFVIII.
The second substitution case concerned the gonadotropins. Among other indications,
gonadotropins are used for ovarian hyperstimulation in in-vitro fertilisation. Human
Menopausal Gonadotropins (hMG), containing both Follicle Stimulating Hormone
(FSH) and Luteinising Hormone (LH) derived from the urine of postmenopausal
women, have been commercially available since the 1960s. During the 1980s and the
early 1990s urinary derived products with an increased purity were developed,
containing only FSH and hardly any LH. Subsequently, in 1996 the first follitropin
(=recombinant FSH) was introduced. The aim of Chapter 9 was to describe the
diffusion patterns of these different types of gonadotropins in the Netherlands and to
obtain insight in the processes underlying these patterns. We used clinical sales data,
and analysed data on pivotal articles published, product introductions and
withdrawals, reimbursement decisions, and the like.
The results of this thesis are summarised and discussed in Chapter 10.
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ABSTRACT
Background - Biotechnology is increasingly regarded upon as an important reservoir
for the development of new and innovative but generally expensive, pharmaceuticals.
At the same time, concerns about cost containment have triggered a keen interest in
evaluating and comparing the values of diverse health care interventions.
Aim and methods - In this paper we studied the process of assessment and diffusion
of biotechnology drugs by studying three cases, i.e. nebacumab, colony stimulating
factors and recombinant human growth hormone. These cases are evaluated in a
standardised format, concerning safety, efficacy, cost-effectiveness and ethical, legal
and social issues.
Results - Many factors that determine the fate of a biotechnology drug seemed to be
similar to those of ‘classical’ drugs. The definition and measurement of clinically
relevant outcomes has been identified as a key factor in the assessment process.
Another important issue is the relatively small population for the primary indications
of biotechnology drugs and the subsequent process of broadening of indications.
Conclusion - Paradoxically, the current trend towards evidence based medicine
means that we will increasingly have to make decisions based on ‘incomplete
knowledge’.
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INTRODUCTION
In the pharmaceutical sector a new category of drugs has emerged: biotechnology
drugs [1]. Starting with the introduction of recombinant insulin and recombinant
growth hormone in the early 1980s, many pharmaceutical proteins have entered the
market which are produced by cell cultures of genetically modified cells, mostly
bacteria [1, 2]. Many of them are indicated for the treatment or prevention of serious
life threatening diseases [1].
The rapid clinical success of the first recombinant proteins drove large investments
and placed high expectations on this young industry [3]. Analysts predict that in the
long term, about 20-25% of the world drug market will be supplied with products
based on genetic engineering methods [4]. Pharmaceutical products derived from
European biotechnology are expected to grow by 15% per year [5]. Clearly, the early
promise of pharmaceutical biotechnology has been, and still is, enormous.
On the other hand, it has been noted that applications for new biotechnology drugs to
the FDA were highly successful in the early period between 1980 and 1984, but that
current success rates are lower and do not exceed the success rates for ‘classical’
drugs [3]. Notwithstanding the early promises, clearly not all biopharmaceuticals
have been proven to be efficacious and safe [3]. From a list of 22 potentially
important protein drugs, only about one third are in practical use today [6]. It has
been acknowledged that, in spite of great progress, pharmaceutical companies still
cannot create gold. However, it has been stated that the pharmaceutical companies
scarcely need to [7]: ‘Gold is worth a mere US$10 a gram. Human growth hormone,
as synthesised by Genentech, sells for the equivalent of more than US$20,000 a
gram.’ It is true that recombinant proteins are generally expensive and weigh heavily
on the annual drug budget [6].
Most developed countries currently spend about 10% of their gross domestic product
on health care [8, 9]. Expenditures are on the rise due to the general ageing of the
population and the introduction of new medical technologies. Pharmaceutical
expenses increase much faster than health care expenditures in general. In the
Netherlands for example, pharmaceutical expenses showed an average annual
growth of more than 7% during the period 1982-1995, while in the same period the
growth of health care expenses amounted to 3.5% [10]. As a consequence awareness
is growing amongst the parties involved of the need for a more efficient use of the
available resources [8].
The availability of expensive biotechnology drugs, also raises ethical problems in
some instances, especially with regard to the limits of ethically justified use (e.g.
growth hormone, colony stimulating factors), or abuse (epoetin, growth hormone).
The assessment of biotechnology drugs takes place at different levels. Besides the
assessment for registration and reimbursement on a macro level, products are also
assessed on a meso and micro level by specialist organisations and formulary
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commissions in hospitals and by individual practitioners [11]. The fate of a
biotechnology drug, its adoption and diffusion, is determined by these assessments
and decisions. The process of assessment, however, is not merely a rational process
based on facts only; politics is inevitable [12, 13]. The players in the health care field,
industry, patient organisations, physicians, insurers and government authorities,
each have their own values, which influence their selection and interpretation of
evidence considered relevant. The degree of impact that they can exert on the
decision-making process may differ [12].
In order to study the factors that are important in the process of the assessment of
biotechnology drugs, we collected data on three pharmaceutical recombinant
proteins: nebacumab, filgrastim and recombinant human growth hormone. These
data were assessed in a standardised way to determine which are relevant issues in
the assessment process and which parameters are important for a biotechnology drug
to be successful.
METHODS AND SELECTION OF CASES
For this study we chose three cases that, at first sight, had very different
characteristics and could present a good mix of possible issues that play a role in the
assessment and diffusion process of biotechnology drugs, namely nebacumab
(Centoxin®), colony stimulating factors (focusing on filgrastim; Neupogen®) and
recombinant human growth hormone (several products/brands).
Nebacumab can be considered a failure, since it has only been on the European
market for two years. In the United States it has never received marketing approval.
In contrast, filgrastim is a very successful product that is generating a lot of profit
[14]. Although filgrastim is fairly expensive, its value does not seem to be questioned.
Filgrastim is a member of the family of colony stimulating factors, which form a
subgroup of the hematopoietic growth factors. Although several pharmaceutical
differences between the various the colony stimulating factors exist, in this study
filgrastim represents the case of the colony stimulating factors in general. In review
articles and clinical guidelines the colony stimulating factors usually are treated as
one group of equivalent drugs. Although this approach may not be entirely correct, it
is representative of the general way of dealing with these medicines, which is the
subject of this study.
Recombinant human growth hormone (rhGH) has been also a successful drug, but it
encounters much more concern about unwarranted uses and a lack of long-term
utility. This recombinant protein has substituted the previously used pituitary
derived compound. Several products and brands are on the market, with slightly
different pharmaceutical characteristics. Even more than the colony stimulating
factors, they are generally described as one group. We adopted this approach and
described rhGH in general, without focusing on a single representative brand.
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To structure the different factors that may be important in the process, we looked at:
1) safety, 2) efficacy/effectiveness, 3) cost-benefit/cost-effectiveness/cost-utility and
4) ethical, legal and social factors [15]. The data for analysis were collected from
scientific papers and government reports. The three cases were analysed by these
categories and subsequently a comparison was made to draw conclusions as to which
extent the similarities and differences between these cases could give us more insight
in the process of assessment and diffusion of biotechnology products.
DESCRIPTION OF CASES
Nebacumab
Nebacumab (HA-1A, Centoxin®) is a human monoclonal antibody that in vitro binds
specifically to endotoxin, a compound of the cell envelope of Gram-negative bacteria.
The antibody was produced by Centocor and was thought to be effective in the
treatment of Gram-negative bacteremia (the presence of Gram-negative bacteria in
the blood). To confirm a Gram-negative bacteremia, a blood culture has to be
performed. However, because Gram-negative bacteremia may have a rapidly fatal
course, treatment has to be started before the results of the blood culture are
available (this takes 48 hours). In four large trials that used entry criteria that met
the definition of severe sepsis, only 20-40% of the patients turned out to have Gram-
negative bacteremia [16].
Application for marketing authorisation of nebacumab in Europe was requested by
Centocor in February 1990, through a European procedure for approval of
biotechnology products by the Committee for Proprietary Medicinal Products
(CPMP). The CPMP decided in March 1991 that there was sufficient evidence for
efficacy of the drug and recommended marketing authorisation to its member states
[17]. On April 4, 1991 nebacumab was registered in the Netherlands, being the first
country in the world. However, in the United States the drug was denied approval by
the FDA, based on the same clinical trial conducted by Ziegler et al. [18]. To meet the
FDA’s requirements, Centocor started a second trial, the CHESS trial [19]. This trial
was stopped at the first interim analysis, because of excess mortality in the treatment
group. Shortly after that, the distribution of nebacumab was stopped (Table 1).
Safety
In the first trial conducted by Ziegler et al., no important side-effects were found in
the complete study population [18]. However, in a subgroup of patients who turned
out not to have had Gram-negative bacteremia, mortality was higher in the
nebacumab arm (45%) than in the placebo arm (40%; p=0.36) [20]. Initially, not
much attention was paid to this observation.
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Table 1 History of nebacumab
February, 1990 Centocor applied with CPMP for a marketing authorisation
February 14, 1991 N Engl J Med: publication of Ziegler’s data
March, 1991 CPMP approved application
April, 1991 Nebacumab’s first registration (in the Netherlands)
September 4, 1991 FDA Advisory Committee Hearing
April 15, 1992 FDA denies approval
April 23, 1992 N Engl J Med: Warren, Wenzel and Ziegler
June, 1992 Start of CHESS trial
January, 1993 CHESS trial suspended
January 20, 1993 Distribution of nebacumab stopped
CPMP=Committee for Propietary Medicinal Products, FDA=Food and Drugs
Administration
The CHESS trial, however, was stopped after the first interim analysis, because in
patients who did not have Gram-negative bacteremia, the mortality rate was
significantly higher in the nebacumab treated group than in the placebo group
(p=0.09). In patients who did have Gram-negative bacteremia (28%), the mortality
rate in both groups was practically the same [19]. This result let to the total removal
of nebacumab from the market.
Efficacy/effectiveness
The robustness of the preclinical data and the rationale for starting clinical studies
have been disputed. There has been discussion about the binding characteristics of
nebacumab and about the fact that nebacumab had not consistently protected
animals from endotoxic challenge in experimental models [21-23]. The high species
specificity of nebacumab hindered the design of appropriate animal models [22-24].
Some people felt that the company developed the product too fast because of the
competition [25].
Efficacy has been the most important issue in the nebacumab case. The efficacy as
demonstrated by Ziegler’s trial was disputed. In the total population no significant
difference could be demonstrated; a significant decrease in mortality through the use
of nebacumab was found only in the subgroup of patients with confirmed Gram-
negative bacteremia [18]. The trial produced a lot of criticism, including that the level
of significance was marginal [26]; that patient characteristics were different in the
placebo and the treatment group [21, 27]; and that the primary endpoint of the study
had been changed, after the results of the first interim analysis became known to the
Centocor staff [26]. In particular this last point was the reason for the FDA to deny
approval and demand a second trial [26].
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Before this trial was stopped prematurely, 621 patients with confirmed Gram-
negative bacteremia were included. Efficacy of nebacumab was not demonstrated;
mortality rates in treatment and placebo group were 33% and 32%, respectively
(p=0.86) [19].
The identification of targeted patients presented another problem in the nebacumab
case. It was not possible to identify patients with Gram-negative bacteremia before
the onset of treatment. Work has been done to develop a test to determine the level
of endotoxins in the blood [28-32]. However, up until now such a method is not
available.
Cost-benefit/cost-effectiveness/cost-utility
Costing over US$ 3000 dollars a dose, nebacumab was one of the most expensive
drugs ever, and raised many concerns in this respect [33]. From 1991 to 1993 three
cost-effectiveness studies on nebacumab were conducted [34-36]. Schulman et al.
[34] concluded that the use of nebacumab could add US$2.3 billion to the annual
U.S. health care budget, if the treatment guidelines were strictly adhered to. He also
included a ‘test scenario’ in his study, in which the availability of a quick and reliable
testing method is presumed, so that only patients with known Gram-negative
bacteremia would receive nebacumab. Obviously, the cost-effectiveness of
nebacumab was generally lower in this scenario, depending on the sensitivity and
specificity of the hypothetical diagnostic test.
Although, Van Hout [36] noted that the cost per life year gained compared
favourably with other health care programs, nebacumab never lost the image of being
expensive. This idea has probably attributed significantly to the call for better criteria
to identify the patients to whom the product might be beneficial. Both in the United
States (before the FDA denied approval) and in Europe hospitals established
guidelines for the prescription of nebacumab [29, 37, 38]. It seems that economic
considerations were the driving forces to draw up guidelines, rather than the concern
that some patients may be unnecessarily exposed to the adverse effects of a drug that
was not effective for them.
Ethical, legal and social issues
It is remarkable that the FDA and the CPMP reached two different decisions based on
the same data. There are several factors that might have influenced the CPMP’s
decision to approve nebacumab. Firstly, nebacumab represented a new and attractive
therapeutic approach awaited for more than 10 years. Secondly, it proposed a
treatment for a highly fatal disease, for which only limited therapeutic possibilities
exist. Moreover the application was filed by a company whose whole future depended
on this one innovative product [17, 37].
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As Luce described in his article, the decisions to be made about the use of nebacumab
raised an ethical dilemma, especially in American hospitals that cared for a large
number of unsponsored patients. The physicians wanted their patients to receive the
best possible treatment and they were concerned that not using nebacumab while
physicians elsewhere were using the drug would constitute malpractice. On the other
hand they were aware that adding nebacumab might require the removal of other
drugs from the formulary [37]. This ethical issue is, of course, strongly related to the
cost factor.
Colony stimulating factors: filgrastim
Filgrastim is a member of the family of hematopoietic growth factors (HGFs), which
consists of granulocyte colony-stimulating factor (G-CSF), macrophage colony
stimulating factor (M-CSF), granulocyte macrophage colony-stimulating factor (GM-
CSF), erythropoietin (EPO) and others. Filgrastim is a G-CSF, produced by Amgen
through an E. coli bacteria into which has been inserted the human G-CSF gene. It
regulates the production of neutrophils within the bone marrow and affects
neutrophil progenitor proliferation, differentiation and cell functional activation. In
1991 filgrastim received marketing authorisation to decrease the incidence of
infection as manifested by febrile neutropenia for patients undergoing chemotherapy
(Table 2). Subsequently the drug was also registered for the treatment of chronic
neutropenia, to reduce the duration of neutropenia after bone marrow
transplantation and to support peripheral blood progenitor transplantation (PBPC
transplantation). In 1994 (update in 1996) the American Society of Clinical Oncology
(ASCO) conducted a literature review and formulated recommendations for the use
of hematopoietic colony-stimulating factors [39, 40].
Safety
So far very little evidence of serious side-effects has been shown. The ASCO
Guidelines report that the predominant side effect associated with administration of
G-CSF has been medullary bone pain. This effect is reported in 15-40% of patients
receiving an average dose [39].
Efficacy/effectiveness
Neutropenia and infection are major dose limiting side effects of chemotherapy.
Patients who present with fever usually are hospitalised and given intravenous broad
spectrum antibiotics. In current practice, infectious mortality resulting from febrile
neutropenia is about 10% [41-43]. Moreover episodes of febrile neutropenia may
result in subsequent chemotherapy delays or dose reductions.
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Table 2 History of filgrastim
February, 1991 Registration in Europe and in the US to decrease the incidence of
febrile neutropenia in patients undergoing chemotherapy
1992-1997 Registration for additional indications:
to reduce the duration of neutropenia after BMT
to treat patients with severe chronic neutropenia
to support PBPC transplantations
to treat neutropenia in people with advanced HIV infection
Present time Research for new indications in disease- and treatment related
cytopenia and in infectious diseases
PBPC=peripheral blood progenitor cell, BMT= bone marrow transplantation
Administration of filgrastim has been shown to significantly reduce the risk of febrile
neutropenia in patients undergoing a chemotherapy that bears a risk of more than
40% to develop febrile neutropenia [41, 42, 44]. In two trials filgrastim admini-
stration resulted in a decrease in antibiotic use and hospitalisation [42, 44]. A
significant difference in confirmed infections, infectious mortality, response rates
or survival between filgrastim and placebo treated patients has not been
demonstrated [39, 40].
Bone marrow transplantation (BMT) enables the use of very high doses of
chemotherapy to eliminate malignant cells from patients with refractory tumours.
Before the bone marrow recovers after transplantation, the neutrophil count usually
plunges to zero; filgrastim is indicated to reduce the duration of this neutropenia.
Many trials have been performed in this area. Neutrophil recovery is generally
enhanced, the incidence of infection is either not affected or lower, and hospital stay
is generally not affected or is of shorter duration in G-CSF-treated patients [45].
Peripheral blood progenitor cell (PBPC) transplantation is increasingly applied as an
alternative to BMT. Progenitor cells found in the blood can be collected and
concentrated for reinfusion after myelosuppressive cancer chemotherapy. Normally
the number of progenitor cells circulating in the blood is too low to harvest for
transplantation. However, HGFs such as filgrastim expand the population of
circulating hematopoietic progenitor cells and may be used to facilitate peripheral
collection. PBPC transplantation is attractive, because it is less invasive and
technologically complex than BMT. It can be performed in the outpatient setting
without anaesthetising the donor. Three randomised trials have shown a difference in
favour of PBPC transplantation over BMT, with respect to haematological recovery
and hospitalisation [46-48]. There is, however, no evidence that PBPC
transplantation significantly improves cancer-free survival rates, the primary goal of
PBPC transplantation. Moreover, there might be a risk that the apheresis products
Chapter 2
30
may be contaminated with tumour cells [49]. A recent article in the Lancet reported
that high dose chemotherapy supported with PBPC transplantation did not have an
effect on tumour recurrence in breast cancer [50].
Filgrastim has recently received approval to treat clinically significant neutropenia in
HIV patients during treatment with antiviral and/or other myelosuppressive
medications [51].
Amgen is also investigating filgrastim as an adjunct to dose intensified chemotherapy
in patients with various tumour types. Moreover, the company is investigating
filgrastim’s potential benefits for patients in severe infectious disease settings.
Cost-benefit/cost-effectiveness/cost-utility
The use of filgrastim as an adjuvant to chemotherapy, has been calculated to result in
savings when the risk of developing febrile neutropenia is greater than 40-50% [43,
52, 53]. If drug wastage is considered as well, the risk has to be higher [43]. Drug
wastage may especially be an issue in paediatrics, since dosing is based on weight (i.e.
5µg/kg) and the product is marketed as single dose vials of 300 and 480µg. It
remains to be seen if this high risk criterion is met in practice. A Canadian survey
determined that on average only 12.3% of new chemotherapy patients develop febrile
neutropenia [43]. Based on this number, it was calculated that the use of G-CSF
would incur a cost of US$19,567 per case of febrile neutropenia avoided [43].
In two cost-minimisation analyses comparing PBPC transplantation and autologous
BMT, PBPC transplantation resulted in a cost reduction of 15-30% compared to
autologous BMT [54, 55].
Ethical, legal and social issues
There does not seem to be great concern in the health care field about unbridled use
of filgrastim and associated risks and costs. In fact it has remained remarkably quiet
around filgrastim. Large political or public debates and assessment reports are
absent.
Recombinant human growth hormone
From 1958 to 1985 pituitary derived growth hormone (pit-hGH) was used as
replacement therapy for growth hormone deficient children (Table 3). At that time
growth hormone (GH) was scarce and expensive and exploration of other therapeutic
applications was not possible. The introduction of recombinant human growth
hormone (rhGH) in 1985 coincided with reports of a number of cases of Creutzfeldt-
Jakob disease in patients who received pit-hGH in the past. This led to the removal of
pit-hGH products from the market. With the large scale production of rhGH, new
indications for use could be explored. Besides the use in growth hormone (GH)
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deficient children, GH has since 1985 also been registered for use in children with
chronic renal insufficiency, children with Turner’s syndrome and adults with growth
hormone deficiency (GHD). Current dosing schedules consist of daily subcutaneous
injections, which are often self administered. The pharmaceutical industry is working
on the development of sustained release preparations.
As rhGH exerts a wide scope of actions, many indications like osteoporosis,
malnutrition, wasting syndromes, female infertility, wound healing and burns are
currently being investigated [56].
Safety
Children are remarkably free of side-effects when they use rhGH. The single concern
has been whether children receiving rhGH have an increased risk of developing
leukaemia. However, the current consensus is that this is not the case. A shortterm
side effect of rhGH administration to adults can be fluid retention and in the long run
there may also be an increased cancer risk. No data are available to address this
issue, because no adults have received long-term rhGH therapy yet [57].
Efficacy/effectiveness
To determine the effectiveness of rhGH therapy is a very complicated matter. In the
first place, it is difficult to distinguish between growth hormone deficiency (GHD)
and idiopathic short stature (short stature without an underlying pathology), which
is not an approved indication for rhGH treatment. In practice doctors have to work
with a continuum of probability of GHD, based on several clinical parameters and
tests. Secondly, there is the problem of predicting what the children’s untreated
height would have been: prediction models and controls both have disadvantages to
them. Using controls is difficult because of the numbers of variables to be considered
(e.g. age, sex, parental height, bone-age delay, nutrition, and disease and treatment
characteristics for Turner’s syndrome and renal insufficiency). For the height
prediction models, the confidence limits are wide, especially in younger children
[58]. Because of the uncertainties in the diagnosis of GHD and in measuring the
effect of treatment on final height, it is difficult to apply the results of clinical trials to
individual patients.
Untreated, men and women with GHD will reach a height of approximately 140 and
130 cm, respectively. Roughly speaking, rhGH treatment can add 20-30 cm to their
final height [59].
Turner’s syndrome is a disease of females caused by partial or total loss of one sex
chromosome and is characterised by incomplete development of secondary sexual
characteristics, infertility and physical abnormalities like short stature (147 cm on
average). In the late 1980s, when rhGH was registered for this indication, there was
great optimism. However, more recent data, have been relatively disappointing [58].
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Table 3 History of growth hormone
1956-1957 Isolation of human growth hormone from pituitary glands
1957-1985 Use of pit-hGH as replacement therapy in GH deficient children
1979 Human GH was first cloned
1982 First use of rhGH in humans
1985 Creutzfeldt-Jakob disease in patients who had received pit-hGH
Removal of pit-hGH from the market
First marketing authorisation for rhGH to treat hormone inadequacy
in children (USA)
1987 – 1998 rhGH on European market
Registrations for Turner’s syndrome, renal insufficiency, and GH
deficiency in adults
Research for many new indications (diabetes, osteoporosis, fertility
problems, total parenteral nutrition, HIV associated wasting)
1997 Advancement of sustained release preparation to phase III trial
GH=growth hormone, pit-hGH= pituitary-derived human growth hormone,
rhGH=recombinant human growth hormone
In the Netherlands, for example, reimbursement for this indication has recently been
suspended because the small increase in final height (3 cm on average) would not
justify the costs associated with the treatment.
The group of children with renal insufficiency is a very heterogeneous group. Several
variables, like stage of the disease, time of transplantation, dialysis schedule and
comedication, could influence the effect of rhGH therapy [56].
GHD in adults is associated with obesity, reduced extracellular water, reduced bone
density, increased LDL cholesterol, increased body fat and decreased lean muscle
mass and strength [60]. In clinical trials it has been shown that rhGH therapy can
reverse these biological changes to varying degrees. However, although rhGH
treatment can improve lipid profile and bone density, it has not been shown to have
an effect on cardiovascular risk and fracture risk [61-64].
Cost-benefit/cost-effectiveness/cost-utility
When treating children with rhGH, an improvement of final height is not a goal in
itself. The question is, does short stature have a negative influence on the quality of
life and, if so, can GH treatment improve this impaired quality of life. Several studies
have shown that children with GHD, Turner’s syndrome or renal insufficiency
remain behind in social and psychological functioning, and have difficulties in
finding a partner. For Turner’s syndrome and renal insufficiency it is hard to tell
what causes these symptoms, because these diseases consist of multiple pathology.
Up until now, an objective, measurable improvement of quality of life has not been
consistently demonstrated after GH treatment of children [59]. In the vast majority
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of studies costs are left out of consideration. Reasons for this might be that GH
treatment is regarded as a substitution therapy and an alternative treatment does
not exist.
In adults with GHD, quality of life is improved in about 50% of patients receiving GH
replacement therapy. It is not known exactly what causes this improved quality of
life and how to identify ‘the good responders’ beforehand [61]. It has been argued,
however, that economic evaluations of treating GH deficient adults should measure
not only quality of life, but also the impact on cardiovascular risk and fracture
risk and on disability and early retirement costs [62]. Others have responded to
that by noting that there is not enough evidence on which such an evaluation can be
based [63].
Ethical, legal and social issues
rhGH is indicated for conditions that are not life threatening and it is used mostly in
a domestic setting. Although the users of rhGH are united in patient organisations,
these organisations are too small to exert influence on national policy-making. It
seems that rhGH raises much more concern about containing its proper use than
other biotechnology drugs. Since it is not easy to make a clear diagnosis in GHD, one
might fear that it would be easy to use GH treatment for healthy short children,
which is perceived as being unethical by some strong opponents [65]. Also, the non-
specific nature of the clinical features experienced by GH deficient adults (obesity,
mild depression and fatigue), have made people fear that greater public awareness of
the beneficial effects of replacement will lead to ‘media onset GHD’ [61].
SYNTHESIS AND COMPARISON OF CASES
A synthesis of the three cases was made. When looking through the cases we found
several issues that have been of importance in all three cases and other issues that
were special for one drug and had great impact on its fate. Below we describe
the issues that we consider relevant for the assessment and fate of the three cases
(Table 4).
Safety
Previous usage in non-recombinant form
rhGH is the only product that previously had been used in a non-recombinant form.
This means that there was already substantial insight in the therapeutic potential,
which there was not for HGFs and nebacumab. Moreover the non-recombinant form
is often derived from human material and bears a risk of contamination with micro-
organisms.
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The switch to the recombinant form is usually associated with an improved safety,
although this does not necessarily have to be true. Nevertheless this association does
constitute an advantage to the biotech drug in question.
Species specificity
High species specificity, as we can see in the nebacumab case, is a great disadvantage,
since it restrains the usefulness of animal models. Pharmaceutical companies, and
ultimately society, are thus faced with bigger risks when introducing the product in
people. Moreover, the absence of a reliable animal model to test the compound’s
activity may also cause problems with quality assurance [21].
Adverse effects
Obviously, an acceptable safety profile is one of the most important characteristics
for a pharmaceutical to be successful. Today’s society is very safety driven. Cars, food,
toys, domestic appliances etc., all have to comply with strict safety regulations. A
pharmaceutical can not afford its safety image to be damaged. In the case of
nebacumab, it has been a safety problem, combined with a lack of efficacy, that let to
its removal from the market. Although, in this case, one could also consider the safety
issue a patient targeting problem, since the problem arose in a group of patients that
was not supposed to receive nebacumab in the first place.
Efficacy/effectiveness
Indication dynamics
A striking similarity between filgrastim and rhGH, is the growing number of
indications over time. Both drugs entered the market registered for one, relatively
small and well defined indication. At the present time, however, they possess
registrations for four or five additional indications and many clinical studies are
under way to evaluate other applications. We labelled this phenomenon ‘indication
dynamics’. For the industry, of course, it is very attractive to develop additional
indications for an existing product, since production facilities, quality assurance
procedures, stability data etc. are already in place. The phenomenon of ‘indication
dynamics’ illustrates that pharmaceutical innovation does not have to be a linear
process originating from knowledge about a disease. In this case, innovation is
prompted by drugs that are ‘looking for more diseases’ [66]. Filgrastim and rhGH are
both eligible candidates to ‘look for diseases’: neutropenia presents in many different
circumstances and GH exerts a very broad range of actions. For nebacumab it would
have been more difficult to expand its number of indications.
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Managed entry
While pharmaceutical industries try to expand the field of application of their
products, government authorities and third parties are often acting from a cost-
containment policy and they try to restrict the use of these products strictly to the
approved indications and to patients for whom benefit has been demonstrated.
This may be pursued by formulating guidelines for usage or by allowing only
designated clinicians, from highly specialised provider units, to prescribe the
drug. These methods, of managed entry, have also been applied to filgrastim, rhGH
and nebacumab.
Effectiveness versus efficacy
It is not an easy task to decide for which category of patients treatment would be
beneficial and to formulate clinical guidelines. Many papers have noticed the
difficulty in translating the data from clinical trials into everyday, clinical practice
effectiveness [8, 9, 67-69]. Leufkens and Urquhart [70] have described the deter-
minants of drug exposure that influence the safety and effectiveness of drug usage:
demographic and socio-economic patient-characteristics, severity of disease,
comorbidity, time-schedules of drug-usage, and compliance with therapy. In a
clinical trial the variation in these determinants is kept to a minimum, in order to be
able to reach sufficient statistical power. Therefore, uncertainties remain about the
total effectiveness in general practice and about the efficacy in special subgroups or
circumstances. In the cases of filgrastim and rhGH we found many examples of this,
sometimes inevitable, lack of knowledge.
Intermediate endpoints
In the cases of both filgrastim and rhGH, little data is available on final clinical
endpoints, and therefore intermediate endpoints are often used instead. In literature
it has been pointed out that it is necessary to be careful with the usage of surrogate
endpoints, since they do not always turn out to be good predictors for the primary
outcome of interest [71]. In some cases, however their usage may be inevitable. In the
case of rhGH for example, we are confronted with a primary outcome that lies 10-15
years in the future and it would not be beneficial to both industry or patients to keep
the product of the market for so long. In today’s opinion, we should strive for the
usage of clinical endpoints, but if this it not possible, prediction models will be
needed to establish the value of certain intermediate outcome measures [72].
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Cost-benefit/cost-effectiveness/cost-utility
The uncertainties about efficacy and effectiveness, make themselves felt in cost-
effectiveness studies as well. Moreover, health economics is a relatively young science
and methodologies are still being developed and improved [73]. However,
cost-effectiveness is becoming increasingly important. At this moment cost-
effectiveness evaluation is not yet part of the formal assessment of drugs in most
countries (excluding Canada and Australia), but many governments are developing
policies to integrate this criterion in their decision-making process in the very near
future. When comparing the cases of filgrastim and rhGH, we noticed that the
perception of filgrastim as being a cost-saving agent does contribute to its success.
Additional indications for rhGH, however, encounter more opposition from
government authorities and payers, since they cause substantial increases in the
health care budget.
Ethical, legal and social issues
Besides cost-effectiveness, another reason for the fact that filgrastim encounters less
opposition than rhGH, may be that it is used in cancer patients. The lobby for cancer
is very strong and few people dare to raise doubts about new therapies in this field.
Centocor, the manufacturer of nebacumab, was in a hurry to get nebacumab into the
market [25]. Many biotechnology companies are small start-up companies that are
under a lot of pressure from their investors to generate returns. In general they will
be in a hurry and also they will have difficulties in conducting more than one large
clinical trial. Moreover, sometimes early promises are already communicated to
society through the media at an early stage of development. This mechanism also
increases the pressure on companies to come up with results.
DISCUSSION
By studying three cases of biotechnology drugs, i.e. nebacumab, colony stimulating
factors and rhGH, we have evaluated the factors that are important in the assessment
and diffusion of such pharmaceuticals. An important question is how the results of
the study are affected by the choice of the three cases. The selection of the cases has
not been random. The cases have been chosen to cover a broad range of potentially
relevant issues. All three cases are different in terms of therapeutic class, origin, time
period of introduction, market position, etc. and represent very likely a best available
mix of features determining the success or failure of a biotech pharmaceutical. We do
realise, however, that factors related to pre-marketing failure of a product might have
been missed. Our cases were all products that received marketing authorisation at
some point. By studying cases that never reached that point, one could possibly
encounter other issues as well. The study has only been based on published literature
and written reports.
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We did not acquire inside information from the parties involved, e.g. government
authorities or industry. Inside information, however, would probably provide
valuable additional data to our study and we are considering using that strategy in a
further study.
Many issues that determine the fate of a biotechnology drug seem to be similar to
those of classical drugs. Only the high costs of a biotechnology drugs and the small
number of patients involved generally attract extra attention, which makes these
issues more pronounced. The economics of biotech drugs are an important driver of
complex adoption processes (reimbursement, formulary decisions, etc.). The
relatively small number of patients is an important limiting factor for clinical
programs evaluating efficacy, as only small trials are feasible. In cases of
pharmaceuticals previously used in a non-recombinant form, i.e. rhGH, this is mostly
only a minor issue because efficacy mostly has been previously evaluated. Success
factors of biotech drugs in the R&D phase are low species specificity (so that it is
possible to develop good animal models), proof of efficacy in a well conducted clinical
trial of sufficient size, a good safety profile and the availability of diagnostic tests for
easily identifying patients who may benefit from the treatment.
This analysis has shown that the possibility of broadening the range of indications is
an important strategy in this class of drugs. In both colony stimulating factors and
rhGH, we have seen patterns of indication dynamics. We consider this feature as a
key factor to investigate further as it will strongly determine the rationing of the
usage and cost containment of these compounds. At the moment other biotech drugs
are entering the market with well-defined indications at the beginning, but with a
clear tendency of being used and/or approved for other indications as well. A good
example is abciximab (ReoPro®, a glycoprotein IIb/IIIa inhibitor), that is registered
as an adjuvant treatment in addition to heparin and acetylsalicylic acid to prevent
ischemic cardial complications in high-risk patients during percutaneous
transluminal coronary angioplasty (PTCA) [74]. Because of its mode of action it is a
feasible candidate for off label use and/of approval for other indications (instable
angina and other coronary diseases) in the near future. However, broadening of
indications in itself does not have to be negative; it can also be considered an
important form of medical innovation. [75] Another related issue concerns the fact
that many of these biotechnology compounds, like colony stimulating factors and
abciximab, are linked to other intervention strategies like surgery, chemotherapy,
percutaneous transluminal angioplasty etc.
A key factor identified in this study is the definition and measurement of clinically
relevant outcomes (short and long-term). In all three cases it has been shown that
market approval and adoption in clinical practice relies heavily on the appraisal of
various clinical, economical and societal outcomes. Recently, Detsky and Redelmeier
[76] have put health outcomes and gains in perspective.
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Their comments focus on the misunderstanding of data on health gains by clinicians,
policy makers and the public. The trade-off between the costs and benefits in the
assessment of drug therapy depends strongly on the appraisal of various outcomes,
where facts and values from the perspective of the parties involved may differ [13]. In
such circumstances, strong lobbies for or against drug treatment in certain disease
categories (e.g. cancer and HIV) emerge. However, society also needs treatments for
diseases that do not have a strong lobby and diseases with more problematical
outcomes. The current trend towards evidence-based medicine means that we will
increasingly have to take decisions based on ‘uncertain ‘ or incomplete’ knowledge.
The challenge to technology assessment will be to deal with such uncertainties in a
sensible way. Only then, it can be a good tool to support medical decision-making.
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ABSTRACT
Aim - To investigate differences in attitudes, knowledge and actual use of economic
evaluations in different groups of decision-makers and to compare the results from
the Netherlands with the overall results of the European Network on Methodology
and Application of Economic Evaluation Techniques (EUROMET) project.
Methods - Members of the EUROMET group conducted interviews and surveys with
politicians, regulators, hospital pharmacists and physicians in the Netherlands. Three
approaches of investigation could be adopted: (i) a postal questionnaire survey, (ii)
semi-structured interviews, and (iii) a focus-group approach.
Results - In the Netherlands, decision-makers generally have a positive attitude
towards economic evaluations. Nevertheless, their actual use and knowledge of
economic evaluations are still limited. Hospital pharmacists and regulators are more
objective than physicians and politicians, who also base their judgements on other
societal values. Hospital pharmacists and regulators have a greater knowledge of
economic evaluations, and they use them more often than the other groups. Most
decision-makers do not want to base their decisions strictly on a cost-effectiveness
ranking alone. Our findings are similar to the findings in other European countries.
Conclusion - Decision-makers prefer to make their own broad comparisons of
advantages and disadvantages, and do not base their decisions solely on a single
summary measure.
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INTRODUCTION
As a society, we have mixed feelings about the increasing costs of healthcare [1]. On
the one hand, people are concerned about the enormous increase of healthcare
expenditures during the past decades. From 1980 until 1995, healthcare expenditures
per capita have increased by 300% in Europe [2]. Healthcare, which was equivalent
to only 3.8% of the Dutch gross national product (GNP) in 1960, is now at between 8
and 10% GNP [2]. Obviously, these developments raise political concerns, as less
money can be spent in other areas. Moreover, employers and employees do not like
to spend ever-increasingly on healthcare. Raising taxes and premiums is not
acceptable for most stakeholders, and doing so may cause severe economic side
effects. Consequently, there is a strong call for cost containment in healthcare.
On the other hand, no matter how high the costs are, or how small or uncertain the
benefits, patients generally expect every effort to be made to improve their health.
Bringing costs into medical decision-making is often considered to be unethical [3].
These conflicting views are also found with regard to cost-effectiveness analysis
(CEA). Advocates of CEA argue that it is the most sensible way to allocate scarce
resources, while some opponents are of the opinion that decision-making in
healthcare should not be based on costs. Moreover, there is criticism of the
techniques used in economic evaluations because some of the methodological and
standardisation issues have not been completely resolved.
There is only limited knowledge about the influence of economic evaluation studies
on healthcare decision-making. Alban [4,5] and Davies et al.[6] asked researchers
from Denmark and ten European Community countries, respectively, about the
impact of their work. Only two studies, both in the UK, have surveyed decision-
makers rather than researchers: Drummond et al. [7] sent a postal questionnaire
survey to pharmacists and directors of public health services; and Duthie et al. [8]
used interviews on the relevance of a number of diverse health economic measures.
Generally, it was concluded that the impact of economic studies was limited.
However, little is known about European countries other than the UK, about the
reasons and attitudes behind this possible lack of impact, and about potential
differences between different type of decision-makers.
Decision-making about healthcare technologies takes place at different levels. On the
macro level, politicians and regulators have to decide, for example, about the
licensing and reimbursement of pharmaceuticals. On the intermediate level,
decisions are made by specialist organisations (in developing good practice
guidelines) and formulary committees. Ultimately, on the micro level, physicians and
patients make choices about individual treatments. Since these decision-makers view
the process from different perspectives, their attitudes towards economic evaluations
as a tool for decision-making may also vary. We conducted interviews and surveys
with politicians, regulators, hospital pharmacists, and physicians in the Netherlands
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to gain insight into their attitudes, knowledge and use of economic evaluations, and
to learn whether differences exist between these groups.
Our second research question arises from our participation in the European Network
on Methodology and Application of Economic Evaluation Techniques (EUROMET):
do decision-makers in the Netherlands have similar opinions on CEA as their
colleagues in other European countries? The EUROMET project aims for the
standardisation of methodology in Europe, to enhance the status of economic
evaluation. There are eleven project partners from nine European countries (Finland,
France, Germany, Norway, Portugal, Spain, Sweden, the Netherlands and the UK). In
each of the nine countries, three groups of decision-makers were surveyed:
physicians, government agencies and a third group that each participant was free to
choose. Three approaches of investigation could be adopted: a postal questionnaire
survey, semi-structured interviews, and a focus-group approach.
The healthcare system in the Netherlands consists of a mix of public and private
elements. Practically all care is provided through private organisations. The
government, on the other hand, exerts influence on the insurance system, on the
pricing of care and on the quality of care and patients’ rights. The insurance system is
partly public and partly private. Since the mid-1980s there has been a slow ongoing
shift more towards the market and self-regulation. In hospitals and other healthcare
organisations, budgeting systems were already in place, but now the government is
extending financial responsibility to insurers as well. Through this measure, the
government aims to encourage selective contracting and managed care [9].
At the time of our investigation (late 1998 to early 1999), there were no government
regulations on the use of economic evaluations in any decision-making process.
While we were performing our interviews, the Ministry of Health, through the Health
Insurance Fund Council, was preparing a policy to formally include economic
evaluation in the decision-making process for the reimbursement of extramural
pharmaceuticals that cannot be clustered into the price reference system. In March
1999, this requirement came into effect. In all other areas, economic evaluations are
still not officially required.
In this study, we investigated differences in attitudes, knowledge and actual use of
economic evaluations in different groups of decision-makers, and compared the
results from the Netherlands with the overall results of the EUROMET project.
METHODS
In the Netherlands, nine opinion-leading physicians involved in the development of
therapeutic guidelines, six senior regulators and four politicians, were interviewed
about economic evaluations. In addition, fifteen hospital pharmacists were surveyed
by postal questionnaire.
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Interview
We used the semi-structured interview technique developed by the EUROMET group
[10]. The content of the questions is presented in Table 1. Four dimensions of the
respondents’ position concerning economic evaluation in healthcare were assessed,
namely: (i) potential use of economic evaluation and attitudes towards it; (ii) actual
use of economic evaluations; (iii) extent of knowledge about economic evaluation;
and (iv) potential barriers to the use of economic evaluations.
To assess which criteria decision-makers generally use when assessing new
technologies, we started the interviews with a discussion about a hypothetical new
drug to treat obesity. We then left this hypothetical scenario and spoke in general
about cost-effectiveness as a criterion for decision-making.
Names of opinion-leading physicians were given to us by the National Organisation
for Quality Assurance in Hospitals, an organisation that supports the development
and implementation of consensus guidelines in the Netherlands. We interviewed
physicians from nine different fields of medicine: general practice, internal medicine,
dermatology, gynaecology, anaesthesia, neurology, pathology, surgery, and
cardiology. The four politicians we interviewed, were the spokespersons for
healthcare in parliament for the four largest political parties in the Netherlands. The
regulators consisted of three executives of the Health Insurance Fund Council, one
executive from the Ministry of Health, one executive of the National Health Council
and one executive of the Medicines Evaluation Board.
Postal questionnaire
The fourteen hospital pharmacists surveyed by a postal questionnaire were
considered to be either key individuals in Dutch hospital pharmacy or a member of
the Efficient Pharmacotherapy Study Group from the Dutch Society for Hospital
Pharmacists. Two hospital pharmacists affiliated to our department made this
selection. The questionnaire was based on the same format that we used for the semi-
structured interviews. The content of the questions is presented in Table 1.
Definitions
Economic evaluation studies were meant to include all formal studies comparing the
costs and (if required) consequences of relevant alternatives: cost-minimisation,
cost-effectiveness, cost-benefit and cost-utility studies. In the interviews, and in this
article, we often used the term ‘cost-effectiveness’ to encompass each of these
different forms of economic evaluation. Healthcare technologies were generally
understood to cover all instruments and conditions under which medical practice is
exercised. These included drugs, devices, procedures, facilities and the organisational
and support systems within which healthcare is delivered. In this study, however, we
focused mainly on diagnostic procedures and treatment possibilities.
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RESULTS
The main results of this survey are summarised in Table 1 and depicted in Figure 1.
Criteria for the assessment of healthcare technologies (hypothetical scenario)
Both the interview and the postal questionnaire began with a hypothetical scenario
about the introduction of a new drug to treat obesity that was likely to considerably
increase the drug bill in the Netherlands. Respondents were asked about which
criteria they would base their judgement on about this drug.
All respondents referred to efficacy and safety, although two politicians used terms
like ‘a revolutionary new drug that really works’, without getting into the technical
details of how this should be determined. In fact, the Members of Parliament
answered that their role in drug assessment was limited. In most cases, Parliament
simply accepts the Health Minister’s decision, which is based on advice from the
Health Insurance Fund Council. If Parliament interferes with this decision, it tends
to become an issue in which politics are more important than the facts. Many
physicians, hospital pharmacists and regulators made the efficacy criterion more
explicit by using terms such as the therapeutic value as compared with alternative
treatments, looking at total outcome, avoiding surrogate endpoints and looking at
the long term preventive effect (on morbidity and mortality) or at the improvement
of quality of life.
Costs and savings, cost-effectiveness or budgetary impact were mentioned by
approximately three out of four respondents. Only a few respondents answered that
(i) costs are only of secondary importance, (ii) on the micro level, costs should only
be considered when dealing with ‘me-too drugs’, or (iii) the national drug budget
should be less rigid, since it now hampers innovation. About one out of four
physicians and regulators, and 1 politician (who was also a practising general
practitioner) brought up the issue of defining certain subgroups or sub indications
for which the treatment might be most cost-effective. Related to this factor is the
likelihood of broadening indications, that is, the chance that a product that is
registered or reimbursed for a relatively small indication (or subgroup) may
subsequently be used in a much wider range of patients. This was of special concern
to the regulators. Other criteria that were mentioned once or twice are listed with the
type of respondent who brought up the criterion stated in parentheses:
- severity of the disease (regulator, politician)
- burden of treatment for the patient (physician, regulator)
- pharmaceutical quality of the product (regulator)
- amount of experience with the technology (physician, regulator)
- user friendliness of diagnostic equipment (physician)
- whether the technology can be charged to the patient himself (regulator)
- fit with the main areas of attention of the clinic (hospital pharmacist)
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Table 1 Economic evaluations in healthcare: opinions from physicians, hospital 
pharmacists, regulators and politicians
Parameter Physicians
(n=9)
Hospital
pharmacists
(n=15)
Regulators
(n= 6)
Politicians
(n=4)
Criteria for the
assessment of
healthcare
technologies
What are the most
important criteria for
the assessment of a
new technology?
Efficacy and
safety, costs,
subgroupa
Efficacy and
safety, costs
Efficacy and
safety, costs,
Subgroupa
Regulators’
advice, costs,
and politics
Attitude towards
economic evaluations
Ethical to refuse treat-
ments for CE reasons?
Yes
(majority)
Yes (all) Yes
(majority)
Yes (n=2)
and no (n=2)
Use an explicit cut-off
point for CE?
Mixed Yes (80%) Generally no Generally no
Responsibility for
allocative efficiency
Who is responsible for
allocative efficiency in
healthcare: government
or the professionals?
Professionals
(government
facilitating &
controlling)
Professionals
(government
facilitating &
controlling)
Government
(profes-
sionals
should mainly
worry about
good care)
Government
(emphasis on
technical
efficiency)
Actual use of
economic evaluations
Are EAs a requirement
for decision-making in
your situation?
No (1 yes) Not asked No No
Did you ever use an
economic evaluation for
decision-making?
Only in
consensus
committees
(majority)
Yes (some) Yes No
Knowledge about
economic evaluations
Education in health
economics?
Little Not asked Yes
(majority)
Generally not
Knowing the difference
between a CEA and
CEU?
No Yes
(majority)
A few No
a Subgroups or subindications for which treatment might be most cost-effective
CE=cost-effectiveness; CEA=cost-effectiveness analysis; CUA=cost-utility analysis;
EA= economic evaluation
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YES
NO
Politicians
Hospital
pharmacists/
RegulatorsPhysicians
Actual use
YES
NO
Politicians
Hospital
pharmacists/
RegulatorsPhysicians
Knowledge
FACTS
VALUES
Politicians
Hospital
pharmacists/
RegulatorsPhysicians
Attitude
Figure 1 Attitudes, knowledge and actual use of economic evaluations
a schematic representation of the respondents’ answers
Attitudes toward economic evaluations
Both the interview and the postal questionnaire included the question: ‘Do you think
it is ethical to refuse to adopt or finance a new treatment for cost-effectiveness
reasons?’. The majority of respondents answered ‘yes’ to this question. The
arguments against refusing treatments for cost-effectiveness reasons were:
- treatments in terminally ill patients are probably not cost-effective, yet it would
be unethical to withhold such treatments (politician)
- it is unethical to refuse treatments since savings can still be achieved from within
the healthcare organisation, for example, by lowering specialists’ incomes and
lowering the marketing costs of the pharmaceutical industry (regulator)
- one should not look at the healthcare sector as only a generator of costs, it is also
an environmentally clean sector that generates a lot of employment and social
gains (regulator)
Three regulators emphasised that it is most important to critically assess the efficacy
of a treatment: They commented that ‘whenever a treatment is really effective, it will
generally also have a favourable cost-effectiveness ratio’. Furthermore, it was
mentioned that before refusing a treatment, one would have to explore all
alternatives to try and define subgroups in which the treatment does have an
acceptable cost-effectiveness ratio.
The respondents were also asked to what extent they agreed or disagreed with the use
of an explicit cut-off point for cost-effectiveness (e.g. €20,000 per life year saved, as
used in the Dutch consensus guideline for treating hypercholesterolaemia [11]). The
majority of physicians, regulators and politicians were not in favour of the use of an
explicit cut-off point for cost-effectiveness. Hospital pharmacists, however, generally
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agreed with the use of such a cut-off point. They were of the opinion that this would
promote an objective and transparent decision-making process to allocate scarce
resources. Regulators and politicians were generally against an explicit cut-off point
although two of them did favour a cut-off point, but not for it being the only criterion
and not as a sharp and rigid boundary. For two politicians, the idea of summarising
the total value of a treatment in one figure was totally new and it aroused a lot
of resistance.
The attitudes of physicians towards a cut-off point were varied. One physician
recognised that cut-off points are already implicitly used in defining subgroups
eligible for certain treatments. Two other physicians, although in favour of an
explicit cut-off point, took the view that ultimately the media and political opinion
would eventually determine what decisions are taken. Arguments against a cut-off
point included:
- the foundation and standardisation of economic evaluations are not yet strong
enough, and large margins of uncertainty surround cost-effectiveness ratios
(physician, regulator, politician)
- doubts exist about the concept of measuring quality of life and the validity of the
quality adjusted life year (physician, regulator, politician)
- discrimination of older and disabled people  (regulator)
- for a specific individual, a small health effect can mean a lot in terms of quality of
life (e.g. treatment of a small dysfunctioning of a musician’s hand) (physician)
- we cannot measure the cost-effectiveness of affectionate care for the elderly; only
cure can be assessed, not care (regulator)
- it is an a-historical approach: ‘In the middle of the 19th century there appeared
not to be enough money for good care for many. Through social battle and co-
operation, and not through static bookkeeping, enormous progress has
nevertheless been achieved’ (regulator)
Responsibility for efficiency in healthcare
When asked where the responsibility for efficiency in healthcare lies, physicians and
hospital pharmacists tended to place it more with the professionals in the
field, while regulators and politicians were more inclined to attribute the
responsibility to the government. However, most respondents emphasised that
professionals and the government should co-operate closely since they both play a
part in enhancing efficiency.
Physicians generally stressed that the government should turn to the professionals
for the relevant knowledge and for performing clinical studies. The government was
ascribed a controlling and facilitatory role.
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The government should facilitate and stimulate efficiency policy through financing
the development of guidelines and offering instruments such as electronic
prescription systems and continuing education possibilities.
Like physicians, the hospital pharmacists also mentioned that the professionals,
not the government, have the relevant knowledge, that the government should
play a facilitory role, and that the professionals and the government needed to co-
operate. Remarkably, 4 out of 6 regulators believed that the professionals in the field
should just pay attention to ‘appropriate care’, i.e. the right treatment in the
right dosage to the right patient at the right time. This would automatically be the
most efficient treatment.
Politicians were more concerned with technical efficiency (‘doing things right’) than
with allocative efficiency (‘doing the right things’). To make choices and set priorities
between treatments was not a topic on the political agenda. More popular subjects in
politics were simplifying existing legislation and the development of relevant criteria
to assess the quality of care delivered by healthcare professionals and institutions.
Actual use of economic evaluations
We asked the physicians, regulators and politicians if economic studies are a formal
requirement for decision-making in their situation. Only one physician answered
‘yes’, while all of the other respondents said ‘no’. Several respondents noted that good
studies were often lacking. This question was not included in the questionnaire that
was sent to the hospital pharmacists.
We then asked the participants (including hospital pharmacists) if they had ever used
an economic evaluation for decision-making. Five physicians had used economic
evaluations while working within consensus committees developing good practice
guidelines. One physician had used an economic evaluation to convince a hospital’s
management of the advantages of a pre-surgery clinic to perform the necessary
examinations before a patient can undergo surgery. The physicians never used
economic evaluations to support decisions in the individual patient setting. About
one third of the hospital pharmacists and all but one regulator had ever used an
economic for decision-making. One out of the four politicians said that he had used
economic evaluations for decision-making in healthcare, although he could not come
up with an example.
Extent of knowledge about economic evaluations
Both in the interview and in the postal questionnaire, respondents were asked if they
had had any formal training in health economics. Only one physician participated in
a one-day retraining course on pharmacoeconomics for physicians. Two physicians
said they learned about economic evaluations in healthcare through self-education,
one of whom is now actually teaching health economics courses.
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In the group of regulators, most of the respondents had had some training in health
economics. One of them went to an extensive three-week course. A politician who is a
practising family doctor went to a one-day retraining course for physicians. The
question about education was not included in the questionnaire for hospital
pharmacists since it is normal practice within this group of professionals to attend
courses on pharmacoeconomics on a regular basis.
We also asked politicians, regulators and physicians if they knew the difference
between a CEA and cost-utility analysis (CUA) and, if so, which type of analysis they
preferred. In the postal questionnaire for hospital pharmacists, this question was
slightly altered since we expected the hospital pharmacists to be more knowledgeable
about this subject. The revised question read, ‘Are you familiar with the techniques of
cost-minimisation analyses (CMAs), costs-benefit analyses (CBAs), CEAs and CUAs?
Which type of analysis is the most useful to you?’.
Neither the physicians nor the politicians knew enough about the differences
between CEA and CUA to state the advantages and disadvantages of these methods.
Two regulators knew the difference between the two methods. They identified the
ability to compare treatments for different diseases as an advantage of the CUA,
while abstraction from the actual disorder, difficulties in valuing quality of life, and
the question of whose values should be used were named as disadvantages. In the
group of hospital pharmacists, twelve out of fifteen respondents answered that they
were familiar with these different types of analyses. Their preference was equally
distributed between CMA, CBA and CEA. CUA was the least popular method.
Barriers to the use of economic evaluations
Respondents were asked to rate the importance of a list of potential barriers to the
use of economic evaluations on a 5-points scale: from ‘not important at al’ (0) to ‘very
important’ (4). Participants could also add other barriers they felt were missing from
our list. The average ratings for the barriers are presented in Figure 2.
The difficulty of moving resources from one budget to another, the fact that cost-
effectiveness in real practice can be very different from that predicted in a clinical
trial (efficacy versus effectiveness), and economic evaluations making too many
assumptions were viewed as the most important barriers by all four groups of
respondents. Different views existed between the regulators and politicians with
regard to cost containment and the fact that the studies are complicated and hard to
understand. Regulators considered cost containment much more important than
politicians did. Politicians, in particular, considered economic studies to be
complicated and hard to understand.
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Figure 2 Ratings of the importance of eight potential barriers to the use of
economic evaluations opinions from physicians, hospital pharmacists,
regulators and politicians, and mean score of the 4 groups
(i) Difficulty in moving resources from one sector/budget to another; (ii) Cost-
effectiveness in real practice can be very different than predicted from a clinical trial
(efficacy versus effectiveness); (iii) Economic studies make to many assumptions; (iv)
Sponsorship of studies, e.g. by industry, biases the results; (v) Savings in economic
studies are anticipated not real; empty beds are filled again; (vi) Cost containment is
more important than cost-effectiveness; (vii) Studies are complicated and hard to
understand; (viii) Economic studies are not required in the Netherlands
Potential barriers to the use of economic evaluations that were added to our list by
the respondents included:
- economic evaluations are not accepted as a tool by the medical profession
(physician)
- economic evaluations discriminate against the ‘non-productive’ population and
against people with a lower starting utility, e.g. chronically ill or (mentally)
disabled people (regulator)
- there is a lack of available economic evaluation studies (hospital pharmacist)
- many resources and time required to perform an economic evaluation (regulator)
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A number of methodological arguments against the use of economic evaluations were
also received:
- difficulties in determining the efficacy of treatments, especially in the care sector
(regulator)
- difficulties with international comparability (regulators, hospital pharmacist)
- lack of detailed information on care consumption and quality of life scores
(physician)
- too much unfamiliarity with new drugs: modelling ignores sudden adverse events
that may occur (hospital pharmacist)
- there are no ‘good practice guidelines’ for economic evaluation studies (regulator,
hospital pharmacist)
- difficulties in determining the overhead costs: often too few costs are included
(physician)
- difficulties in handling indirect costs (regulator)
Comparison with other European countries
The combined analysis of the results from all of the participating countries revealed
that decision-makers generally have a positive attitude towards and interest in
economic evaluations. About 75% of all decision-makers felt that economic
considerations should be taken into account, at least to some extent. Approximately,
20% thought that efficiency considerations were very important. The respondents
judged ethical issues very differently. Most of the British and Spanish respondents
thought that it is ethical to refuse to adopt or to finance a new treatment for cost-
effectiveness reasons, whereas only 2% of the Portuguese respondents took this view.
In general, most decision-makers did not want to adopt a strict attitude and stated
that the refusal might not be based on economic reasoning alone. The actual use of
economic evaluation studies in decision-making processes is still limited. At most, a
third of respondents across all of the countries stated that they have ever actually
used an economic evaluation study. Furthermore, the majority of respondents had
only poor knowledge of economic evaluation. Overall, a low percentage of
respondents had undergone training in health economics; approximately one third
had participated in health economics courses [10].
DISCUSSION
Safety, efficacy, cost-effectiveness, the definition of relevant outcome measures and
subgroups, the likelihood of broadening of indications, and politics are important
factors in the assessment of healthcare technologies in the Netherlands. Generally,
decision-makers have a positive attitude towards economic evaluations in healthcare.
However, most decision-makers do not want to adopt a strict attitude and they state
that decisions may not be based on economic reasoning alone.
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The actual use of economic evaluation, and knowledge about it, are still limited.
These observations correspond with findings in other European countries. In the
Netherlands, hospital pharmacists and regulators use economic evaluations more
frequently, and have more knowledge about them than physicians and politicians. In
developing guidelines, consensus committees of physicians sometimes use economic
evaluations; in an individual patient setting, however, they do not. Politicians are
more concerned with technical efficiency than with allocative efficiency.
The results from the hospital pharmacists were obtained through a postal
questionnaire survey, while the other data were obtained using semi-structured
interviews. This may weaken the comparability of the results. In general, interviews
are likely to be a superior method to mailed questionnaires in situations where: (i)
the respondent is unlikely to answer a mailed questionnaire, (ii) the number of
respondents is small, (iii) the data required are (mainly) qualitative in nature, and
(iv) the researcher does not have a previous clear understanding of the issues nor of
the likely responses. When we started the research with the physicians, regulators
and politicians, this was generally the case; the number of regulators and politicians
we considered it relevant to include was small and they were unlikely to respond to a
postal questionnaire. Moreover, since little research had so far been performed in
this area in the Netherlands, we had insufficient prior information to develop a valid
postal questionnaire.
During the interviews, our opinion was confirmed that it was necessary to speak
directly to the respondents to get a good understanding of their views. With the
hospital pharmacists, however, the situation was different, in that: (i) a larger group
could be easily contacted; (ii) we were more confident that they would respond to a
postal questionnaire since they belonged to the same professional group as the
investigators; and (iii) by that time, we had enough experience to formulate the
appropriate questions, since we conducted the interviews with the other groups first.
Indeed, after a reminder by phone, the response to the postal questionnaire was
100% and, as was anticipated, hospital pharmacists were shown to have enough
insight into the field of economic evaluations to fill in the questionnaire properly.
Therefore, we believe that the methods used were appropriate and that they do not
seriously hamper comparability.
Although decision-makers generally have a positive attitude toward economic
evaluations, they also criticise them. In an article series in the Journal of the
American Medical Association, Eddy [12] mentioned that misunderstanding is an
important factor in this criticism. He stated that many people have never attended a
simple presentation about the fundamentals of healthcare rationing according to
cost-effectiveness ratios. We can indeed conclude that all of the decision-makers in
the Netherlands do not know the principles of economic evaluations. For instance,
neither the physicians nor the members of parliament knew enough about the
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differences between cost-effectiveness analysis and cost-utility analysis to name the
advantages and disadvantages of these methods.
There are other factors, as well as misunderstanding, that can cause controversy,
which Eddy [12] groups into different categories. We would like to modify and extend
these categories, based on the arguments we encountered during our interviews and
survey (see Table 2). The first category consists of methodological issues, for which
we can identify many arguments that were provided by our respondents, namely the
absence of a good practice guideline, difficulties in measuring quality of life, and
difficulties in determining and measuring all of the relevant costs, etc.
Furthermore, there are clinical arguments against cost-effectiveness reasoning. The
main clinical argument is that the results from a cost-effectiveness analysis are often
counter-intuitive. For example, in a ranking based on efficiency drawn up by the
Oregon Health Services Commission, tooth caps were ranked ahead of surgery for
ectopic pregnancy [1]. This reluctance to strictly follow cost-utility league tables also
emerged in our interviews.
There is also a group that consists of psychological arguments. Initially, the field of
economic evaluation may, by itself, cause scepticism because it is relatively new field
of medicine. It utilises a lot of mathematics and abstract thinking, which not all
decision-makers are familiar with and which makes it difficult for them to assess the
validity of the conclusions. Also, territorial feelings may play a part. Decisions that
used to be the practitioners’ private domain must now be shared; providers of
relatively inefficient care services may feel especially threatened.
Another group of arguments has a more philosophical/ethical character. One philo-
sophical question is, which perspective is the correct one: the practitioner’s
perspective, which focuses on an individual patient, or the population perspective,
which tries to maximise the health of the entire population of patients? Another
philosophical problem is the disagreement about whether resources are truly limited.
Both questions recurred in the interviews we conducted.
Even if people are willing to accept cost-effectiveness as a tool for decision-making,
some practical issues may arise. Several of our respondents felt that good studies are
often lacking. The difficulty in moving resources from one budget to another also
hampers the implementation of economic studies in the decision-making process.
CONCLUSION
Hospital pharmacists and regulators are the groups most likely to base their
judgements on scientific evidence alone, that is, they are more fact oriented than
physicians and politicians. Since they do not have to face individual patients or
voters, they may take less account of feelings that exist in the general population,
political strategies and other contextual factors (values).
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Table 2 Summary of the barriers encountered in the use of economic
evaluations, based on Eddy [12] and modified and extended using the
findings from our research
Methodological Clinical Psychological Philosophical /
ethical
Practical
Difficult to
quantify the
health benefits
Results are
often
counter-
intuitive
Saving an
identifiable
patient is more
desirable than
preventing
anonymous
deaths
Pain treatment
in terminally ill
patients:
unfavourable
cost-
effectiveness
but unethical to
withhold
Difficult to
move
resources from
one budget to
another
There is no ‘good
practice guideline’
A treatment
that really is
effective is
generally
also cost-
effective
Scepticism
because the
field is
relatively new
to medicine
Discrimination
against older
and disabled
people
Not enough
studies are
available
Difficult to
calculate costs
For an
individual
patient a
small health
benefit can
mean a lot
It requires a lot
of mathematics
and abstract
thinking
Doubts about
whether
resources are
really limited
Difficulties with
international
comparability
Territorial
feelingsa
Which
perspective is
the correct one:
the individual
patient
perspective or
the population
perspective?
Political
emotions have
an important
influence on
decision-
making
a Providers of relatively inefficient care services may feel threatened.
For individual physicians and politicians, these values play a more integral part in
decision-making. Is it necessarily a bad thing that some decision-makers do not base
their decisions on scientific facts alone, but take into account humanitarian values as
well?
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Economists teach that priority setting should take place according to league tables of
cost-effectiveness ratios if the dominant objective is to maximise the health benefits
that are generated by the scarce resources that are available for healthcare. From our
interviews, however, it is clear that many of the respondents were reluctant to base
their decisions on cost-effectiveness ratios alone. Considering values, such as
concerns about the severity of illness, reluctance to discriminate against patients that
happen to have less potential to benefit from treatment than others, territorial
feelings and political deliberations, can add to the quality of decision-making.
Moreover, it would be an illusion to think that we can succeed in eliminating these
factors from the decision-making process.
Should we then try to incorporate broader societal values into economic evaluations?
Some health economists are working on incorporating equity concerns into cost-
utility analyses [13,14]. We are of the opinion that this will not increase the impact of
economic evaluations. Generally, people do not want the solutions to complicated
problems to be summed up in single numbers [15]. When registration authorities like
the US Food and Drug Administration and European Medicines Evaluation Board
assess the balance between the positive effects and adverse events of a new drug, they
do not abstract these diverse characteristics into a single number, which is then to be
compared with a fixed cut-off point. Rather, they choose to make their own
judgements based on perceived benefits and losses. The more factors that become
included in cost-effectiveness ratios, the less transparent and comprehensible
these ratios will become, and the less likely that people will accept them as being
valuable information.
In summary, the impact of cost-effectiveness data may increase through education of
the decision-makers and through keeping the calculations transparent and
understandable. However, we must not expect decisions to be based on cost-
effectiveness ratios alone. Decision-makers prefer to weight a broad range of
advantages and disadvantages in their own minds, and not base their decisions on a
single summary measure alone. This may also be of importance to the present debate
in the Netherlands regarding how to integrate the pharmacoeconomic guidelines that
have recently been approved into the assessment procedure for reimbursement [16].
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ABSTRACT
Aim - The EPISTENT study has demonstrated that the combined use of abciximab
and stenting as an adjunct to PTCA leads to increased event-free survival compared
to either using abciximab or stenting alone. However, this combined strategy may be
costly and the additional costs have to be weighted against the additional effects.
Methods and results - The 6-months efficacy data from the EPISTENT study are
combined with Dutch estimates of unit costs. Adding a stent to a procedure with
abciximab, further decreases the number of revascularisations at an extra cost of
€12,000 (95% upper limit (u.l) € 31,00) per additional major adverse cardiac event-
free (MACE-free) survivor. Adding abciximab to a stenting procedure, decreases the
incidence of myocardial infarctions at an extra cost of at €13,000 (95% u.l. €27,000)
per additional myocardial infarction-free survivor. In the subgroup of diabetics,
adding abciximab improves revascularisation rates as well, resulting in a cost-efficacy
rate of €2,000 (95% u.l. €25,000) per additional MACE-free survivor, with
uncertainty regions indicating potential costs savings.
Conclusion - The combination of stenting and abciximab costs about €13,000 to
avoid one event after PTCA. In diabetic patients the strategy may be cost saving.
The EPISTENT study
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INTRODUCTION
Over the last decade at least two technologies have changed the face of interventional
cardiology. First, intracoronary stents, which have been shown to reduce the need for
repeat revascularisations by 20-50% [1-7]. Second, the GP IIb/IIIa receptor blockers,
most notably abciximab (ReoPro®), which have been shown to be effective in
reducing the rate of myocardial infarction and the necessity for urgent
revascularisation in patients undergoing percutaneous transluminal coronary
angioplasty (PTCA) [8-11]. Both technologies are now common practice, stents
probably more than abciximab, as in most American and European institutions 60-
90% of all angioplasty cases now involve stent implantation [12].
Given the ‘separate’ effects of stenting and abciximab – stents on revascularisation-
free and abciximab on myocardial infarction-free survival – the question that needed
to be addressed was whether their combination would lead to a synergistic effect.
This was done in the ‘Evaluation of Platelet IIb/IIIa Inhibitor For Stenting Trial
(EPISTENT)’ study [13,14]. Here, three treatments were compared: (1) elective
stenting and placebo, (2) elective stenting and abciximab, and (3) balloon angioplasty
with abciximab. The combined use of stents and abciximab turned out to be the
superior treatment showing both an effect on myocardial infarctions and early
re-PTCAs due to the use of abciximab, and effects on late revascularisations due to
the use of stents.
Nowadays, the fact that the combination of stents with abciximab has been shown to
lead to a significant improvement in event-free survival, or even survival, is not a
guarantee for widespread use. Many hospitals, especially European hospitals, face
budgetary constraints and the use of stents plus abciximab is associated with
additional costs. In these cases, questions may be raised about the balance between
the additional costs and the additional efficacy. Additionally, when assessing this
balance, the question may not only be whether to treat patients with this
combination, but also whom to treat. As such, finding that the combination of
stenting and abciximab proved to be especially valuable in diabetic patients was
important [15]. Diabetes is an important determinant of restenosis and the need for
revascularisations after conventional PTCA. In a subgroup analysis of EPISTENT,
however, diabetics in the stent-abciximab group had a similar target
revascularisation rate after 6 months compared with non-diabetic patients in the
same group. In the diabetic cohort, there was a >50% reduction in the 6-month
target revascularisation rate for the stent-abciximab group compared to the stent-
placebo group, while in the non-diabetics this reduction was <3%.
Here, we address the question on the balance between the costs and effects of
combined use of abciximab and stenting using the 6-months efficacy data from the
EPISTENT study, in combination with Dutch estimates of unit costs. We assess both
the cost-efficacy of adding a stent to a procedure where the use of abciximab is
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planned, as well as the cost-efficacy of adding abciximab to a procedure where
the use of a stent is planned. Special attention is given to the uncertainties
surrounding the estimates, especially when breaking down the results between
diabetics and non-diabetics.
METHODS
The presented analysis can be labelled as a cost-efficacy analysis from a societal
perspective in which only direct medical costs are taken into account. The analysis is
based on individual data per patient with a time horizon of six months. The analysis
includes a subgroup analysis considering diabetic and non-diabetic patients.
The EPISTENT study
In the EPISTENT trial 2,399 patients (75% males, aged 60 ± 11 years) were enrolled
at 63 hospitals in the U.S.A. and Canada between July 1996 and September 1997 [13].
All patients had ischaemic heart disease and coronary artery lesions that had caused
stenosis of at least 60%, amenable to balloon angioplasty or stenting. Patients were
randomly assigned to stenting and placebo (n=809), stenting plus abciximab
(n=794), or balloon angioplasty plus abciximab (n=796). The primary endpoint of
the trial included any of the following events over the first 30 days after
randomisation: death from any cause, myocardial infarction or reinfarction, or severe
myocardial ischaemia requiring urgent coronary artery bypass surgery, stent
placement or PTCA. Further details have been published elsewhere [13].
Efficacy
The analysis of cost-efficacy starts with the assumption that the results from the
EPISTENT study can be extrapolated to Europe. The clinical endpoint used in the
EPISTENT trial and in three other large trials that have been conducted with
abciximab, was ‘event-free survival’, including death, myocardial infarction and
urgent revascularisations as events. From an economic perspective, there are various
reasons why this outcome may be subject to criticism. Using this composite endpoint,
a repeat PTCA receives the same weight as a myocardial infarction, and a myocardial
infarction has the same weight as dying. Moreover, revascularisations – even ‘urgent’
revascularisations – may be subject to clinicians’ decisions. Ideally, one would want
to use the number of Quality Adjusted Life Years (QALYs) gained through the use of
abciximab. However, no data on the quality of life of the study population has been
collected. Therefore, we followed the same approach as followed earlier in cost-
efficacy studies with abciximab and stenting using two definitions of ‘event-free
survival’. The first is defined as the percentage of patients surviving 6 months
without a myocardial infarction (‘myocardial infarction-free survival’); the second is
defined as the percentage of patients surviving 6 months with neither a myocardial
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infarction nor a revascularisation procedure (major adverse cardiac event-free
survival or ‘MACE-free survival’). It is noted that we include the urgent as well as the
non-urgent revascularisations as events. As such, ‘event-free survival’ is used as the
measure of efficacy, since all events that are included in the definition are very likely
to be associated with quality of life and survival probabilities. Also, the various
components do not change in opposite directions (in the sense that the use of
abciximab would, for example, lead to fewer revascularisations but more deaths).
Differences in effects are tested using the Chi-square test.
Costs
Costs are calculated by multiplying the number of events recorded in the trial
database by the estimates of costs per event. The estimates of these unit costs are
based on the economic evaluation study from the BENESTENT II trial [5].
The costs of initial stenting procedures, including an average number of hospital
days, are estimated higher than the costs for initial PTCA procedures. This difference
results from the price of the stent, the use of additional balloons and other devices,
and a slightly longer duration of the procedure [16]. The costs of the initial
procedures are complemented with the costs of abciximab (blinded and open use),
the costs associated with bail-out stent implantation, and the costs associated with
additional stents.
During the follow-up period, the costs take into consideration open abciximab usage,
revascularisations and the resources associated with myocardial infarctions. We
estimated that patients experiencing a Q wave myocardial infarction required
hospitalisation for 2 days at a coronary care unit (CCU) and another 6 days at a
normal care unit. For non-Q wave myocardial infarction patients, we estimated half a
CCU day plus half a day at a normal care unit. The costs for a re-PTCA or a repeat
stent procedure are estimated higher than the costs for the initial procedures. While
the latter does not include the costs for diagnostic procedures (visits, tests, and
angiography), the first do. All costs are expressed in 1998 Euros. Differences in costs
are tested using oneway ANOVA and contrasts.
Cost-efficacy
The balance between costs and effects is addressed by computing incremental cost-
efficacy ratios, i.e. the additional costs per additional event-free survivor. We assess
the cost-efficacy of adding stents to a procedure with abciximab by a comparison of
the stent plus abciximab arm with the PTCA plus abciximab arm. The cost efficacy of
adding abciximab to a stent procedure is assessed by a comparison between the stent
plus abciximab arm and the stent plus placebo arm. Additionally, as in the clinical
report about efficacy, a breakdown is presented distinguishing between diabetes and
non-diabetes patients. The uncertainties surrounding the estimates are addressed by
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way of probability ellipses and by presenting upper 95% limits to the cost-efficacy
ratios [17].  It is noted that the trial did not include any European patients and that
the results are conditional on the assumption that the clinical findings can be
extrapolated to a European context.
RESULTS
Efficacy
The results for all patients confirm that the main effect of abciximab on myocardial
infarctions is mainly during the first month, and the main effect of stenting on the
number of revascularisations is mainly after the first month. After 1 month, only 45
patients had either died or experienced a myocardial infarction after combined
therapy, compared to 90 patients in the stent+placebo arm and 54 patients in the
PTCA+abciximab arm. The number of revascularisations during the first month was
25 in the combined arm, 42 in the stent+placebo arm, and 41 in the PTCA+abciximab
arm. The additional number of patients who either died or experienced a myocardial
infarction during the subsequent months was six in the combined arm, 10 in the
stent+placebo arm, and 15 in the PTCA+abciximab arm. The additional number of
revascularisations during the subsequent months was 66 in the combined arm, 66 in
the stent+placebo arm, and 98 in the PTCA+abciximab arm.
As such, a combination stenting and abciximab leads to significant improvement in
efficacy, when compared with a procedure with stent implantation and when
compared to a procedure with abciximab. The results in terms of survival, myocardial
infarction-free survival and MACE-free survival are presented in Table 1.
The results – not using abciximab – confirm that stenting is associated with lower
MACE-free survival in diabetics when compared to non-diabetics (73% vs. 80%,
p=0.07). However, it appears that when abciximab is used, MACE-free survival after
stenting is approximately equal for diabetics and non-diabetics. Thus, in diabetics the
use of abciximab not only decreases the numbers of myocardial infarctions – as it
does in non-diabetic patients – but it decreases the number of revascularisations as
well, suggesting not only an additional effect to stent implantation but also a
synergistic effect.
Costs
Table 2 presents the estimates of the average cost per patient for the different
contributing factors after 6 months of treatment. The results differ slightly from
those that would be obtained by simply multiplying the volumes with the unit costs.
This is related to the fact that when two events were observed for one patient, this
contributed only once to the efficacy measure, but twice to the costs.
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Table 1 Efficacy at 1 month and 6 months for all patients, non-diabetics and
diabetics
p-value when adding:Stent +
placebo
Stent +
abciximab
PTCA +
abciximab abciximab stenting
All patients
N 809 794 796
Survival
1 month 99.38% 99.62% 99.25% 0.50 0.32
6 months 98.76% 99.50% 98.24% 0.19 0.02
MI-free survival
1 month 88.88% 94.33% 93.22% <0.001 0.36
6 months 87.64% 93.58% 91.33% <0.001 0.09
MACE-free survival
1 month 85.78% 92.32% 89.32% <0.001 0.04
6 months 78.37% 83.75% 76.51% 0.006 <0.001
Non-diabetics
N 636 632 640
Survival
1 month 99.69% 99.68% 99.22% 0.99 0.26
6 months 98.90% 99.53% 98.13% 0.21 0.02
MI-free survival
1 month 89.15% 94.30% 92.81% <0.001 0.28
6 months 87.74% 93.51% 91.25% <0.001 0.13
MACE-free survival
1 month 86.32% 92.09% 88.28% <0.001 0.02
6 months 79.72% 83.54% 76.72% 0.08 <0.01
Diabetics
N 173 162 156
Survival
1 month 98.27% 99.38% 99.36% 0.35 0.98
6 months 98.27% 99.38% 98.72% 0.35 0.54
MI-free survival
1 month 87.86% 94.44% 94.87% 0.04 0.87
6 months 87.28% 93.83% 91.67% 0.04 0.46
MACE-free survival
1 month 83.82% 93.21% 93.59% <0.01 0.89
6 months 73.41% 84.57% 75.64% 0.01 <0.05
PTCA=percutaneous transluminal coronary angioplasty; MI=myocardial infarction;
MACE=major adverse cardiac event
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Table 2 Costs after six months for all patients
Incidence of events Costs per patient (€)
Stent/
place-
bo
Stent/
Abcixi-
mab
PTCA/
Abcixi-
mab
Unit
costs
(€)
Stent/
Place-
bo
Stent/
abcixi-
mab
PTCA/
abcixi-
mab
Initial procedure
PTCA / stenting 98.5% 98.7% 98.6%
4,505/
5,904
5,816 5,829 4,442
Bail out stenting 0.00% 0.00% 18.3% 2,211 0 0 406
Additional stents 0.38 0.30 0.00 1,397 527 419 0
Vials abciximab 0 3.23 3.23 347 0 1,122 1,122
Open abciximab 1.85% 0.38% 0.25% 1,121 21 4 3
6,363 7,375 5,972
Follow-up
Open abciximab 1.40% 1.12% 1.01% 1,121 15 13 11
Q wave MI 1.85% 1.64% 2.51% 4,753 88 78 131
Non-Q wave MI 9.39% 4.41% 4.90% 719 68 33 36
Re-PTCA 6.30% 4.79% 4.15% 7,178 497 380 325
Re-Stent 4.45% 3.78% 11.3% 7,678 361 309 916
Re-Bypass 4.57% 4.28% 3.89% 17,795 814 784 693
1,843 1,597 2,113
Average costs
per patient
8,207 8,971* 8,085
* Compared to stent/placebo p=0.003, compared to PTCA/abciximab p<0.001
PTCA=percutaneous transluminal coronary angioplasty; MI=myocardial infarction
It is noted that 6 months after the initial procedure, 29% of the patients who were
not planned to have a stent implanted had indeed received a stent, either by bail-out
(18%) or during follow-up (11%).
The combination of both stenting and abciximab administration leads to higher costs
for the initial procedure when compared to a procedure where only stenting or
abciximab is used. However, a substantial part of the additional costs are compen-
sated for by savings as a result of a decrease in revascularisation procedures and
myocardial infarctions. After 6 months, the net costs of adding abciximab to a stent
procedure were estimated at €764, after an initial increase of  €1,012. After 6 months,
the net costs of adding a stent to a procedure with abciximab were estimated at €886,
after an initial increase of €1,403.
The EPISTENT study
71
Table 3 Incremental cost-efficacy ratios at 6 months for all patients,
non-diabetics and diabetics
All patients
Stent /
placebo
Stent /
abciximab
PTCA /
abciximab
N 809 764 796
Costs (€) 8,207 8,971 8,085
MI-free survivors 87.64 % 93.58 % 91.33 %
MACE-free survivors 78.37 % 83.75 % 76.51 %
No-diabetics
N 636 632 640
Costs (€) 8,047 8,955 8,029
MI-free survivors 87.74% 93.51% 91.25%
MACE-free survivors 79.72% 83.54% 76.72%
Diabetics
N 173 162 156
Costs (€) 8,792 9,034 8,317
MI-free survivors 87.28% 93.83% 91.67%
MACE-free survivors 73.41% 84.57% 75.64%
Incremental CE-ratio
adding abciximab (one-
sided 95% upper limit)
Incremental CE-ratio
adding stents (one-sided
95% upper limit)
All patients
MI-free survival 12,876 (27,366) 39,463 (1,438,868)
MACE-free survival 14,198 (49,873) 12,228 (30,597)
Non-diabetics
MI-free survival 15,713 (36,381) 40,936 (ns)
MACE-free survival 23,717 (487,232) 13,570 (40,555)
Diabetics
MI-free survival 3,695 (42,521) 33,219 (ns)
MACE-free survival 2,167 (25,246) 8,040 (91,103)
PTCA=percutaneous transluminal coronary angioplasty; MI=myocardial infarction;
MACE=major adverse cardiac event; ns=if efficacy is not significant at 10% then no
upper limit for the CE-ratio is calculated.
Cost-efficacy
From the above results, it may be concluded that the combination of abciximab and
stenting is not expected to be cost saving within the first 6 months. Table 3 presents
the estimates of costs, effects and cost-efficacy ratios for all patients, diabetics and
non-diabetics.
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Figure 1a The added value of abciximab: diabetics
MI-free survival after 6 months
Figure 1b The added value of abciximab: diabetics
MACE-free survival after 6 months
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Figure 1c The added value of abciximab: non-diabetics
MI-free survival after 6 months
Figure 1d The added value of abciximab: non-diabetics
MACE-free survival after 6 months
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The results show that adding stenting to a procedure where the use of abciximab is
planned, may only be considered efficient when the goal is to prevent
revascularisations, not so much when the goal is to improve myocardial infarction-
free survival. The value of adding abciximab to a stenting procedure differs among
subgroups. For the majority of patients, adding abciximab may be efficient especially
to increase myocardial infarction-free survival. However, in the subgroup of
diabetic patients, adding abciximab affects revascularisations as well, and may be
an efficient strategy in terms of myocardial infarction-free survival as well as
MACE-free survival.
While there are substantial differences between the point estimates when comparing
diabetics and non-diabetics, these differences are not evident when comparing the
one-sided 95% upper limits. This is, of course, related to the fact that the subgroup of
diabetic patients contained fewer patients. This is confirmed by Figures 1 and 2,
which indicate both costs and effects in two-dimensional planes, together with the
estimated uncertainties, for diabetic and non-diabetic patients. Figure 1 illustrates
the value of adding abciximab to a procedure involving stent implantation, and
Figure 2 shows the added value of stenting when the use of abciximab was planned.
Points in the right upper quadrant denote that the addition of abciximab (Figure 1),
respectively the addition of a stent (Figure 2), is more effective and more costly; the
right lower quadrant denotes the addition to be more effective and less costly; the left
lower quadrant denotes lower efficacy and lower costs; and the left upper quadrant
denotes both higher efficacy and higher costs.
It is noted that there is more uncertainty surrounding diabetic patients, and that
there is a substantial probability that the combination of abciximab and stenting
might result in cost savings (and more event-free survivors), especially when
abciximab is added to a procedure where stenting is scheduled.
DISCUSSION
The results of the EPISTENT study may help in deciding whether one should add
abciximab to an elective stent procedure, or whether one should add a stent to a
procedure planned with abciximab. As such, they do not answer the question should
one use a stent or abciximab at the first place. For these questions, one should
consider the results from the BENESTENT II study (for stenting) [5] or from the
EPIC study [18]. In the BENESTENT II study the costs for stenting were estimated at
€8,780 per MACE-free survivor [5]. For abciximab the costs per additional
myocardial infarction free survivor were estimated in the EPIC study at €2,900 [19].
The result confirm the hypothesis, given that one already has decided to use
abciximab, that stenting will further decrease the number of revascularisations in
both diabetic and other patients. The costs per additional MACE-free survivor are
estimated at €12,000 (95% upper limit (u.l) €31,000); for diabetics at €8,000
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(95% u.l. €91,000). Additionally, the result confirms the hypothesis, given that one
will use a stent, that use of abciximab will decrease the incidence of myocardial
infarctions. The additional costs per additional myocardial infarction-free survivor
are estimated at €13,000 (95% u.l. €27,000); for diabetics at €3,700 (95% u.l.
€46,000). Most notably, in the subgroup of diabetic patients, adding abciximab not
only improves myocardial infarction-free survival, but also it decreases the
revascularisation rate. This results in a cost-efficacy rate of €2,000 per MACE-free
survivor (95% u.l. €25,000), and even the possibility of costs savings.
The calculations presented here are obtained by combining event rates in the
EPISTENT study with estimated of costs from the Dijkzigt hospital in the
Netherlands. It is emphasised that the results presented here need to be interpreted
with some care since: (1) only direct medical costs have been included, (2) no data on
health related quality of life have been included, and (3) no analysis of costs per life
year gained has been performed. The trial was not powered to analyse differences in
survival, although the 6 month results show a significant difference due to stenting.
The recently reported 12 month results confirm this difference, and also show a
significant survival difference at that point in time, due to abciximab [20]. These
results could be used to calculate an extrapolated survival difference, to estimate
future costs and to estimate costs per life year gained. However, we feel that these
estimates would need to be surrounded with lots of uncertainties, in light of the
limited power and the fact that, until now, stents have never been able to
convincingly show a decrease in mortality [21].
Also, a number of assumptions have been made in the analysis. Most notably, it has
been assumed that the results from the EPISTENT trial can be reproduced in The
Netherlands. This assumption may not be correct, especially when certain treatment
decisions affect the costs and effects. For example, it should be appreciated that the
average number of PTCAs per 100,000 citizens is between 115 and 143 in the United
States, while it is only about 70 in the Netherlands [22]. Another concern is the
definition of efficacy. The analysis includes death, myocardial infarctions and
revascularisation procedures in the outcome measure without any distinction with
respect to the severity of the various events. This can only be labelled as a very rough
approach. When additional research is initiated, it would be worthwhile to
incorporate quality of life measures in the assessment of the effects. Additionally, to
calculate quality adjusted life years gained, it would be worthwhile to incorporate a
utility measure, such as the EuroQol or a patient preference method.
The question can now be raised, how can these results be translated into clinical
practice? Clinicians might ask themselves whether these incremental cost-efficacy
ratios are acceptable.
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Figure 2a The added value of stenting: diabetics
MI-free survival after 6 months
Figure 2b The added value of stenting: diabetics
MACE-free survival after 6 months
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Figure 2c The added value of stenting: non-diabetics
MI-free survival after 6 months
Figure 2d The added value of stenting: non-diabetics
MACE-free survival after 6 months
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Is it worth €13,000 to prevent a myocardial infarction (in most cases a non-Q wave
myocardial infarction), and is it worth €12,000 to prevent a revascularisation? The
answers are difficult to give and may also depend on the possibility of finding
additional funds. One way may be to limit the combined strategy to diabetic patients
for whom the cost-efficacy ratios are much lower, with the need of correspondingly
fewer funds. On the one hand, this is due to the fact that fewer patients are treated,
on the other hand, to the reduced need for repeat interventions in these patients.
However, the latter needs to be interpreted with care. A reduction in the
revascularisation rate was demonstrated only in the EPIC trial [9], while in other
trials (including the overall results from EPISTENT) this finding could not be
replicated. More important than whether this finding is coincidental, may be the
question whether one should stent a diabetic patient in the first place. The literature
does not present any uniform conclusions about efficacy, let alone about cost-efficacy
[23,24]. In such cases, the CE ratio of combined use of stenting and abciximab
should be calculated against a plain PTCA procedure or even better, with diabetic
patients, against bypass surgery. Indeed, if one buys a Ferrari, it is better to buy one
with wheels; however, the question is, of course, whether one should have bought a
Ferrari in the first place. As such, a further refinement of whom to stent and who
should be given abciximab in the first place, may prompt the creation of an additional
budget for treating patients with the combination of the two.
As a conclusion, there are still unanswered questions about which treatment is the
most efficient for patients scheduled for revascularisation. Potentially, the main
problem may be that a PTCA is already a very efficient procedure and it will always
be difficult to improve on something that is already so good. As such, one might
conclude that interventional cardiologists are being punished for their own success.
However, and this may offer some comfort, there are probably many specialists that
would like to be in this position.
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ABSTRACT
Aim - The combined use of stents and abciximab in percutaneous coronary
intervention has been evaluated in the EPISTENT trial. However, the clinical and
economic findings in trials are not necessarily generalisable to a general population
setting. We conducted a study in daily clinical practice comparing stented and non-
stented patients undergoing coronary angioplasty with abciximab administration.
Furthermore, we compare our results with the findings of the EPISTENT trial.
Methods - From 1995 to 1999, refractory unstable patients scheduled for angioplasty
and receiving abciximab in a Dutch regional hospital were followed prospectively for 6
months. Total costs were considered in addition to 2 composite clinical endpoints: (1)
death or myocardial infarction (MI); and (2) death, MI, or any revascularisation
procedure (major adverse cardiac events, MACE).
Results - Stented patients (n=101) experienced less MACE than non-stented patients
(n=83) (6.9% vs. 16.9%, OR= 0.37, p=0.04). The total costs were similar for stented
and non-stented patients (€7,844 vs. €7,904, p=0.93). Adjustment for baseline
characteristics yielded similar results, although significance subsided. The relative
risk reduction of 44% that we found closely resembles the 42% that was found in the
EPISTENT trial.
Conclusion - In everyday practice, as in the EPISTENT trial, the addition of a stent to
abciximab treatment does seem to reduce the risk of MACE by about 40% at no
additional costs.
Abciximab in daily practice
83
INTRODUCTION
A series of randomised controlled trials (RCTs), which directly compared elective
stent implantation with balloon angioplasty, have shown that stenting reduces the
need for repeat revascularisation procedures [1-7]. However, there is an ongoing
debate about the respective merits of RCTs and observational studies in the
assessment of treatments [8-12]. The results of RCTs are not necessarily
generalisable to a general population setting. For example, it has been shown that
patients included in RCTs of cardiovascular drugs have different characteristics from
the people who use these products in daily practice [13], and also that the treatment
effects of antihypertensive therapy in daily practice may be different from the effects
in RCTs [14,15].
Also, the spectrum of patients undergoing a percutaneous coronary intervention in
current practice may be much broader than the patients included in clinical trials,
since the trials applied strict clinical and anatomical entry criteria. Therefore, it is
important to evaluate the effectiveness of stenting under circumstances of everyday
clinical practice [11,12]. This has been done already in several observational studies.
These studies have found that the widespread use of coronary stents coincided with
improved short-term outcomes and reduced or equal revascularisation rates during
follow-up [16-18].
Over the recent years GP IIb/IIIa receptor blockers became available, most notably
abciximab (ReoPro®). In RCTs abciximab has been shown to be effective in reducing
the rate of myocardial infarction (MI) and the necessity for urgent revascularisation
in patients undergoing percutaneous transluminal coronary angioplasty (PTCA).
Given the ‘separate’ positive effects of stenting and abciximab – stents on
revascularisation-free and abciximab on MI-free survival – the ‘Evaluation of Platelet
IIb/IIIa Inhibitor For Stenting Trial (EPISTENT)’ study was performed to evaluate
whether the combination of abciximab and stenting would lead to a synergistic effect.
In this American/Canadian study, the combined use of stents and abciximab indeed
turned out to be the superior treatment compared both to abciximab administration
alone and to stenting alone [19].
However, again the question remains if this finding applies to everyday clinical
practice in Europe as well. In daily practice, does the implantation of a stent have
additional value when the patient is already receiving abciximab treatment? As far as
we know, this question has not yet been addressed. Here we present a study which
included all patients from a regional hospital in the Netherlands (Alkmaar) who were
administered abciximab and who were subsequently transported to one of two
specialised centers to undergo PTCA either with or without stent implantation. We
compare cardiovascular outcome events and costs between stented and non-stented
patients. Subsequently, we compare our findings to the EPISTENT study.
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Table 1 Baseline characteristics of non-stented and
stented patients in our study a
Non-stented Stented p-value
Number 83 101
Age (years) 63.5 ± 2.4 62.8 ± 2.2 0.67
Male (%) 68.7% 80.2% 0.09
Braunwald score 0.18
1b 0.0% 3.0%
2b 16.9% 25.7%
2c 24.1% 24.8%
3b 27.7% 26.7%
3c 31.3% 19.8%
Number of vessels 1.58 ± 0.16 1.64 ± 0.15 0.81
Hypertension 32.5 % 27.7 % 0.52
Hypercholesterol-
emia treatment 60.2 % 66.3 % 0.44
Diabetes 6.0 % 9.9 % 0.42
Smoking 30.1 % 36.6 % 0.43
Family history 43.4 % 48.5 % 0.55
Previous MI 60.2 % 56.4 % 0.65
Previous PTCA 14.5 % 7.9 % 0.23
Restenosis 6.0 % 2.0 % 0.25
Previous CABG 8.4 % 11.9 % 0.48
a MI, myocardial infarction; PTCA, percutaneous transluminal coronary angioplasty;
CABG, coronary artery bypass graft
METHODS
From June 1995 to June 1999, all PTCA patients that received abciximab were
followed consecutively for six months. Characteristics such as age, gender,
Braunwald score, previous PTCA and other related risk factors were registered
at baseline. If the PTCA procedure involved the same vessel that had already been the
target of a previous procedure, this is noted as ‘restenosis’. Approximately 6 hours
after the intervention, creatine kinase and its MB isoenzyme levels in the blood
were determined. At 1 month and at 6 months after the procedure the patients
revisited the regional hospital for a clinical check-up, including an electrocardiogram
(ECG). The following events were recorded: death, myocardial infarction (MI),
repeated transluminal coronary intervention, and coronary artery bypass graft
(CABG). We used the same criteria as in the CAPTURE and the EPISTENT trial to
define a MI [19,20].
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Table 2 Odds ratios for clinical endpoints at 6 months of stented compared to
non-stented patients in our study a
Non-
stented
Stented OR
unadjusted
OR
adjusted b
Deaths   1.2 % 0.0 % -
MIs   2.4 % 1.0 % 0.41 (0.03 – 4.5) 0.30 (0.02 – 4.4)
Re-PTCA/re-stent   9.6 % 5.0 % 0.49 (0.15 – 1.6) 0.73 (0.19 – 2.7)
CABG   6.0 % 2.0 % 0.32 (0.06 – 1.7) 0.48 (0.06 – 4.0)
Death or MI   3.6 % 1.0 % 0.27 (0.03 – 2.6) 0.20 (0.01 – 2.8)
MACE 16.9 % 6.9 % 0.37 (0.14 – 0.96) 0.56 (0.19 – 1.7)
Costs (€) 7,908 7,844
a MI, myocardial infarction; PTCA, percutaneous transluminal coronary angioplasty;
CABG, coronary artery bypass graft; MACE, major adverse cardiac event
b Adjusted for age, gender, Braunwald score, previous PTCA, restenosis, previous
CABG and previous MI.
Two composite endpoints were considered: (1) death or MI; and (2) death, MI, or any
revascularisation procedure (major adverse cardiac events, MACE). Costs were
calculated by multiplying the number of events recorded in the trial database by the
estimates of costs per event. The estimates of these unit costs are derived from The
Netherlands and are based on the economic evaluation study from the BENESTENT
II trial [3].
Baseline characteristics, outcomes and costs were compared using Fisher’s Exact test
and the Student’s t-test. (Adjusted) odds ratios for outcomes were estimated using
logistic regression.
RESULTS
From 1995 to 1999, 184 patients were administered abciximab and then transported
for PTCA. Of these patients 83 underwent plain balloon angioplasty and 101 were
stented. Baseline characteristics are shown in Table 1. There were no significant
differences. However, patients receiving a stent tended to be more often male,
hypercholesterolemic, diabetic and smoker. On the other hand, in this group there is
also a tendency towards fewer patients with restenosis or a previous MI.
Cardiovascular outcomes for stented and non-stented patients are shown in Table 2.
The risk of MACE is significantly lower for stented patients compared to patients who
received only balloon angioplasty (6.9% vs. 16.9%, OR=0.37, p=0.04). This improved
outcome is mainly driven by a decrease in the number of revascularisations.
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Table 3 Costs at 6 months of stented compared to non-stented patients
in our studya
Incidence of events Costs per patient (€)
Non-
stented
Stented Unit
costs
(€)
Non-
stented
Stented
Initial procedure 2,718 / 3,959 b 2,718 3,959
Abciximab (3 vials) 1,041 1,041 1,041
Additional stents 0 0.20 1,354        0    268
Hospital stay
(days per patient)
CCU or ICU 0.92 0.68 969     887    662
Other 5.17 3.38 469 2,424 1,583
Revascularisation 9.64% 4.95% 3,304 / 3,222 b    318   160
CABG 6.02% 1.98% 8,622    519   171
7,908 7,844
a CCU, coronary care unit; ICU, intensive care unit; CABG, coronary artery bypass graft
b Unit costs for non-stented and stented patients respectively
Age, gender, Braunwald score, previous PTCA, restenosis, previous CABG and
previous MI were identified as confounders and were subsequently adjusted for.
After adjustment the occurrence of MACE after stenting is still decreased compared
to plain balloon angioplasty, although not statistically significant (OR=0.56, p=0.28).
General risk factors for developing cardiovascular diseases (CVD), such as hyper-
tension, diabetes, smoking, and a history of CVD in the family, were not adjusted for,
since their influence was negligible.
Table 3 shows that, although the implantation of a stent increases the cost of the
initial procedure with about €1,250 per patient (from €3,959 to €2,718), the total
costs after 6 months of follow-up are similar for stented and non-stented patients
(€7,844 and €7,904 respectively, p=0.93).
In Table 4 the baseline characteristics of the patients in our study are compared to
the patients in the EPISTENT trial. In our study there are less patients with
hypertension or diabetes, and more patients who had had a previous MI.
Nonetheless, the baseline rate of events without stent implantation is similar in our
study as in EPISTENT (death/MI 3.6% respectively 7.8%, p=0.27; MACE 16.9%
respectively 20.4%, p=0.56).
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Table 4 Baseline characteristics of patients in our
study and of patients in the EPISTENT trial a
Our study EPISTENT p-value
Number 184 1,590
Age (years) 63.2 ± 1.6 60 ± 0.5
Male 75.0 % 75.3 % 0.93
Hypertension 29.9 % 51.1 % <0.001
Diabetes  8.2 % 20.0 % <0.001
Smoking 33.7 % 35.7 % 0.63
Previous MI 58.2 % 48.9 % 0.02
Previous CABG 10.3 % 8.0 % 0.26
a MI, myocardial infarction; CABG, coronary artery bypass graft
As shown in Table 5, the relative risk reductions (RRR) and the numbers needed to
treat to avoid one event (NNT) that we found in our study are similar to the findings
in EPISTENT. Looking at death and MIs, 35-43 patients need to be stented to avoid
one event; if revascularisations are considered as well, about 13 patients need to be
stented to avoid one event.
DISCUSSION
In our observational study in daily clinical practice, the number of MACE during 6
months of follow-up improved by about 44% after stenting compared to plain
balloon angioplasty, whereas the direct medical costs are similar in both groups. Our
results correspond very well to the findings in the EPISTENT trial, where a reduction
of 42% was found in the incidence of death, MI and target vessel revascularisations.
The difference between our study including all revascularisations in the composite
endpoint, and EPISTENT including only target vessel revascularisations, is negligible
since the vast majority of all revascularisations are indeed target vessel
revascularisations [19,21,22]. The fact that the reduction of MACE in our study does
not remain significant after adjustment for baseline characteristics is most likely due
to the small sample size. The indication as such, that the combined usage of stents
and abciximab leads to improved event-free survival in daily practice in Europe, is
not a guarantee for widespread use. Many hospitals face budgetary constraints and
the use of stents initially is associated with increased costs. However, our study
suggests that these additional costs are offset by savings through a reduction in the
number of revascularisations and MIs during follow-up.
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Table 5 Relative risk reduction (RRR), 6 months absolute risk (AR6m), and
6 month number needed to treat (NNT6m) for combined events in our
study and in the EPISTENT trial a
Our study EPISTENT b
RRR (%)
(95% c.i.)
AR6m (%)
non-stented
/ stented
NNT6m RRR (%) AR6m (%)
non-stented
/ stented
NNT6m
(95% c.i.)
Death/ MI 80
(-180-99)
3.6 / 0.72 35 (8-NA) 31 (-5-54) 7.8 / 5.5 43
(24-NA)
MACE 44
(-70-81)
16.9 / 9.5 13 (7-NA) 42 (24-56) 20.4 /12.8 13
(9-20)
a MI, myocardial infarction; MACE, major adverse cardiac event; c.i., confidence
interval; NA, not applicable since OR included one
b in EPISTENT only target vessel revascularisations are included in MACE, while we
included all revascularisations in our study
An important limitation of our study is that stenting was not randomly assigned, but
decided upon by physicians. This may have introduced bias. Despite adjustment for a
large number of potential confounding factors, residual confounding due to
unmeasured factors cannot be excluded.
In sensitivity analyses of the influence of differences in baseline characteristics on the
estimates of the odds ratios, it turned out that previous coronary interventions or
MIs have more influence than general risk factors for developing CVD, such as
hypertension, smoking and a family history of CVD. Adjustment for diabetes did not
influence the OR either. Diabetes is often mentioned as an indicator for inferior
outcomes after PTCA [23,24]. In our study group there are fifteen diabetes patients;
the percentage of MACE occurring among them did not differ significantly from the
non-diabetics (11.8% in non-diabetics vs. 6.7% for diabetics, p=1.0).
The issue of the additional value, in actual clinical practice, of stent implantation in
PTCA patients who are already administered abciximab, remains an important topic
to be addressed. In a relatively small study we found a beneficial effect of stenting,
which is very comparable to the findings in the EPISTENT trial. In everyday practice,
the addition of a stent to abciximab treatment does seem to yield additional benefit.
However, this finding needs to be confirmed in larger scale studies.
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ABSTRACT
Aim - Abciximab improves outcomes in patients undergoing percutaneous
transluminal coronary intervention (PTCA). Clinicians, however, have expressed
concerns that they do not have enough budget to administer abciximab to all eligible
patients. We studied the patterns of prescribing of abciximab and identified factors
that correlate with the level of usage.
Methods - In each of all 13 Dutch PTCA centers one opinion-leading cardiologist
was approached to provide data on the abciximab prescribing in their center and to
co-operate in an interview on this topic. We performed linear regression analysis
in which the level of abciximab prescribing was the dependent variable.
Potential determinants investigated were the number of PTCAs performed, the
criteria for abciximab prescribing, funding and possible financial restrictions,
participation in clinical trials in the past, percentage stenting, and desired level of
abciximab prescribing.
Results - All 13 PTCA centers in the Netherlands participated in our study. The level
of abciximab prescribing varied from 2% to 36% of all PTCAs. The criteria for patient
selection significantly differed between centers. Together: budget, investigatorship,
size, and type of the institution were highly predictive for the level of abciximab
prescribing (R2=0.93, p<0.001). The more patients doctors had included in clinical
trials in the past, the higher was the likelihood that they prescribed abciximab.
Conclusion - Shortly after its introduction, patterns of abciximab prescribing varied
widely between PTCA centers. There was no agreement on which patients to select
for this preventive treatment. Budget and involvement in clinical trials in the past
were important predictors of the level of prescribing in each center.
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INTRODUCTION
Today’s health care increasingly has to face budget constraints, while the possibilities
for treatment are getting more and more advanced and expensive [1]. In particular
biotechnology has increased our understanding of disease processes and has
facilitated the discovery and production of therapeutic proteins. Several
biotechnology drugs have entered the market, and many others are expected to
follow [2,3]. On the one hand this implies a promise for the future, on the other hand
it raises concerns about the increasing costs of health care, since most innovative
drugs bear considerable price tags. The risk of waste on expensive and less effective
drugs has so be set against the risk of strangling innovations and inducing
suboptimal quality of care. Finding a balance in this delicate equilibrium is one of the
biggest challenges in medical decision making. Case studies of existing drugs can be
an important means to improve our decision-making in the future. Therefore, we
present here the case of abciximab (ReoPro®), a new drug that inhibits platelet
aggregation and is used in patients undergoing percutaneous transluminal coronary
angioplasty (PTCA). PTCA is a technique to dilate narrowed parts of the coronary
artery in patients with angina pectoris or myocardial infarction by inserting a small
balloon in the coronary artery and inflating it at the spot of the stenosis. The two
main complications associated with a PTCA procedure are abrupt vessel closure (4-
9% of patients), leading to myocardial infarction or death, and gradual re-occlusion
of the coronary artery (restenosis, 20-55% of patients). Based on the first trial with
high-risk PTCA patients, in 1994 the European Medicines Evaluation Agency
(EMEA) approved abciximab as an adjuvant treatment to prevent ischaemic cardiac
complications in high-risk patients undergoing PTCA [4,5]. Subsequent trials
demonstrated that abciximab also improved outcomes in a broader category of
patients [6-8] and the official indication was extended to include all PTCA patients
by the end of 1997. From a cost-effectiveness perspective, however, it may be
worthwhile to know in which category of patients the benefit of abciximab is largest.
Data on cost-effectiveness and on specific subsets of patients has so far been limited
and inconclusive [9-13]. In 1998 in the Dutch media cardiologists have expressed
their concern that their budgets do not allow them to give abciximab to all eligible
patients. Public exposure of this issue has been high. We studied the patterns of
prescribing of abciximab and identified factors that determine the level of
prescribing per center.
BACKGROUND
In the Dutch health care system all hospitals are budgeted. The budget for
pharmaceuticals is the responsibility of either the department of Hospital Pharmacy,
or of each clinical department separately for their own share in it. The procedure cost
of a PTCA procedure (fixed costs plus variable costs, without hospital days) amounts
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to about €2,700 without stent implantation, and €4,100 with the implantation of one
or more stents [14]. The prescribing of abciximab adds about €1,200 to this amount.
A stent is a tiny wire mesh tube, which is implanted in the dilated artery to prevent
acute coronary occlusion and later restenosis. It has been estimated that 60-80% of
all PTCA procedures involve the implantation of a stent [15].
Economic evaluations from a societal perspective have demonstrated that the
additional costs of abciximab are partly offset by savings through a reduction in the
number of revascularisations and MIs during follow-up [12,16,17]. From the
perspective of the hospital management, however, these savings may not actually
become apparent, since within the hospital the total number of MIs treated or the
number of revascularisations performed will probably not decrease for various
reasons (e.g. existing waiting lists). In the Netherlands, there are no official national
guidelines in use concerning the prescription of abciximab.
METHODS
From April till August 1999 one opinion-leading cardiologist in each of all 13 PTCA
centers in the Netherlands was approached to provide data on the abciximab
prescribing in his center and to co-operate in an interview on this topic. Names of the
opinion-leading cardiologist in each center were given to us by a leading Dutch
cardiologist. All cardiologists were first sent a letter, in which they were requested to
look up the data that were asked for in the questionnaire that was included.
Subsequently we contacted them again to collect the filled-in questionnaires and
discuss the outcomes. Ten respondents were interviewed in person, 3 respondents
were interviewed by telephone, and 1 respondent returned the questionnaire by fax.
All respondents provided us with exact data on the budget arrangements and the
utilisation of abciximab in 1998.
The primary outcome measured was the level of abciximab prescribing in 1998,
which was deduced from the number of PTCAs performed and the number of
patients treated with abciximab. Potential determinants which were addressed in the
questionnaire concerned criteria for prescribing, the funding and possible financial
restrictions on the treatment, participation in clinical trials in the past, the
proportion of patients receiving stents, and opinion on the appropriate level of
abciximab prescribing. A summary of the interview and the provided data was sent to
each respondent for confirmation. The quantitative data provided were analysed
using both univariate and multivariate linear regression analysis, with the level of
abciximab prescribing being the dependent variable.
The level of abciximab prescribing is expressed as the percentage of all PTCA
procedures in which abciximab was used. ‘Budget’ refers to any imposed financial
restrictions and is expressed as the percentage of PTCAs in which abciximab
treatment was allowed.
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Figure 1 Levels of abciximab prescribing in the 13 PTCA centers in
the Netherlands
(between parentheses are the number of PTCAs that are performed in each center)
‘Investigatorship’ is defined as the number of patients that was included in clinical
trials with abciximab in the past (in the center in which the respondent was working
at that time). ‘Type of institution’ refers to academic and non-academic hospitals.
‘Size of institution’ is the number of authorised beds in the total institution, including
departments other than Cardiology.
RESULTS
The level of overall abciximab prescribing varied considerably between centers,
ranging from prescription in 2% to 36% of all PTCAs performed (see Table 1 and
Figure1). Of total abciximab prescribing 75% was administered surrounding
stenting procedures.
Nine out of the 13 centers indicated that the use of abciximab was restricted because
of economic reasons. Only 4 centers were completely satisfied with the available
budget at that time (their prescribing ranged from 13% to 36%). Two of these had
no budgetary constraints at all, and the other 2 reported that the available budget
was sufficient.
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Table 1 PTCAs, abciximab, budget and stenting
in all 13 Dutch PTCA centers in 1998
minimum maximum median average
Number PTCAs performed 700 2,025 1,114 1,176
Number of abciximab treatments 15 364 145 153
% of PTCAs in which abciximab is used 2% 36% 11% 14%
Desired reasonable percentage of
prescribing 13% 95% 28% 34%
Percentage of abciximab used
electively 0% 90% 35% 37%
Percentage of abciximab used with
stents 33% 96% 76% 75%
Budget
- number of abciximab treatments 0 460 84 128
- % of PTCAs in which
  abciximab can be used 0% 40% 10% 12%
Number of patients included in clinical
trials in the past 0 184 15 37
% of PTCAs in which a stent is
implanted 40% 85% 60% 61%
PTCA, percutaneous transluminal coronary angioplasty
Criteria for the selection of patients eligible for abciximab treatment varied between
centers. In total, half of all treated patients received abciximab not before PTCA to
prevent thrombotic complications (elective use), but during or after the procedure to
treat impending complications or to improve suboptimal results (rescue or bail-out
use). Five centers used abciximab almost exclusively (90-100%) as a rescue drug.
These 5 centers all indicated that they used this strategy out of budgetary
considerations, to limit the administration of scarce abciximab to those patients who
were most likely to benefit. Other centers administered at least part of their
abciximab electively. The various criteria for prescribing are summarised in Table 2.
When respondents were asked how much abciximab would reasonably be needed
and which would be the appropriate criteria for prescribing, the answers also were
very different from one center to another (see ‘Desired reasonable percentage of
prescribing’ in Table 1).
As is shown is Table 3, the use of abciximab was higher in academic centers than in
non-academic hospitals (not statistically significant). In all academic centers except
one, abciximab was financed from the Cardiology budget, while in all non-academic
centers abciximab was part of the budget of Hospital Pharmacy.
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Table 2 Criteria for abciximab prescribing in 1998
Criterion Number of centers
using this criterion
(% of all 13
centers)
Rescue or bail-out situations 13 (100%)
Elective prescribing
PTCA of a bypass graft 7 (54%)
Angiographic suspicion of a thrombus 5 (38%)
Myocardial infarction patients 4 (31%)
Unstable patients 3 (23%)
Multi-vessel disease 2 (15%)
Complex or extensive lesions 2 (15%)
Diabetic patients with very bad arteries 1 (8%)
PTCA, percutaneous transluminal coronary angioplasty
In univariate regression analysis, budget and investigatorship (the number of
patients included in clinical trials with abciximab in the past) were the most
important determinants to explain the variation in the current level of abciximab
prescribing in each center (Table 4). The higher the budget and the higher
investigatorship, the higher the level of use.
Using a multiple linear regression model, we found that together four parameters
were highly predictive of the level of prescribing (R2=0.93, p<0.001) namely: budget,
investigatorship, type of institution and size of institution (Table 5).
DISCUSSION
We found a large variability in the level of abciximab prescribing, which could be
largely explained by budget, investigatorship, and type of institution (academic/non-
academic). In the literature, investigatorship has already been identified as an
important determinant for drug prescribing before. Pieters described the ‘marketing
push’ of clinical trials for the case of interferon [18]. Clinical trialists are likely to
have earlier and better knowledge and prepare budget decisions in a more timely
fashion, which may result in more early use of the product. On average more
abciximab was used in academic than in non-academic hospitals, although this
difference was not statistically significant due to the small number of PTCA centers
in the Netherlands (n=13). Since academic centers are more research oriented, they
are probably faster to pick up new developments. The fact that abciximab is financed
from the budget of Hospital Pharmacy in most non-academic centers and financed
through the department of Cardiology in most academic centers, may also partly
explain the difference between academic and non-academic centers.
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Table 3 Abciximab prescribing in academic and non-academic hospitals
Academic Non-academic p
Budget (percentage) 15.0% 6.3% 0.27
Actual percentage of PTCAs in
which abciximab is prescribed 16.3% 10.2% 0.33
Dept. Cardiology
responsible for
budget
Pharmacy
responsible for
budget
p
Budget (percentage) 15.4% 5.5% 0.21
Actual percentage of PTCAs in
which abciximab is prescribed 16.0% 10.6% 0.39
PTCA, percutaneous transluminal coronary angioplasty
The situation that we encountered, in which non-medical factors like budget and
investigatorship so strongly determined the level of abciximab prescribing, could
only exist because there was no agreement on the appropriate criteria for abciximab
prescribing. We found that there are large differences in the criteria to select patients
for abciximab administration. Rescue use of abciximab is frequently practised
although this strategy has hardly ever been tested in clinical trials and is not an
approved indication. This indicates that there is budgetary pressure but also, more
importantly, that there is a problem to choose beforehand which patients to
prescribe abciximab. This is a common problem in preventive therapies. It has been
stated that no PTCA patient subgroup has been identified who do not benefit from
treatment with abciximab [19,20]. One could compare this with cholesterol lowering
treatment with statins, which has been proven effective in a broad category of
patients, including people with just average cholesterol levels [21-23]. The question
then becomes a cost-effectiveness issue: in which subgroups of patients we feel the
balance between effects and costs is still acceptable, and in which not? On statin
prescribing consensus has been reasonably established by now [24], but for
abciximab treatment the debate still has to begin. Moreover, for abciximab patient
numbers are much smaller and evidence on subgroups and cost-effectiveness is
much more limited than for statins. There are already some indications that
abciximab may be especially beneficial in patients with evolving myocardial
infarction, unstable angina or diabetes [10,19,20,25]. More research and debate in
the area of cost-effectiveness in specific subgroups is needed.
In 1998, 75% of total abciximab prescribing took place surrounding stenting
procedures, although this indication had not been separately established.
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Table 4 Determinants of the level of abciximab prescribing in 1998: univariate
linear regression analysis
coefficient p R2
Budget (percentage)   0.82 < 0.001 0.77
Number of patients included in clinical trials in the past   0.001 < 0.001 0.66
Percentage of PTCAs in which a stent is implanted   0.58    0.007 0.45
Size of institution (number of beds)   0.0002    0.05 0.25
Desired reasonable percentage of prescribing   0.21    0.12 0.13
Percentage of abciximab prescribed electively   0.13    0.14 0.11
Number of PTCAs performed - 0.0001    0.32 0.06
Budget responsibility (Pharmacy / Dept. Cardiology) - 0.05    0.39 0.00
Type of institution (academic / non-academic)   0.14    0.33 0.00
PTCA, percutaneous transluminal coronary angioplasty
The clinical trials performed with abciximab so far had focussed primarily on balloon
patients; however, some patients underwent bail-out stenting as well [26,27]. Only in
1999 the indication of abciximab was officially extended to include its prescribing
with stents as well, based on a fourth randomised controlled trial investigating the
effects of combining both stenting and abciximab [8]. Apparently, the official
broadening of indications lags behind the practice in real life.
In this study we did not investigate patient records, but we used data that the
opinion-leading cardiologists from each center reported to us. All PTCA centers in
The Netherlands participated in our study (not a sample). The use of abciximab is
such an innovative and expensive therapy, that the policy on, and the budget for its
administration, is agreed upon within the team of cardiologists, and does not vary
from person to person within a center. As such, we feel that the data that we obtained
are valid and representative. In addition, any potential lack of precision has certainly
not hampered the interpretation of the data. The differences between centers are so
large, that very clear associations could be established, as can been seen in the results
from the linear regression analysis (R2=0.96, p=0.0003). In theory, differences in
patient characteristics may be an important determinant to explain the observed
variation in abciximab prescribing, which we did not investigate. However, each
center included in our study was designated by the government to provide highly
specialised interventional cardiology care to all patients in their catchment
area. Together, these 13 centers serve the whole of the Netherlands. Therefore, we
think that it is highly unlikely that were considerable differences in patient mix
between centers.
The variability in prescribing may be partly due to the fact that abciximab had only
recently been approved for a broad category of patients.
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Table 5 Determinants of the level of abciximab prescribing in 1998:
backwards multivariate linear regression analysis
value p
(Intercept)  0.0830 0.059
Budget (percentage)  0.5582 0.016
Number of patients included in clinical trials in the past  0.0010 0.005
Type of institution (academic / non-academic)  0.0702 0.046
Size of institution (number of beds) -0.0001 0.086
R2=0.93, p<0.001
In theories of diffusion of innovations, it is well known that in an early phase only a
small group of enthusiastics uses the product, the early adopters [28]. In the
transition phase from prescribing by early adopters to prescribing by the majority,
large differences in level of prescribing can appear. This was seen as well in the early
phases of stent prescribing [29]. Therefore, it would be interesting to see what the
pattern of prescribing of abciximab and other GP IIb-IIIa blockers looks like in a few
years. It takes time before new knowledge is generally diffused into medical practice
[30]. Our study presents just a snapshot of a field with rapid developments. In 1998
abciximab was the only available representative of a new category of drugs. By now,
two drugs with the same mechanism of action have already entered the market:
eptifibatide and tirofiban [31-35].
CONCLUSION
In conclusion, in 1998 patterns of abciximab prescribing varied significantly between
PTCA centers. Since there was no agreement on the appropriate indications to select
patients eligible for treatment, other factors such as budget and investigatorship had
a large influence on the level of prescribing. The cost-effectiveness issue of whom to
treat and whom not needs to be made explicit and ultimately needs to be agreed
upon by cardiologists and budget keepers on a national level. More innovative
biotechnology drugs are about to enter the market in the coming years. This
example has illustrated the uncertainties and practice variation that can be
associated with that. Government and health care professionals should be aware of
that and try to prevent the resulting retreat from evidence based medicine into
budget based medicine.
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ABSTRACT
Aim and methods - In comparison with other biotech substitutions, the adoption of
recombinant Factor VIII (rFVIII) has been relatively slow. We sent a postal
questionnaire to all Dutch hemophilia patients, to determine which factors predict
whether a patient uses plasma derived FVIII (pdFVIII) or rFVIII and to investigate
patients’ opinions about both products.
Results - Older age, infection with HIV or hepatitis C, and having family members
who use pdFVIII, were negatively associated with switching from pdFVIII to rFVIII.
Innovativeness, having family members who use rFVIII, and treatment in a large
hemophilia treatment center, were positively associated with switching.
Generally the respondents did not see large differences between rFVIII and pdFVIII,
except for the risk of infections and the knowledge on long-term effects (both larger
for pdFVIII).
Conclusion - Although hemophilia patients may well represent one of the most
empowered patient groups, physicians appear to have been very influential in
choosing between pdFVIII and rFVIII.
Factor VIII: patients’ preference
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INTRODUCTION
Starting in 1982 with the introduction of recombinant human insulin, over
50 biopharmaceuticals have been introduced to the market in the last two
decades [1,2]. Attitudes towards modern biotechnology and life sciences are
ambivalent. On the one hand, these developments are considered as a major force for
medical progress and innovation. On the other hand there is concern about the
health, environmental and social hazards of advanced technologies. People are aware
that scientific developments may have negative effects as well. This is true especially
for hemophilia patients.
The discovery in 1964, that Factor VIII is concentrated in cryoprecipitate, was an
enormous step forward in the treatment of hemophilia, which until then could only
deploy infusion of whole plasma. Further purification let to what is generally called
plasma derived Factor VIII (pdFVIII). The enthusiasm that greeted these advances,
however, was soon dimmed by the discovery that many products were contaminated
with viruses. In the Netherlands, 16-17% of the hemophilia patients who were treated
with clotting factor products before 1985 became infected with the human
immunodeficiency virus (HIV) [3,4]. In addition, the large majority (about 80%) of
patients have been infected with hepatitis C virus [5,6]. Since the early 1980s
methods such as donor screening, heat treatment, solvent detergent treatment and
immunoaffinity purification, have been developed to inactivate infectious agents.
Infections with HIV have not been documented after 1985 in the Netherlands, and
Factor VIII (FVIII) concentrates have been free from hepatitis C virus since 1991 [5].
Because of this history of infectivity with plasma derived clotting factors, one may
have expected that recombinant Factor VIII (rFVIII), which was introduced in the
Netherlands in 1995, would receive a warm welcome and would be quickly adopted
by the market. This, however, has not been the case. While recombinant human
insulin and recombinant human growth hormone have quickly replaced their non-
biotech counterparts, and while the recombinant follitropins have captured 80%
market share 4 years after their introduction, rFVIII is still only used by about 50%
of patients in the Netherlands [7-10] .
Apparently, doctors or patients are hesitant to adopt rFVIII. Reasons for that could
be several. They may fear some long-term unforeseen negative effect caused by the
use of rFVIII. They may be afraid of increased antigenicity of rFVIII, as this was
debated in the early 1990s [11,12 ,13], even though the current scientific believe is
that this is not the case [14-16] Loyalty towards the Central Laboratory of the
Netherlands Red Cross Blood Transfusion Service (CLB), the major provider of
pdFVIII in the Netherlands, might be another reason. Since in the past the
prevalence of HIV positivity was highest in countries that predominantly used FVIII
preparations derived from plasma of paid donors from the United States [4], there
might be a preference for a Dutch not-for-profit organisation with non-paid donors.
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Also, it has been argued that it is not possible to switch all patients to rFVIII, even if
they would want so, because the supply of rFVIII is not sufficient [10]. Indeed, at the
time of our study there was a sudden shortage of rFVIII, as Bayer, one of the major
producers of rFVIII, had just suspended market release for its worldwide market.
[17] In addition, there may be doubts about the advertised increased safety of rFVIII
with regard to transmission of infections. The first rFVIII preparations contained
plasma derived albumin as a stabiliser. In 1999 and 2000, three virtually albumin-
free formulations (Refacto®, Kogenate Bayer® and Helixate NexGen®) were
introduced. They contain 1000 times less plasma derived albumin than the former
formulations, and have an additional detergent based purification step, further
reducing the potential for virus transmission [18].
As far as we know, the factors that underlie the choice for either plasma derived or
rFVIII have never been systematically studied. Who is the most influential in
choosing between pdFVIII and rFVIII: the doctor or the patient? Can the adoption of
rFVIII be predicted from medical characteristics such as severity of the disease,
treatment modality, or infections contracted through the use of clotting factors (HIV,
hepatitis C)? What do patients actually think on the safety and antigenicity of rFVIII
and pdFVIII? To address these questions we sent a postal questionnaire to all
hemophilia patients in the Netherlands. The objective was to investigate the opinions
of hemophilia A patients on the choice between pdFVIII and rFVIII, and to
determine which factors predict whether a patient uses pdFVIII or rFVIII.
METHODS
Mailing procedure
The study was carried out as part of the Hemophilia in the Netherlands 5 (HiN-5)
project. During the past 30 years, the effects of changes in hemophilia treatment
have been monitored by four nation-wide postal surveys among Dutch hemophilia
patients conducted in 1972, 1978, 1985 and 1992. In April 2001, patients received a
letter about the forthcoming HiN-5 study on hemophilia. Where possible, this
announcement was sent by their physician. Other patients were first informed by the
Dutch Hemophilia Patients Society or directly by the Study Group HiN-5. All
hemophilia patients who were listed with the hemophilia treatment centers, with the
Dutch Hemophilia Patients Society, or on updated mailing lists from previous
survey(s) were included in the mailing. After an extensive search for addresses the
questionnaire was sent to 1,566 patients in May 2001. The closing date for data
collection for the current study was set at 12 September 2001.
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Content
The prestructured questionnaire in 2001 was largely based on the four previous
questionnaires. For this study we added specific questions which followed from a
prior model which we developed that incorporated all factors we assumed to be
predictive of the choice between recombinant and plasma derived clotting factors. To
formulate this model and these questions, literature on clotting factors was
consulted, and interviews were held with patients and representatives of the Dutch
Hemophilia Patients Society, hemophilia treating physicians, and clotting factor
producers. Before the questionnaire was actually sent out, a small number of
patients and a panel of experts was asked to complete the questionnaire and to
give their comments. These ‘pilots’ were helpful in optimising the structure and
content of the questionnaire.
Questions on age, type of hemophilia, severity of disease, treatment modality,
inhibitor formation, infectious diseases (HIV, hepatitis C), treatment center,
membership of the Dutch Hemophilia Patients Society, education level and net
income were routinely included in the questionnaire. Items were added on: attitude
towards innovations (innovativeness), aversion against switching, empowerment,
first clotting factor used, current product used, consideration of future product
switch, clotting factor used by family members, number of family members with HIV
or hepatitis C through the use of clotting factors, most important influence in clotting
factor choice (respondent himself, physician, or both equally influential), physician’s
advice (recombinant, plasma derived or neutral), preference for a specific producer
(Dutch over foreign, not-for-profit over for-profit), and opinion on albumin-free
formulations of rFVIII (5-points scale: large deterioration, deterioration, no
difference, large improvement, improvement). The first three items are described in
Table 1, and were included at the beginning of the questionnaire, before the issue of
recombinant versus plasma derived clotting factors was introduced.
From a list of 8 characteristics which may be important to patients in choosing
between different clotting factor products (price, effectiveness, user friendliness,
producer’s image, knowledge on long-term effects, risk of infections, risk of product
shortages and risk of inhibitor formation), respondents were asked to rank the five
most important characteristics (5 through 1 points). The average rating for a product
characteristic could be 5 at the most (if all respondents ranked the characteristic as
the most important one), and 0 at the least (if none of the respondents selected the
characteristic in the top 5 most important). In addition, their opinion on the 8
characteristics was asked on a 5-points scale (-2 very favourable for plasma, -1
favourable for plasma, 0 the same for plasma and recombinant, 1 favourable for
recombinant, 2 very favourable for recombinant).
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Table 1 Selection of items included in the questionnaire
Innovativeness
- If a new treatment for hemophilia would become available, e.g. gene therapy,
how would you react to that?
1 very negative
2 negative
3 neutral
4 positive
5 very positive
- In general, if a new treatment for hemophilia would become available, when
would you adopt it?
1 never
2 when the treatment can hardly be escaped anymore
3 when the treatment is proven superior in a large number of patients,
4 when the treatment succesful in some other patients
5 immediately
- With regard to the adoption of the latest insights and treatments in health care,
patients can be categorised into five groups. In which group would you place
yourself?
1 laggards (10%)
2 late majority (35%)
3 early majority (35%)
4 early adopters (15%)
5 innovators (5%)
Empowerment
- I always make clear to my physician which treatment I prefer myself.
- I am well informed about the different treatment possibilities for hemophilia.
- I follow my physician’s advice without questioning.*
- Besides the information my physician gives me, I look for information about
clotting factors myself, as well.
- When my physician proposes a certain treatment, I ask if there are other
treatment options as well.
1 not at all
2 a little bit
3 quite a lot
4 very much
Aversion against switching
- Switching from one clotting factor product to another may cause problems (e.g.
inhibitor formation).
- If you are doing well with your current treatment, you should never change to
another clotting factor product.
1 totally disagree
2 disagree
3 neither agree nor disagree
4 agree
5 totally agree
* reverse coding
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Analysis
As we were interested in the choice between, and the opinions about rFVIII and
pdFVIII, we included in the analysis only patients with hemophilia A who had used
FVIII during the 1½ year preceding our questionnaire, and for whom we knew
whether the first clotting factor product used had been recombinant or plasma
derived. The type of first clotting factor used (recombinant or plasma derived) was
investigated in relation to year of birth. In this analysis year of birth was used as a
marker for the year of first treatment.
Subsequently, to study switching behaviour, we included only those respondents who
had started on plasma derived clotting factor, and excluded the respondents who had
started on rFVIII, as switching from rFVIII to pdFVIII is very rare. Odds ratios (OR)
for the association with switching from pdFVIII to rFVIII were calculated by use of
the logistic regression technique for all factors in our prior model. The factors that
were statistically significantly associated with switching in these univariate analyses
were subsequently included in a multivariate logistic regression model to calculate
the adjusted ORs. The severity of hemophilia was classified according to the residual
percentage of FVIII clotting activity: severe (<1%, i.e. <1IU/dl), moderate (1-5%),
or mild (>5-40%).
Hemophilia treatment centers were categorised into ‘small’ and ‘large’ centers
according to the number of respondents (n ≤10 respondents, respectively n >10).
Different items that were designed to measure one common factor, such as e.g. the
three items on innovativeness, were clustered together (as the average over the
items), if Crohnbach’s alpha for correlation was ≥0.70.
For each respondent, the opinion on each of the eight product characteristic was
multiplied with the importance attached to that characteristic. The sum of these eight
multiplications was used as a summarising measure of the respondent’s opinion on
recombinant versus plasma derived clotting factor (range -30 to 30).
RESULTS
Response, participants and first use
The total response to the questionnaire was 69% (n=1,084). Respondents who were
excluded from the analysis were patients who did not have hemophilia A (n =188),
patients who had not used FVIII in the past 1½ year (n=337, mainly mild hemophilia
A), and patients for whom the type of first clotting factor used was not known
(n=22). In total, 537 respondents were eligible for analysis. Characteristics of the
respondents are presented in Table 2.
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Table 2 Characteristics of the participants
First use was rFVIII
(n=84)
First use was plasma
derived clotting factor
(n=453)
Mean age in years (95% CI) 9 (6-11) 37 (35-38)
Male 84 (100) 444 (99)
Severity of disease
mild 25 (31) 85 (19)
moderate 16 (20) 81 (18)
severe 41 (50) 277 (63)
Treatment modality
Home treatment 27 (33) 318 (72)
Profylactic treatment 37 (45) 234 (53)
Infectious diseases
HIV positive 0 (0) 26 (6)
Hepatitis C 4 (5) 284 (67)
(Past) development of inhibitor 5 (7) 51 (13)
Member of Hemophilia Society 72 (86) 344 (77)
High income 39 (62) 215 (52)
High education 30 (37) 167 (39)
All values are No. (%) except where otherwise indicated.
95% CI=95% confidence interval
First treatment had been with rFVIII for 16% (n=84) of the participants, and with
plasma derived clotting factor for 84% (n=453). Because of the consensus among the
Dutch hemophilia treaters to treat previously untreated patients (PUPs) with rFVIII,
we expected that the large majority of respondents who started using clotting factor
treatment after 1994 would start on rFVIII. As we did not have data on the year of
first treatment, we used year of birth as a marker. Of all 537 respondents, 12% (n=67)
was born after 1994. In Figure 1 it can be seen that these respondents generally
started on rFVIII.
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Figure 1 Percentage of respondents who started on rFVIII versus year of birth
Subsequent switch
For the analysis of subsequent switching behaviour we included the 453 respondents
whose first treatment had been with plasma derived clotting factors. Of these 45%
(n=206, switchers) had switched from pdFVIII to rFVIII and 55% (n=247,
nonswitchers) continued to use pdFVIII at the time of our questionnaire.
Patient characteristics
The average age of the switchers (31 years, 95% confidence interval (CI) 28-33 years)
was lower than of the nonswitchers (41 years, 95% CI 39-44 years). Switching was
not associated with severity of disease, history of inhibitor formation, and home
treatment (see Table 3). Respondents who had been infected with HIV or hepatitis C
switched less to rFVIII than respondents who had not been infected (ORadj. 0.3, 95%
CI 0.1-1.0). The fact whether respondents did or did not have family members who
became infected with HIV or hepatitis C through the use of clotting factors, was not
associated with switching behaviour. The more family members were using pd FVIII,
the less the respondents themselves had switched from pdFVIII to rFVIII (ORadj. 0.7,
95% CI 0.5-0.9). On the other hand, the more family members were using rFVIII, the
more the respondents had switched to rFVIII (ORadj. 2.7, 95% CI 1.6-4.3).
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Table 3 Univariate and multivariate logistic regression model of switching
versus nonswitching
ORcrude
(95% CI)
ORadj.
*
(95% CI)
Parameters included in the multivariate model
Patient characteristics
Age 0.97 (0.96-0.98) 0.98 (0.96-1.0)
HIV positivity 0.4 (0.2-1.0) 0.3 (0.1-0.9)
Hepatitis C infection 0.4 (0.3-0.6) 0.4 (0.2-1.0)
No. of family members on plasma 0.7 (0.6-0.9) 0.6 (0.5-0.9)
No. of family members on recombinant 2.0 (1.4-2.6) 2.7 (1.6-4.4)
Innovativeness (1-5) 1.3 (1.0-1.8) 1.8 (1.1-3.1)
Profylactic treatment 1.5 (1.0-2.2) 1.4 (0.7-2.8)
Membership of Hemophilia Patients Society 1.6 (1.0-2.6) 1.4 (0.6-3.4)
Empowerment (1-4) 1.3 (1.0-1.8) 1.2 (0.7-2.1)
High income 1.4 (1.0-2.1) 1.4 (0.8-2.7)
Treatment center
Size of treatment center (small/large) 5.6 (2.6-12.2) 3.2 (1.1-9.8)
Opinions
Pro-recombinant opinion (-30 through 30) 1.1 (1.1-1.2) 1.1 (1.1-1.2)
‘Never change a winning team’ (1-5) 0.7 (0.6-0.9) 0.8 (0.6-1.1)
Preference for a Dutch producer (1-5) 0.6 (0.5-0.7) 0.8 (0.5-1.1)
Preference for not-for-profit producer (1-5) 0.7 (0.6-0.8) 0.8 (0.6-1.1)
Other parameters from our prior model
Severity of disease 1.1 (0.9-1.4)
(Past) development of inhibitor 1.5 (0.8-2.7)
Home treatment 1.4 (0.9-2.2)
No. of HIV positive family members 0.7 (0.3-1.3)
No. of family members with hepatitis C 1.2 (0.8-1.8)
High education 1.0 (0.7-1.5)
Agreement with ‘Switching might cause
problems, e.g. inhibitors’ (1–5)
0.9 (0.8-1.2)
95% CI=95% confidence interval
* Adjusted for all other parameters in the model
The three items on innovativeness (Crohnbach’s alpha 0.70), as well as the five
items on empowerment (Crohnbach’s alpha 0.75) were clustered together in the
analysis. In univariate analyses both were positively associated with switching from
pdFVIII to rFVIII.
Membership of the Dutch Hemophilia Patients Society was also higher in the
switchers than in the nonswitchers (81% versus 73%). Net income and education
correlated only weakly (Crohnbach’s alpha 0.49), and therefore they were not
clustered together as one measure of socio-economic status. In univariate analysis
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high income was positively associated with switching, while high education was not.
After adjustment for the other parameters in the model (see Table 3), the point
estimates for the influence on switching of empowerment, income and membership
of the Dutch Hemophilia Patients Society, and stayed very much the same, only the
confidence intervals were broader. The influence of innovativeness increased after
adjustment.
Influence of treating physician
The 453 respondents were treated in 30 different treatment centers. Eighty-eight
percent of the respondents were treated in 7 large centers (median number of
respondents per center 31). In these large centers the percentage of respondents who
had switched from pdFVIII derived to rFVIII varied from 26% to 71% (median 40%).
In the small centers (n=23, median number of respondents per center 1) the
percentage of switchers varied from 0% to 100% (median 0%). As such, being treated
in a large hemophilia treatment center was positively associated with switching from
pdFVIII to rFVIII (ORadj. 3.2, 95% CI 1.1-9.8).
To the question who was the most influential in the choice of the type of FVIII
product you are using, 54% of the participants answered ‘my treating physician’, 25%
‘both me and my physician’, and 21% ‘me myself’. There was no difference between
switchers and nonswitchers in this respect. Of the nonswitchers 44% of the
respondents indicated that their physician had spoken with them about the choice
between rFVIII and pdFVIII. Of the respondents who did discuss the topic with their
treating physician (both switchers and nonswitchers), 79% indicated that it was their
physician who brought up the topic. Only 21% initiated the conversation themselves.
Of the nonswitchers who discussed product choice with their physician, 24% was
advised to use pdFVIII, 8% to use rFVIII, and 68% to make their own decision. In the
switchers these percentages were 1%, 52%, and 39% respectively.
Opinions
Of the nonswitchers, 21% (n=45) was thinking about switching to rFVIII in the future
and 79% (n=167) wanted to continue using pdFVIII. Forty percent of the switchers
and 23% of the nonswitchers knew about the introduction of albumin-free
formulations of rFVIII. Only 157 of the 453 participants gave an opinion on this
development. Of these 157, 89% considered the introduction of albumin-free
formulated rFVIII products either a small (n=52) or a big (n=56) improvement. Of
the 45 nonswitchers who indicated to be thinking about switching to rFVIII, 21 (47%)
did so since the introduction of the albumin-free formulations, and 25 (53%) already
before this introduction.
The correlation between the two items measuring aversion against switching of
clotting factor in general was too low to cluster them together in the analysis
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(Crohnbach’s alpha 0.42). With the statement ‘Switching from one clotting factor
product to another may cause problems’, most respondents, both switchers and
nonswitchers, neither agreed nor disagreed. With the statement ‘If you are doing well
with your current treatment, you should never change to another clotting factor
product’, 39% of the switchers and 51% of the nonswitchers agreed.
Figure 2 shows how switchers and nonswitchers respectively, rated the importance of
the 8 predefined product characteristics in choosing between rFVIII and pdFVIII.
Overall, effectiveness and risk of infections were the most important characteristic.
Switchers attached more weight to the risk of infections compared to nonswitchers,
while nonswitchers attached more importance to effectiveness. Risk of inhibitor
development and knowledge on long-term effects rank number 3 and 4 for switchers,
and number 4 and 3 for nonswitchers, respectively.
The large majority of the participants (73%) considered rFVIII and pdFVIII equally
effective (see Figure 3A). The remaining minority was divided: switchers believed
rFVIII to be more effective, while nonswitchers believed the opposite. Also on the
topic of inhibitor formation, the majority of the participants (57%) did not see a
difference between rFVIII and pdFVIII. Thirty percent of the respondents were of the
opinion that the antigenicity of pdFVIII is higher than of rFVIII. At this respect,
there were no differences between switchers and nonswitchers (Figure 3B).
Eighty-four percent of the participants thought that the risk of infection is larger with
pdFVIII than with rFVIII (Figure 3C). On the other hand, for rFVIII less knowledge
is available about the long-term effects, was the opinion of 69% of the respondents
(Figure 3D). Switchers answered these questions more in favour of rFVIII than
nonswitchers did.
The large majority of the participants (67%) rated the image of the producers of
rFVIII and of pdFVIII as equally good. To the remaining switchers the image of
rFVIII producers was better, while the opposite was true for the remaining
nonswitchers. Sixty-six percent of the switchers and 83% of the nonswitchers agreed
with the statement ‘I prefer to use FVIII from a Dutch producer over FVIII from a
foreign producer’ (see Figure 3E). Similarly, 50% of the switchers and 67% of the
nonswitchers agreed with the statement ‘I prefer to use FVIII from a not-for-profit
producer over FVIII from a for-profit producer’ (Figure 3F).
On the topic of user friendliness, the majority of the participants, 58% of switchers
and 78% of nonswitchers respectively, did not see a difference between rFVIII and
pdFVIII. The remaining minority was divided: switchers more in favour of rFVIII
and nonswitchers more in favour of pdFVIII.
With respect to the risk of product shortages, the participants were divided: 26%
thought that shortages are more likely for rFVIII products than for pdFVIII, while
42% thought the other way around. There was no difference between switchers and
nonswitchers on this topic.
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Figure 2 Importance of the different product characteristics in choosing between
pdFVIII and rFVIII: average ratings of switchers and nonswitchers
To the question ‘Have you been troubled by shortages of FVIII product during this
year or last year (2000+2001)?’ 27% (n=56) of switchers and 7% (n=16) of
nonswitchers answered in the affirmative.
The summarised score for respondents’ opinions on product characteristics was 6
(95% CI 5-7) for switchers, and -0.3 (95% CI -1 – 1) for nonswitchers.
DISCUSSION
Approximately 6 years after its introduction, 54% of recent FVIII users in the
Netherlands used rFVIII. From 1995 onwards, nearly all children who had to be
treated with FVIII for the first time (PUPs), were prescribed rFVIII. From all
respondents who had started using pdFVIII in the past, 45% switched to rFVIII and
55% continued using pdFVIII at the time of our questionnaire.
The percentage of respondents who had switched from pdFVIII to rFVIII varied from
0% to 100% in small centers and from 26% to 71% in large centers. From this large
variability one may conclude, that the treating physician strongly influences product
choice. This conclusion is further strengthened by the fact that only 21% of the
respondents regarded themselves as the most influential person in choosing a certain
type of clotting factor and 54% indicated their doctor as such.
Nevertheless, the fact that innovativeness, opinion on rFVIII, and the type of product
family members are using, are associated with switching behaviour, may confirm the
hypothesis that there is a patient influence, as well.
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Figure 3 Opinions of switchers and nonswitchers on various topics
Figure 3a Effectiveness Figure 3b Risk of inhibitor formation
Figure 3c Risk of infections Figure 3d Knowledge on long-term
effects
Figure 3e I prefer a Dutch producer Figure 3f I prefer a not-for-profit over
over a foreign producer a for-profit producer
Here, however, the cross sectional characteristic of our data complicates
interpretation of the results. We cannot determine whether a favourable opinion on
rFVIII caused people to switch, or whether the switch caused the favourable opinion.
The same holds true for the influence of family members using a certain type of
product. Innovativeness, however, is an independent patient characteristic, and as
such its association with switching behaviour does show that the patients themselves
also have a say in the choice between pdFVIII and rFVIII.
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We also cannot firmly conclude whether age, HIV infection, and hepatitis C infection
are associated with switching behaviour through physicians’ policies or through
patient preferences. As there are no treatment guidelines in the Netherlands
indicating that HIV negatives or younger people should preferentially be treated with
rFVIII, the mechanism through patient preferences is the most likely. Probably,
younger people are more willing or demanding to switch to a new treatment than
older people are. We found no significant difference between HIV positives and HIV
negatives with regard to their opinion on the risk of infections for rFVIII compared
to pdFVIII. However, the number of HIV positives (n=26) was small and they
constituted a selected group as many HIV positives have died already.
There seems to be a weak association between preferring a Dutch, or a not-for-profit
producer, and continued use of pdFVIII. Since pdFVIII is available from a non-for-
profit Dutch producer, and rFVIII is not, this association seems logical. As there are
no clear guidelines on which patients to switch from pdFVIII to rFVIII, we
hypothesised that physicians mainly switched those patients to rFVIII who especially
asked for it, which we expected to be the most empowered patients, members of the
Dutch Hemophilia Patients Society, or patients with a higher social economic status.
Except for the absence of an effect of high education, our hypothesis is indeed
confirmed by the data. This, again, points in the direction that the patient does play a
part in the adoption of rFVIII as well, in addition to the strong influence of the
treating physician.
After the many years of discussion about the perceived increased antigenicity of
rFVIII, it is remarkable that only 13% of the respondents thought rFVIII to be more
antigenic than pdFVIII. Generally the respondents do not see large differences
between rFVIII and pdFVIII, except for the risk of infections (larger for pdFVIII) and
the knowledge on long-term effects (larger for pdFVIII, as well).
Given that the Dutch hemophilia treaters prescribe rFVIII to all incident users, why
do they not convert all prevalent patients from pdFVIII to rFVIII, as well? One often
heard answer is that the supply of rFVIII would not be sufficient. Although, there
indeed was a shortage of rFVIII at the time of our questionnaire, the validity of this
answer may be questioned, as countries like Denmark and Scotland did succeed in
switching all their hemophilia patients from pdFVIII to rFVIII in response to the
Bovine Spongiform Encephalopathy (BSE) crisis [19]. Our current study provides
insight only in the opinions of hemophilia patients. It would be very worthwhile to
study hemophilia treaters as well. Although hemophilia patients may well represent
one of the most empowered and well informed patient groups, our results
suggest that, nevertheless, physicians are a major influence in the relatively slow
diffusion of rFVIII.
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ABSTRACT
Aim and methods - The diffusion of recombinant Factor VIII (rFVIII) has been
relatively slow in the Netherlands. In a previous study among hemophilia patients we
found that physicians play an important part in the choice between plasma derived
Factor VIII (pdFVIII) and rFVIII. The objective of the current study was to
investigate the opinions of hemophilia treating physicians on this topic.
Results - On average, the physicians prescribed rFVIII to 56% of their patients. This
percentage varied widely between centers. Only one doctor would choose to use
pdFVIII if he would suffer from hemophilia A himself and 74% would choose to use
rFVIII. Previously untreated patients were preferentially treated with rFVIII by 95%
of the physicians, and young patients by 81%. HIV status, severity of the disease,
prophylaxis, and type of product used by family members were no reasons for most
physicians to change their advice.
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INTRODUCTION
In 1995, recombinant Factor VIII (rFVIII) was introduced in the Netherlands for the
treatment of patients with hemophilia A, as a possible substitute for plasma derived
Factor VIII (pdFVIII ). Now, six years later, rFVIII is used by about 50% of the Dutch
patients, while the other 50% continue to use pdFVIII [1]. Compared to other
biotechnology substitutions, the diffusion of rFVIII is relatively slow. In the
Netherlands, both recombinant human growth hormone and recombinant human
insulin quickly reached a complete replacement of their organic counterparts, and
the recombinant follitropins have captured an 80% market share within 4 years [2-
4]. Also in comparison to other countries, the diffusion of rFVIII in the Netherlands
has been slow. Ireland, Scotland and Denmark have completely switched from
plasma derived to rFVIII as a matter of health policy [5]. In France rFVIII represents
80% of all FVIII used [6], and in Germany it represents 50% [7].
In a previous study, we investigated determinants of the diffusion of rFVIII, by use of
a postal questionnaire among Dutch hemophilia patients. We found that from 1995
onwards, nearly all children who had to be treated with FVIII for the first time
(previously untreated patients, PUPs), were prescribed rFVIII. Older age, human
immunodeficiency virus (HIV) positivity, infection with hepatitis C, and having
family members who use pdFVIII, were negatively associated with switching from
pdFVIII to rFVIII. A positive attitude towards innovations, a positive opinion on
rFVIII, and having family members who use rFVIII, were positively associated with
switching. In addition, there was a strong influence of the center in which patients
were treated. The proportion of patients who had switched from pdFVIII to rFVIII
varied from 0% to 100% in the small centers, and from 26% to 71% in the large
centers. Only 21% of the patients considered themselves as the most influential
person in choosing a certain type of clotting factor, while 54% considered their
physician to be this person.
The objective of the current study was to investigate the opinions of hemophilia
treating physicians on the choice between pdFVIII and rFVIII. The outcomes were
compared with the outcomes from our previous study in patients.
METHODS
Mailing procedure
In May 2001, we sent a postal questionnaire to the 26 directors of the licensed
hemophilia care centers in the Netherlands. Additional questionnaires were
included, which they were asked to distribute among the colleagues in their
department who autonomously treated hemophilia patients as well. To enable us to
measure the response, we requested the directors to report to how many of their
colleagues they had given a questionnaire. Reminders were sent after two weeks.
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Content
The additional questionnaires for the colleagues were identical to the directors’
questionnaires, except that only the directors were asked to fill the characteristics of
their department’s patient population: number of patients with hemophilia A and B,
severity, number of patients on plasma derived and on recombinant clotting factors,
number of patients with inhibitors and number of infections with HIV and
hepatitis C.
The questionnaire for doctors was based on the questionnaire we developed for
patients. To enhance comparability the following items have been copied from the
patient’s questionnaire: aversion against switching, most important influence in
clotting factor choice (physician himself, the patient, or both equally influential),
preference for a specific producer (Dutch over foreign, not-for-profit over for-profit),
and opinion on albumin-free formulations of recombinant Factor VIII. The items on
aversion against switching were located at the beginning of the questionnaire, before
the issue of recombinant versus plasma derived clotting factors was introduced. Also,
we copied the question where, from a list of eight (price, effectiveness, user
friendliness, producer’s image, knowledge on long-term effects, risk of infections,
risk of product shortages and risk of inhibitor formation), respondents were asked to
indicate which they found the five most important characteristics. Their opinion on
the eight characteristics was asked on a 5-points scale (-2 very favourable for plasma,
-1 favourable for plasma, 0 the same for plasma and recombinant, 1 favourable for
recombinant, 2 very favourable for recombinant).
We also included specific questions on the personal characteristics of the responding
doctor, such as age, sex, year of graduation from medical school, medical specialism,
and whether they treated mainly adults, children, or both. In addition, the
respondents were asked which type of clotting factor they would choose for
themselves if they had severe hemophilia (plasma derived, recombinant or no
preference). Before the questionnaire was actually sent out, two doctors were asked
to complete the questionnaire and to give their comments. This ‘pilot’ was helpful in
optimising the structure and the content of the questionnaire.
Analysis
To calculate the response, we assumed that directors who, after the reminder, did not
respond to our questionnaire, had not distributed it among colleagues either. The
departments were categorised into three groups: departments treating mainly adults,
departments treating mainly children, and departments treating both. Personal
characteristics of the respondents were described, as were the influences of patient
characteristics on the doctor’s advice about rFVIII versus pdFVIII. The personal
opinions of doctors on matters related to the choice between pdFVIII and rFVIII
were described and were compared with the opinions patients expressed in our
Factor VIII: physicians’ preference
123
previous study. Details about this study, including the mailing procedure and the
content of the questionnaire, have been described in the previous chapter.
RESULTS
Response and participants
Eighteen directors returned the questionnaire (response 69%). They reported that
they had forwarded the questionnaire to 18 colleagues. Overall, including colleagues,
we received 30 filled-out questionnaires (response 30/44=68%). Together, the
directors reported to take care of 1,316 patients with hemophilia A and 169 patients
with hemophilia B. As such, our sample represents the treating physicians of >95% of
all Dutch hemophilia patients. One director was excluded because he did not see
hemophilia patients anymore. A total of 29 participating physicians, from 17
departments, remained for analysis.
Mean age of the respondents was 47 ± 3 years. Fifty-nine percent was male, and the
average year of graduation from medical school was 1980. Seven percent (n=2) were
MDs, 11% (n=3) internists, 46% (n=13) hematologists, 21% (n=6) pediatricians, and
14% (n=4) pediatric hematologists.
Departments
In total, the 17 departments took care of 1,236 FVIII users, 696 of which were using
rFVIII (56%). However, this percentage varied widely between the departments. In
the departments where they treated mainly adults (n=8; 501 patients), the
proportion of patients using rFVIII ranged from 0 to 75% (median 12%), and in the
departments where they treated mainly children (n=6; 167 patients), it varied
between 0 and 100% (median 84%). On average the proportion of patients using
rFVIII was 2.9 times higher in departments treating children than in departments
treating adults (p=0.02).
Patient characteristics
Seventy percent of the 29 physicians indicated that they had discussed the choice
between pdFVIII and rFVIII with all their patients. When asked on whose initiative
their patients had generally switched from pdFVIII to rFVIII, 11% of the doctors
answered that this had been on the initiative of the patient, 44% answered it was
their own initiative (the physician’s), 30% answered that it varied, and 15% answered
that none of their patients switched from pdFVIII to rFVIII. Only one respondent
indicated the patient to be the most influential in choosing a FVIII product,
41% (n=11) indicated themselves (the physician), and 56% (n=15) said both were
equally influential.
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Table 1 To which patients do you tend to advise rFVIII instead of pdFVIII?
Results are given in percentages (n=22).
Patient
characteristic
Doctor’s preference to advise rFVIII instead of pdFVIII
Severity of the
disease
severe
hemophiliacs
no preference mild hemophiliacs
14 76 10
Previously un-
treated patients
PUPs no preference previously treated
patients
(PUPs) 95 5 0
Age young patients no preference old patients
81 19 0
HIV HIV positives no preference HIV negatives
15 55 30
Prophylaxis patients on
prophylaxis
no preference patients not on
prophylaxis
5 91 5
Home treatment patients on home
treatment
no preference patients not on
home treatment
0 100 0
Family members
using rFVIII
patients with family
members using
rFVIII
no preference patients without
family members
using rFVIII
24 76 0
Compliance compliant patients no preference non-compliant
patients
5 95 0
Inquirement patients who do
inquire about rFVIII
no preference patients who do not
inquire about rFVIII
10 90 0
Fear for BSE patients afraid of
BSE
no preference patients not afraid of
BSE
29 71 0
HIV=Human Immunodeficiency Virus, BSE=Bovine Spongiform Encephalopathy
Five doctors (17%) gave the same advice to all patients: one advised all his patients to
use pdFVIII, two advised all their patients to use rFVIII, and two remained neutral
and had their patients decide for themselves. The remaining 22 doctors gave
differential advices. The reasons given for this were the limited availability of rFVIII
(23%), differences between patients (32%), or both (46%).
The 22 doctors who gave differential advices were asked to which patients they
tended to advise rFVIII instead of pdFVIII. The results are shown in Table 1.
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Young patients were preferentially treated with rFVIII by 81% of the respondents,
and PUPs by 95%. Thirty percent preferred to give rFVIII to HIV negative patients.
Twenty-nine percent of the doctors were more inclined to advise rFVIII to patients
who were afraid of BSE than to patients who were not afraid of BSE. Twenty-four
percent took in consideration whether family members of the patient were already
using rFVIII.
Opinions
Figure 1 shows how doctors and patients rated the importance of the eight
predefined product characteristics in choosing between different clotting factor
products. The average rating for a product characteristic could be 5 at the most and 0
at the least. Risk of infections and knowledge on long-term effects were the most
important characteristic. Risk of product shortages and of inhibitor development
ranked number 3 and 4.
With regard to the transmission of infections, most doctors believed that the risk is
greater with pdFVIII as compared to rFVIII (Figure 2A). However, knowledge on
long-term effects is better on pdFVIII, was the opinion of the majority of the
physicians (Figure 2B). All doctors were of the opinion that rFVIII and pdFVIII are
equally effective. Also on the topics of inhibitor formation (Figure 2C), user
friendliness, and producer’s image, doctors did not see a difference between pdFVIII
and rFVIII. As can be seen in Figure 2D, opinions on the risk of product shortages
were very much divided. The summarised score for the physicians’ opinions on
product characteristics was -0.6 (95% CI -2.0 – 0.1). If the doctors would suffer from
severe hemophilia A themselves, 74% would choose to use rFVIII, 4% pdFVIII, and
22% had no preference.
Most doctors neither agreed nor disagreed with the statement ‘I prefer to use FVIII
from a Dutch producer over FVIII from a foreign producer’(Figure 2E). The
physicians were either neutral or had a preference for a not-for-profit provider
(Figure 2F).  With the statement ‘Switching from one clotting factor product to
another may cause problems’, most doctors (48%) disagreed (Figure 2G). With the
statement ‘If you are doing well with your current treatment, you should never
change to another clotting factor product’(the notion to never change a winning
team), 38% of the doctors (Figure 2H).
In 2000, two virtually albumin-free formulations of rFVIII (Kogenate Bayer® and
Helixate NexGen®) were introduced. They contain 1000 times less plasma derived
albumin than the former formulations, and have an additional detergent based
purification step, further reducing the potential for virus transmission [8]. Twenty-
six of the 29 doctors (90%) knew about the introduction of albumin-free
formulations of rFVIII.
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Producer's image
User friendliness
Price
Risk of inhibitor development
Risk of product shortages
Effectiveness
Knowledge on long-term effects
Risk of infections
RatingDoctors Patients
Figure 1 Importance of different product characteristics in choosing between
pdFVIII and rFVIII: average ratings of doctors and patients
Twenty-one considered it an improvement (81%), while 5 thought it made no
difference. The introduction of albumin-free formulations of rFVIII did not influence
the policy of 89% of the doctors; only 11% started to prescribe more rFVIII.
DISCUSSION
On average, the physicians prescribed rFVIII to 56% of their patients. This
percentage varied tremendously between departments, both within the group of
departments treating mainly children, as well as within the group of departments
treating mainly adults. Unfortunately, the number of departments was too small to
use multiple linear regression and to investigate whether the opinions or the
innovativeness of the physicians within a department were predictive of the
proportion of patients on rFVIII.
According to expectations, PUPs were preferentially treated with rFVIII by 95% of
the physicians. In the study among patients we found that, even when PUPs were
excluded, people of younger age were more likely to have switched from pdFVIII to
rFVIII than people of older age. Here, 81% of the physicians confirmed that they tend
to advise rFVIII more often to younger patients than to older patients. As a result,
the proportion of patients using rFVIII was on average 2.9 times higher in
departments treating mainly children than in children treating mainly adults. In our
study among patients HIV positivity was negatively associated with switching from
pdFVIII to rFVIII.
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Figure 2 Opinions of doctors and patients on various topics
Figure 2a Risk of infections Figure 2b Knowledge on long-term
effects
Figure 2c Risk of inhibitor formation Figure 2d Risk of product shortages
Figure 2e I prefer a Dutch producer Figure 2f I prefer a not-for-profit over
over a foreign producer a for-profit producer
Figure 2g Switching may cause Figure 2h ‘Never change a winning
problems, e.g. inhibitor team’
formation
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The current study among physicians showed that for most doctors HIV positivity was
not a reason to advise pdFVIII. Therefore, the association must go largely through
patient preferences. Similarly, the influence of the product choice of family members
must be explained by patients’ preferences, as only 24% of the doctors’ indicated that
this was a reason for them to adjust their advice.
The doctors’ ranking of the importance of eight predefined product characteristics
was quite similar to that of the patients. On average, the doctors valued the
difference in risk of infections between rFVIII and pdFVIII as smaller than the
patients did. Also, the knowledge on long-term effects and the risk of product
shortages were assessed more in favour of pdFVIII by doctors than by patients.
Overall, doctors were less in favour of rFVIII than patients were (summarised score
-0.6 versus 3.0). Still, if they had suffered from hemophilia A themselves, only one
doctor would choose to use pdFVIII, and 74% would choose to use rFVIII.
Sixty-eight percent of the 22 doctors who gave different advices to different patients,
indicated that they did so, among other things, because of the limited availability of
rFVIII. In the preparatory interviews, which we conducted to construct the
questionnaire for patients, we learned that the hemophilia treating physicians,
united in the Dutch Hemophilia Treatment Society, had agreed upon the launch of
rFVIII to introduce this new product very gradually to build up experience and to
minimise the risk of shortages. They reasoned that a sudden and complete switch to
rFVIII, would mean the end of the production of pdFVIII by the Central Laboratory
of the Netherlands Red Cross Blood Transfusion Service (CLB), the major provider of
plasma derived FVIII (pdFVIII) in the Netherlands. They preferred to keep both the
CLB and the producers of rFVIII into business, as history had learned that
dependence on a single producer makes one vulnerable. It turns out that physicians
have indeed adhered to this agreement.
In conclusion, the decision of physicians united in the Dutch Hemophilia Treatment
Society to introduce rFVIII only gradually has greatly influenced the diffusion of
rFVIII in the Netherlands. The physicians decided to preferentially prescribe rFVIII
to all PUPs, and this agreement was largely followed. Beside this, they left room to
switch some, but not all patients from pdFVIII to rFVIII. Only in this part patient
preferences do come into play.
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ABSTRACT
Aim and methods - Drugs produced through the use of recombinant DNA techniques
have become an integral part of medical practice. Before recombinant Follicle
Stimulating Hormone (rFSH) was introduced in 1996, FSH purified from the urine of
postmenopausal women had been commercially available since the 1960s. We
analysed the diffusion and the substitution patterns of the different FSH
preparations in the Netherlands.
Results  - The fact that rFSH preparations have batch-to-batch consistency, are free
from urinary protein contaminants and have the potential to be produced in limitless
quantities, is advantageous. The question whether newer, more pure FSH products
are beneficial from the clinical perspective, has not been settled without reasonable
doubt. The price of rFSH is three times as high as the price of the former FSH
preparations. Due to the introduction of rFSH, total FSH expenditures have grown
from €5.0 million in 1995, to €26.8 million in 2000, while the volume increased by
less than 100%. Both the pharmaceutical companies and the payers (government,
insurers) have influenced the patterns of substitution of existing FSH products by
biotech equivalents.
Conclusion - In general, the risk of increasing pharmaceutical costs without clear
clinical benefits has so be set against the risk of strangling innovations. Therefore, a
continuous process of technology assessment is necessary.
From hMG to recombinant FSH
133
INTRODUCTION
Since 1982, with the advent of recombinant human insulin, biotechnology drugs
produced through the use of recombinant DNA techniques have become an integral
part of medical practice. However, this has not happened without striking a blow. As
McKelvey described in her book on the development of recombinant human growth
hormone, biotechnology as a new means to produce pharmaceuticals initially could
not always count on a warm welcome [1]. Public opinion on biotechnology is still not
entirely positive, although most opposition is directed at its application in the food
industry. At the same time, high expectations have been placed on the young biotech
industry since its emergence in the 1980s. The euphoria subsided somewhat during
the 1990s, but at the beginning of this century, with the completion of the Human
Genome Project promises rose again. With pharmaceutical recombinant proteins
being around for almost 20 years, the question of how these products are taken up in
medical practice can now be raised.
In this paper we describe and analyse the case of one specific biotechnology drug,
namely recombinant Follicle Stimulating Hormone (rFSH) and its diffusion into
Dutch medical practice. This case touches on a topic which has previously been
identified as an important issue in the assessment of biotechnology drugs, namely
that rFSH constitutes an alternative option for already existing medicines purified
from an organic source [2]. FSH extracted from the urine of postmenopausal women
has been commercially available already since the 1960s, before rFSH was
introduced in 1996. Similarly insulin, growth hormone, and clotting Factor VIII,
respectively derived from animal pancreas, human pituitary tissue and plasma from
blood donors, had already been in use long before the recombinant versions of these
products became available. In this study we will depict the diffusion patterns of the
different FSH preparations and the consequences of the introduction of the
recombinant products. Data on the sales of FSH products were kindly provided to us
by two of the pharmaceutical companies involved. Information on pivotal articles
published, product introductions and withdrawals, reimbursement decisions, and
the like, will be examined along with diffusion data to obtain insight in the processes
underlying the adoption of these products by clinical practice.
FSH and in vitro-fertilisation (IVF)
FSH containing gonadotropin preparations have been commercially available since
the 1960s. Their first use was in ovulation induction in women with anovulatory
disorders. Since 1978, however, when the first IVF baby was born, they have been
used increasingly in assisted reproductive technologies such as IVF and intra uterine
insemination (IUI). Now, ovulation induction comprises only 10% of gonadotropin
usage, while 90% is used for ovarian hyperstimulation in assisted reproductive
technologies (about half for IVF and half for IUI in stimulated cycles) [3].
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In the Netherlands, a total of 200,000 babies are born each year and 1 in 70 of them
is conceived using IVF techniques [4]. IVF starts with ovarian hyperstimulation
using gonadotropins preparations, containing FSH alone, or combined with
luteinising hormone (LH). In the normal menstrual cycle out of a cohort of 10-20
antral follicles only one obtains dominance over the others and shows continued
growth until ovulation takes place. In IVF, through the administration of FSH (for on
average 10 days, starting on day 2-3 of the menstrual cycle), the maturation of a
larger part of the antral follicle cohort is aimed for. During the stimulation phase
pituitary desensitisation with a Gonadotropin-Releasing Hormone (GnRH) agonist is
accomplished to prevent premature LH activity and ovulation. Those follicles that
will grow up till the preovulatory stage, will then be exposed to a surrogate midcycle
LH peak (by using exogenous human Chorion Gonadotropin) and be punctured
under transvaginal ultrasound observation in order to harvest the oocytes contained
in the follicles (oocyte retrieval). In the laboratory the oocytes will be fertilised and,
after in vitro culture for 3 to 4 days, transferred into the uterus, at which time the
embryos will be at the 8 to 64 cell stage (embryo transfer).
Products
FSH containing gonadotropin preparations can be divided into 4 groups (see Table
1): 1) human Menopausal Gonadotropins (hMG), containing both FSH and LH;
2) urinary FSH (uFSH); 3) highly purified urinary FSH (uFSH-HP); and 4) recombi-
nant FSH (rFSH). Both hMG and uFSH contain a lot of, mainly undefined, urinary
protein contaminants, rendering their purity less than 5%. Through the application
of immunochromatography with monoclonal antibodies against FSH, an increased
purity of more than 95% is achieved in uFSH-HP preparations. Because of the
increased purity, both uFSH-HP and rFSH can be administered subcutaneously as
well as intramuscularly.
Urinary derived preparations contain both intact FSH dimers as well as inactive FSH
subunits. As such, mass is not a good indicator of urinary FSH content and the
amount of gonadotropins in each product is usually expressed in international units
(IU) of FSH activity, as measured in a standardised bioassay.
Although both FSH and LH are required for normal follicular growth and
maturation, the precise role of LH is at present still uncertain. Since it was shown in
the late 1980s that too high concentrations of LH might have negative effects on
fertilisation and embryo quality, the idea arose that pure FSH preparations might be
superior to hMG preparations [5,6]. This hypothesis was tested in several clinical
trials comparing uFSH with hMG with respect to pregnancy rates per IVF treatment
cycle. Statistical significance was not reached in any of these individual studies [5,6].
However, in 1995 a meta-analysis by Daya et al.[5] was published, which included 8
studies and demonstrated a significant difference in favour of uFSH (see Table 2).
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Table 1 FSH containing gonadotropin preparations on the Dutch market
hMG uFSH uFSH-HP rFSH
Full name human
menopausal
gonadotropins
urinary FSH highly purified
urinary FSH
recombinant FSH
Source urine from
post-
menopausal
women
urine from
post-
menopausal
women
urine from
post-
menopausal
women
genetically
modified cells
from Chinese
hamster ovary
Ingredients FSH + LH FSH FSH FSH
Purity <5% <5% >95% 99%
Administration i.m. i.m. i.m. or s.c. i.m. or s.c.
Brands Humegon®
(1963,
Organon)
Metrodin®
(1986, Serono)
Metrodin HP®
(1995, Serono)
Gonal-F®
(1996, Serono)
Pergonal ®
(1970, Serono)
Follegon ®
(1995, Organon)
Puregon®
(1997, Organon)
Menogon ®
(1997, Ferring)
A few years later this finding was contradicted by a meta-analysis by Agrawal et
al.[6], who argued that meta-analyses should take into account the different pituitary
desensitisation protocols used. When pooling together 11 trials with the most
commonly used GnRH agonist protocol (the long protocol), the overall odds ratio for
comparing FSH and hMG was not significant. Although this meta-analysis was
criticised on the issue of study selection bias, re-analysis following the inclusion and
exclusion of selected studies did not change the overall results of the study [7-9].
A second issue that has been addressed in scientific literature, is the comparison
between rFSH and urinary FSH (uFSH or uFSH-HP). The fact that recombinant
preparations have batch-to-batch consistency, are free from urinary protein
contaminants and have the potential to be produced in limitless quantities is
advantageous. The question whether rFSH also leads to more clinical pregnancies
per IVF cycle has been addressed by several clinical trials, none of which reached
statistical significance. However, two meta-analyses pooling together the results of
several trials, did show significant treatment effects in favour of rFSH [10,11]. The
interpretation of these meta-analyses is still debated, since they compare two types of
rFSH (the alpha and beta variant), as well as different types of urinary FSH (uFSH
and uFSH-HP, and in Out’s meta-analysis one study with hMG was also included). In
Daya’s analysis, which received Cochrane status, an absolute increase in pregnancy
rates of 3.7% (95% confidence interval (CI) 0.5-6.9%) was demonstrated comparing
rFSH to uFSH/uFSH-HP (see Table 2).
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Table 2 Published meta-analyses
Meta-
analysis
Preparations
compared
No. of trials
included
(period)
Pregnancies per cycle
(confidence interval)
p
Daya et al.,
(1995)
uFSH
hMG
8 (’86-’94) OR=1.71
RD=8.5%
0.013
0.009
Out et al.,
(1997)
rFSH
uFSH / hMG
3 (’95-’96) -
RD=4.9% (0.1 – 9.6 %)
-
0.044
Daya et al.,
(1999)
rFSH
uFSH / uFSH-HP
12 (’93-’98) OR=1.2 (1.02 – 1.42)
RD=3.7% (0.5 – 6.9 %)
0.03
<0.05
Agrawal et
al., (2000)†
uFSH
hMG
11 (’93-’97) OR=0.77 (0.58 – 1.05) 0.76
† Only the meta-analysis for trials using the long protocol for gonadotropin- releasing
hormone (GnRH) analogs is included.
OR=odds ratio; RD= absolute risk difference
Clinical pregnancy rates are influenced by the fact that in most IVF clinics only a
limited (usually 2-3) number of embryos are transferred into the uterus to prevent
large multiple pregnancies. The surplus of embryos usually is frozen, and
subsequently they can be thawed and used in another IVF cycle without follicular
stimulation (cryopreservation). Therefore, it has been suggested that the number of
oocytes retrieved or the number of cumulative pregnancies, including those from
frozen-thawed embryo transfer cycles, might be more appropriate endpoints. Oocyte
retrieval was shown to be significantly higher for rFSH compared to uFSH/uFSH-HP
in several individual trials [12-15]. The reason for this is not yet fully understood [14].
With regard to cumulative pregnancy rates including cryopreservation, a significant
difference in favour of rFSH has been shown in one large trial by Out et al.[12]. In
many other trials [13-15] and in the latest meta-analysis by Daya et al. [11] this
endpoint was not addressed. The long-term effects of IVF on the growth and
development of derived children are not yet totally clear. Cryopreservation and
thawing involve major cellular changes and may cause (additional) adverse effects.
Although the limited data available on this topic are reassuring, more data are
needed to be able to weigh the advantages of using cryopreserved embryos for
transfer without the need of hyperstimulation, against the possibly negative effects
on the children [16].
Data on the third possible comparison, between rFSH and hMG, are scarce. The
studies that have been conducted so far found no statistically significant differences
with respect to ongoing pregnancy rates [17-19].
From hMG to recombinant FSH
137
The evidence available at this time, comparing the different FSH containing
gonadotropin preparations, concerns their usage in IVF. However, almost half of all
gonadotropins are used in other settings, such as IUI. Very little data is available
comparing the preparations for this indication.
With respect to adverse effects of exogenous FSH administration, no significant
differences have been found between products. The main risk associated with the use
of FSH containing gonadotropin products is the development of the ovarian
hyperstimulation syndrome (OHSS). This is a serious condition characterised by
increased vascular permeability and liquid accumulation in the peritoneal, pleural,
and pericardial cavities, which occurs in 1-2% of cases [20]. The incidence of OHSS
does not differ between products [12,13].
PATTERNS OF SUBSTITUTION
Before 1995
Since the 1960s two hMG products have been available on the market: Humegon®
from Organon, and Pergonal® from Serono. The first change in the market came in
1986 with the introduction of uFSH (Metrodin®, Serono). In 1991, a reference pricing
system was introduced in the Netherlands for the reimbursement of prescription
drugs through community pharmacies. This means that all pharmaceuticals are
clustered into groups with the same therapeutic efficacy. Then a price reference is set
as a reimbursement limit in such a way that there is enough opportunity for the
insured to receive proper medication without co-payment. uFSH was categorised in
the same cluster as hMG with a maximum reimbursement level of €10 per 75 IU.
1995-1996
The uFSH-HP preparations were introduced to the Dutch market in February 1995.
As can be seen in Figure 1A, uFSH-HP and hMG divided the market between them,
leaving only a negligible share for uFSH. While in 1995 hMG products held a more
than 90% share of the market volume and uFSH-HP less than 7%, in 1996 uFSH-HP
had increased to a  23% market share. Metrodin HP® was by far the largest uFSH-HP
provider (>95%); the contribution of Follegon® to the gonadotropins market has
been negligible. The question can be raised whether the growth of uFSH-HP at the
expense of hMG preparations was supply driven or demand driven. Probably it was
both. On the one hand, the meta-analysis presented by Daya et al.[5] in 1995, which
concluded that FSH alone was more effective than hMG, may have increased the
demand for FSH-only products. Since Serono phased out Metrodin® when Metrodin
HP® was introduced, uFSH-HP was the only available pure FSH option. On the other
hand, the choice for FSH-only products may also have partly been forced on the
market, since there was a shortage of hMG products.
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Table 3 History
No. Date Event
(1) February 1995 Introduction of Follegon® and Metrodin HP®
(2) April 1995 Presentation of meta-analysis by Daya et al.[5] at conference
(publication follows in August 1995)
(3) 1995 – 1996 Shortages of hMG (Pergonal® and Humegon®).
Delivery of Metrodin HP® directly to certain pharmacies
below the official price.
May 1996 Production of Pergonal® has been stopped [11].
(4) July 1996 Metrodin® removed from Z-index.
(5) September 1996 Introduction of Gonal-F®.
(6) January 1997 Introduction of Puregon®.
(7) March 1997 Introduction of Menogon®.
(8) April 1997 Start of Puregon® restitution action.
(9) July 1997 Meta-analysis Out et al.[10]
(10) November 1997 Start of Metrodin HP® action: now available at a price equal
to the reimbursement level.
(11) August 1998 Report by Study Group Recombinant Gonadotropins sent to
Health Insurance Fund Council.
(12) February 1999 rFSH gets a separate reimbursement cluster: now fully
reimbursed.
End of Puregon® restitution action.
End of Metrodin HP® action
(13) September 1999 Meta-analysis Daya et al.[11]
(14) February 2000 Meta-analysis Agrawal et al.[6]
(15) May 2000 Metrodin HP® removed from Z-index.
In May 1995, Serono sent a letter to all Dutch gynaecologists explaining the
decreased production of Pergonal® (capacity problems and a shortage of urine due to
the production of Metrodin HP®) [21]. One year later, in May 1996, the Newsletter of
Freya, the patient federation for fertility problems, reported that the production of
Pergonal® for the Netherlands had been totally abandoned [22]. Organon
experienced difficulties as well, with the production of its hMG product Humegon®
[23,24]. The shortage of hMG products may have forced doctors and their patients to
use uFSH-HP; a worry that was indeed expressed by Freya [22]. Freya was all the
more concerned, since uFSH-HP products required a co-payment. Like uFSH, uFSH-
HP had been included in the same cluster as hMG with a maximum reimbursement
level of €10 per 75 IU. This meant that for Metrodin HP® one had to pay a co-
payment of €8 per 75 IU ampoule, which gave an average co-payment of €160-240
per cycle (150-225 IU for 10 days) (see Table 4).
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Figure 1a Diffusion of gonadotropin preparations in the Netherlands
The numbers refer to the events in Table 3
Figure 1b Substitution of urinary products by recombinant products
The numbers refer to the events in Table 3
Chapter 9
140
In some selected pharmacies, however, patients were able to purchase the product at
a reduced cost, since Serono, the producer of Metrodin HP®, made direct deliveries
to these pharmacies, thus circumventing the wholesaler’s margin. IVF centers were
informed to refer their patients specifically to the selected pharmacies. This
construction soon had to be abandoned, since it caused a lot of criticism, especially
from the Royal Dutch Association for the Advancement of Pharmacy  [25-28].
1997-1998
The rFSH products Gonal-F® and Puregon® were introduced in September 1996 and
January 1997 respectively, and in the subsequent 2 years they conquered 11% of the
total FSH market. The volume of uFSH-HP continued to increase, and hMG further
decreased so that both had a ca. 45% market share in 1998 (see Figure 1A).
The 11% market share of rFSH within 2 years appears relatively modest. There may
be two reasons for that. First, the clinical benefits of rFSH were debated. The
discussions centered around the clinical trials being industry sponsored or
associated, the potency of rFSH preparations (should 50 IU rFSH be regarded as
equipotent to 75 IU urinary FSH?), and the quality of the harvested oocytes [29-33].
In any event, it appears that at first the evidence that had to support the superiority
of rFSH was convincing neither to the Dutch Health Insurance Fund Council or to
the Minister of Health, as they decided to categorise rFSH in the same reimburse-
ment cluster as the urinary preparations, setting its reimbursement level at €10 per
75 IU. This is the second reason to explain the relatively slow uptake of rFSH: the co-
payment for rFSH products could amount to €700 per cycle. Organon, the producer
of Puregon®, started a campaign in which patients could submit the receipt of their
co-payment and get a refund of about 75%. At the same time, Serono started a
similar campaign, not for its rFSH product Gonal-F®, but for Metrodin-HP®:
temporarily this could be obtained from Serono’s distributor by all Dutch
pharmacists at a price of €10 per 75 IU (official price was €16) [34].
Another important event was the introduction of a third hMG preparation,
Menogon®, by a new player in the field, Ferring. While Organon and Serono brought
down or even abandoned the production of hMG preparations, either voluntarily or
forced by circumstances, the introduction of Menogon® made hMG available again.
For sure, this has played a significant role in the persistence of hMG as one of the
available products in this class.
1999-2000
In March 1998, the Study Group Recombinant Gonadotropins, in which were
represented among others the patient federation Freya and the Dutch Association of
Gynaecologists, sent a report to the Health Insurance Fund Council entitled
‘Therapeutic Value of Recombinant Gonadotropins’.
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Table 4 Product availability
1990-1994 1995-1996
product brand supply
75 IU
price
(€) product brand supply
75 IU
price
(€)
HMG Humegon® OK 10 hMG Humegon® shortage 10
Pergonal® OK 10 Pergonal® shortage 10
UFSH Metrodin® OK 15 uFSH Metrodin® phased
out
16
uFSH-
HP
Metrodin
HP®
OK 18
Follegon® OK 16
1997-1998 1999-2000
product brand supply
75 IU
price
(€) product brand supply
75 IU
price
(€)
hMG Humegon® shortage 10 hMG Humegon® shortage 10
Menogon® OK 10 Menogon® OK 10
uFSH-
HP
Metrodin
HP®
OK 16 uFSH-
HP
Metrodin
HP®
phased
out
16
Follegon® OK 22 Follegon® OK 22/10
rFSH Gonal-F® OK 30 rFSH Gonal-F® OK 34
Puregon® OK 34 Puregon® OK 34
The Study Group concluded that the recombinant gonadotropins are safer, and that
they carry therapeutic and economic benefits, compared to the urinary
gonadotropins [35]. The goal was to convince the Health Insurance Fund Council
(HIFC) and the Minister of Health to create a separate reimbursement cluster for the
rFSH preparations. In an advice to the Minister, the HIFC adopted the increased
efficacy of rFSH, but not the economic benefits nor the increased safety profile [36].
Based on this advice, the Minister decided to introduce a separate cluster for rFSH
with a reimbursement level of €34 per 75 IU. As a result, from 1 February 1999
onwards, rFSH was fully reimbursed. Both the Puregon® and the Metrodin HP®
campaigns of refunding patient's co-payments were stopped immediately by
Organon and Serono, respectively.
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As a consequence of this development, the volume of rFSH increased explosively to a
64% market share in 1999 (see Figure 1A). The growth levelled off in 2000 (80%
volume for rFSH). The large increase of rFSH was mainly at the expense of uFSH-
HP, which dropped to 9% volume share in 1999, and 0% in 2000. The market share
of hMG continued to decrease to 19%, with Menogon® providing more than 70% of
the total hMG market in 2000.
In 1999, the market share of uFSH-HP started to decrease for the first time since
1995. In 2000, Metrodin-HP® even disappeared from the market. An important
explanation for this is of course that Metrodin-HP® was the only product for which a
co-payment was still required.
It seems that in 2000 the growth of rFSH levelled off, and that the decrease of
urinary preparations slowed down (see Figure 1B). While in 1995-1999 the idea ruled
that uFSH was probably superior to hMG for use in ovary stimulation for IVF, in
2000 this was questioned again, mainly through the meta-analysis by Agrawal et
al.[6] Agrawal argued that some exposure to LH may be beneficial, and indeed her
meta-analysis of 11 trials using the long GnRH agonist protocol showed that hMG
and uFSH yielded similar results. On the other hand, Daya’s analysis [11] pointed in
the direction of rFSH being superior to urinary FSH.
Current developments
For each IVF cycle, women need a once daily injection during an average 10 days and
in the Netherlands almost all the women administer these themselves. In the period
1995-1999, the products described were marketed as a lyophilised powder (generally
50, 75, 100 or 150 IU) with a separate container of 1 ml solvent. Thus, before
injecting themselves, the women first had to dissolve the lyophilised FSH powder in
the solvent. Since June 2000, Puregon® has been available as a ready-made solution
(Puregon® Solution). This makes its administration easier and, moreover, the
volume has been decreased from 1 ml to 0.5 ml. Generally, a smaller volume is
associated with less pain upon injection. In addition, Organon has introduced a pen
for self-injection, similar to the ones used by diabetics to administer insulin. The
Puregon® Pen is to be filled with cartridges of 300 or 600 IU (for multiple injections)
and has a dosing mechanism, which can be adjusted in steps of 25 IU. For 50 IU, the
volume of injection is only 0.06 ml. The pen can be re-used and costs €23, although
many gynaecologists received copies for free distribution among their patients. In
April 2000, Organon sent a letter to all Dutch gynaecologists stating that the
availability of Humegon® would be terminated on 1 July 2000 [37]. Serono
introduced Gonal-F® 600 IU/ml Multidose to the Dutch market in June 2001. This
lyophilised powder of 1200 IU (retrieval 1050 IU) has to be dissolved once in the
accompanying solvent and can subsequently be used for several days. The injection
volume is small. However, the increased convenience for patients of these newly
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introduced rFSH products may come at a cost, since the increased amount of rFSH
per package (minimum 300 IU for Puregon® Pen and 1050 IU for Gonal-F®
Multidose) might lead to more waste.
In July 2000 Ferring introduced a new product: Menopur®. This consists of highly
purified (purity >97.5%) urinary FSH 75 IU and LH 75 IU (hMG-HP). It is marketed
as a lyophilised powder with a separate container of 1 ml solvent. The price is €23 per
75 IU, which means that a co-payment of €13 is required per ampoule, since the
product is clustered with the other, less pure, hMG products. However, Ferring has
started a campaign through which patients can receive a complete refund of their co-
payments. In 2000, the market share of Menopur® was 1%.
DISCUSSION
Decision-making about (biotechnology) drugs takes place at different levels [38]. On
the macro level, politicians, regulators and health insurers have to decide about the
licensing and reimbursement of pharmaceuticals. On the intermediate level,
decisions are made by specialist organisations, e.g. in developing good practice
guidelines, and formulary committees. Ultimately, on the micro level, physicians and
patients make choices about individual treatments. Together, all these decisions
determine the fate of a biotechnology drug, and its diffusion into society and medical
practice. When looking at the diffusion of rFSH, the most crucial decision-making
has taken place on the macro level, namely the decisions about its reimbursement.
The uptake of rFSH was held back by the fact that a substantial co-payment was
required and as soon as this matter was resolved, the switch towards rFSH assumed
high proportions. Apparently, gynaecologists and patients (on the meso and micro
level) were already in favour of rFSH, but not enough to accept the accompanying co-
payment. That is why they brought together the Study Group Recombinant
Gonadotropins, which successfully requested the Minister of Health to reconsider a
separate reimbursement cluster for rFSH.
In addition, the pharmaceutical companies constitute an important influence in the
diffusion process. Regularly, the topic of the influence of the pharmaceutical industry
on the medical community is discussed in the medical scientific journals [39-41]. In
the case of rFSH, the influence of the FSH producing companies is easy to point out.
The fact that the production of hMG and uFSH in the period 1995-1996 remained far
behind the needs at that time, benefited the adoption of uFSH-HP. At a later stage,
this influence was somewhat constrained by the entry of a third player to the market
(Ferring), which marketed hMG as its only gonadotropin product. During the period
1997-1998, both Serono and Organon put together actions to reduce co-payments for
patients. By choosing the products for which these actions were installed, they could
influence the adoption patterns. Organon chose to focus on rFSH, while Serono put
its bet on uFSH-HP.
Chapter 9
144
The first biotech substitutes which were introduced in the 1980s, recombinant
insulin and recombinant growth hormone, have never really needed to show
superiority compared to the previously used products they were replacing. When
recombinant human Growth Hormone (GH) was granted a marketing authorisation
in 1985, the previously used pituitary derived products had just been withdrawn
from the market due to contamination with the agent causing Creutzfeldt-Jakob
disease. As such, recombinant GH automatically gained a 100% market share.
Regarding insulin, the debate was not whether recombinant insulin was better than
animal insulin, but whether it was not worse. Namely, recombinant insulin was
suspected to raise the risk of hypoglycaemia as compared to animal insulin [42-44].
In spite of this discussion, during the 1980s virtually all diabetic patients switched to
recombinant insulin and since the early 1990s animal insulin has not even been
available anymore in the Netherlands. Again, similar to the rFSH case, the
pharmaceutical companies played a major part in this, since they simply withdrew
their animal insulin from the market [45]. Reimbursement was less of an issue at
that time, since the reference pricing system was not yet in place and recombinant
insulin was only a little bit more expensive than animal insulin (<10%).
At the time of the introduction of rFSH, however, the reference pricing system was in
place and evidence of clinical superiority was very important. When comparing rFSH
to uFSH/uFSH-HP, an absolute increase in pregnancy rates of 3.7% (95% CI 0.5-
6.9%) has been demonstrated in a Daya’s meta-analysis [11]. The discussion still
centers around the question whether this difference is clinically relevant. A 3.7%
absolute difference, means that the number of women needed to treat with rFSH
instead of uFSH/uFSH-HP in order to gain one additional pregnancy is 27 (95% CI
14-200). The fact that two types of rFSH (the alpha and beta variant) are compared
to 2 types of urinary FSH (uFSH and uFSH-HP) further complicates the discussion.
Another potential comparison, rFSH versus hMG, initially was not given much
attention. Apparently, in the early period after introduction of rFSH, it was
commonly assumed that if rFSH could be demonstrated to be superior to
uFSH/uFSH-HP, it was also superior to hMG. Given the results of Daya’s meta-
analysis [5] this seemed logical indeed. However, since: (1) a subsequent meta-
analysis [6] pointed in the opposite direction, (2) uFSH is hardly available anymore,
and (3) a hMG-HP preparation has been introduced to the market (Menopur®), the
question about the comparison between rFSH and hMG (and hMG-HP) has started
to become relevant. Overall, the background of several studies using different
comparisons and endpoints gives occasion to the fact that the discussion and
assessment of the different gonadotropin preparations remains twisty.
That the superiority question is not an easy one to answer is illustrated also by the
changeable decisions of the Dutch government. Initially, the Dutch Minister of
Health was not convinced of rFSH’s superiority and included it in the cluster of the
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urinary gonadotropins. A few years later, however, its opinion was altered and a
separate reimbursement cluster for rFSH was created. In the meantime a report by
the Dutch Health Council had been written, in which it was stated that
cryopreservation had become an accepted part of IVF cycles (even though the effects
on the resulting ‘cryo-children’ was unknown and further research on that topic was
required). This made it possible for the Minister to accept the efficacy endpoint of
cumulative pregnancies, including pregnancies from cryo-cycles. The meta-analyses
by Daya [11] and Agrawal [6] were published after the Minister’s decision in 1998,
and as such the debate on the clinical benefit of rFSH is still ongoing [29-33]. It can
be anticipated that further clinical trials and meta-analyses comparing rFSH and
hMG (or hMG-HP) will be published in the future. Moreover, the debate about the
cost-effectiveness of rFSH will continue. The incremental cost-effectiveness ratio of
rFSH compared with uFSH-HP has been estimated at about 12,000 US dollars per
additional ongoing pregnancy, assuming an absolute increase in pregnancy rate of
6.4% (including thawed embryos) [46]. When, a 0.5% difference was assumed the
estimate was about 70,000 US dollars [46]. In spite of the ongoing debate, the total
FSH market has grown from €5.0 million in 1995 to €26.8 million in 2000 (>400%
increase), while the total volume increased by <100% in that same period. This can of
course be explained by the fact that rFSH is >3 times more expensive per unit than
urinary preparations. In 1999, the ovulatory inductive medicines caused the fourth
biggest cost increase for pharmaceuticals after gastric acid inhibitors, cholesterol
lowering agents and antidepressants [4].
In addition to the data provided to us, this study is based only on published
literature, written reports and correspondence filed in the archive of the patient
federation Freya. We did not acquire inside information from the parties involved,
such as government officials, doctors and the pharmaceutical companies. This of
course could constitute a valuable addition, to further deepen the insight in the
processes underlying the diffusion patterns that we observed.
In general, the development of recombinant substitutes for already existing
compounds was based on several factors, such as potential scarcity of the ‘classical’
product (future shortages had been forecasted for animal insulin and for plasma
derived Factor VIII [47-49]) and fascination with genetic engineering, but also on the
assumption that distinct benefits would result from the use of products which were
as pure as possible. With respect to pharmaceutical quality, the increased purity and
batch-to-batch consistency of the recombinant proteins can be considered a
breakthrough. To the pharmaceutical companies it means a more efficient and well-
controlled production process. It frees the companies of the complicated logistics of
collecting of large amounts of pancreas, pituitary tissue, urine or blood plasma, the
supply of which may be uncertain, since it depends on the willingness and co-
operation of donors. Moreover, the use of urine as a source for medicines raises
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concerns about potential contamination with pathogenic micro-organisms. Plasma
derived Factor VIII, for example, has infected many haemophilia patients with HIV
and hepatitis C. Especially in the current era of ‘prion scare’, this may be an
important argument in favour of biotech substitutes. On the other hand, urinary
derived gonadotropins have been available since the beginning of the 1960s, and so
far prion or other infectivity has never been ascribed to them. Notwithstanding the
pharmaceutical advantages, significant medical benefits in clinical practice have
never been convincingly demonstrated for biotech substitutes, such as recombinant
insulin and recombinant Factor VIII, and for rFSH the debate is still ongoing
[45,50]. As such, the adagio ‘the purer, the better’ may be of limited value from the
clinical perspective.
Appraising innovations only on their immediate apparent clinical benefits is not a
very profound method of technology assessment. Recombinant insulin, as such, did
not have relevant clinical benefits over animal insulin [45]. However, it has been an
important incentive to continue the development of other valuable biotechnology
drugs and vaccines, such as erythropoetin and hepatitis B vaccine. As a rule
innovations take place gradually. If the first biotechnology drugs would not have
been given a fair chance, we might not have had the knowledge, the experience and
the new biotech drugs in development that we have now. Similarly, if recombinant
human insulin would not have been given a chance in the 1980s, the short acting
insulin analogues, like insulin lispro and insulin aspart, would today probably not be
available. The gonadotropin market is also still innovating, with the introduction of
ready-made solutions and pens for injection, although these are not necessarily
biotech related. Still, these products may represent a considerable step forward to the
patients who are using them. In general, the risk of increasing pharmaceutical costs
without clear clinical benefits has so be set against the risk of strangling innovations
[2]. This, of course is not an easy judgement to make, especially at the beginning of
the life-cycle of a new pharmaceutical. Usually, the real advantages and dis-
advantages of a new medicine become apparent only after it has been used for some
time. Therefore, a continuous process of technology assessment is warranted.
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BACKGROUND
Modern biotechnology drugs, such as recombinant human insulin and recombinant
human growth hormone, were first developed in the early 1980s. The rapid clinical
success of the first recombinant proteins drove large investments and placed high
expectations on the young biotechnology industry [1]. Later enthusiasm subsided
somewhat, as failures occurred and the number of new biotech introductions did not
live up to the high expectations [2,3]. Still, analysts predict that in the long term,
about 20-25% of the world drug market will be supplied with products based on
genetic engineering methods [4].
Attitudes towards technology vary from great aversion and fear, to technology being
seen as a blessing and the most important, if not the only, tool of value in solving
problems. This applies to biotechnology as well. Advances in medical research and
technology are often the last straw for people suffering from serious disease.
However, in the public opinion genetic engineering is also associated with the danger
of its usage to eliminate displeasing races and create ‘super humans’ [5,6]. High tech
developments strike the imagination, but at the same time there is a plea for a critical
assessment. The continuous increase of the health care costs in the Western
countries further adds to the need of careful evaluation of health care technologies
[7-9]. However, mixed feelings about this topic exist [10]. On the one hand the need
of cost containment is generally acknowledged, on the other hand patients generally
expect every effort to be made to improve their health.
In the light of these ambivalent observations, the general aim of this thesis was to
explore the broad field of the assessment and the diffusion of biotechnology drugs.
Special attention was given to the issue of economic evaluations in health care and to
the substitution of already existing compound by biotechnology alternatives.
MAIN FINDINGS
Medical Technology Assessment
In Chapter 2, we studied the process of assessment and diffusion of biotechnology
drugs by studying three cases, i.e. nebacumab, filgrastim and recombinant human
growth hormone. The cases were evaluated in a standardised format, concerning
safety, efficacy, cost-effectiveness and ethical, legal and social factors.
Many factors that determined the fate of these biotechnology drugs seemed to be
similar to those of ‘classical’ drugs. Uncertainties remained about the effectiveness of
the drugs in general practice and about their efficacy in special subgroups or
circumstances. Another important area of discussion was the definition and
measurement of clinically relevant outcome measures. In the cases studied,
intermediate endpoints were often used. The relatively small number of patients was
an important limiting factor for clinical programs evaluating efficacy, as only small
trials were feasible. We identified the broadening of the range of indications as an
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important strategy in certain classes of drugs, which could strongly influence the
diffusion of these compounds.
The high costs of many biotechnology drugs attracted extra attention and made the
existing issues more pronounced. They were an important driver of the complex
adoption processes.
Economic evaluation and abciximab
In Chapter 3, the attitude of decision-makers towards economic evaluations was
studied. Interviews and surveys were conducted with politicians, regulators, hospital
pharmacists and physicians in the Netherlands. Generally, the decision-makers had a
positive attitude towards economic evaluations. However, most decision-makers did
not want to adopt a strict attitude and they stated that decisions should not be based
on economic reasoning alone. The actual use of economic evaluation, and knowledge
about it, was still limited. Hospital pharmacists and regulators were more fact
oriented than physicians and politicians, who also based their judgements on
other societal values. The decision-makers preferred to make their own broad
comparisons of advantages and disadvantages, and did not base their decisions on a
single summary measure only. Our findings were similar to the findings in other
European countries.
In Chapter 4, we studied the cost-efficacy of the combined usage of stenting and
abciximab in patients undergoing percutaneous transluminal coronary angioplasty
(PTCA). The 6 months efficacy data from a large randomised controlled trial (the
EPISTENT trial [11]) were combined with Dutch estimates of unit costs. The cost-
efficacy ratio that resulted strongly depended on the comparator treatment
considered (either stenting or abciximab usage alone) and the composite endpoint
chosen (either myocardial infarction-free (MI-free) survival or major adverse cardiac
event-free (MACE-free) survival). Compared to abciximab usage alone, the cost-
efficacy ratio was €39,000 (95% upper limit (u.l.) €1,400,000) per additional MI-
free survivor, and €12,000 (95% u.l €31,000) per additional MACE-free survivor.
Compared to stenting alone, the cost-efficacy ratio was €13,000 (95% u.l. €27,000)
per additional MI-free survivor, and €14,000 (95% u.l. €50,000) per additional
MACE-free survivor. In the subgroup of diabetic patients more favourable cost-
efficacy were found, with uncertainty regions indicating potential costs savings.
In Chapter 5, we used effectiveness data from daily clinical practice to study the costs
and effects of stenting plus abciximab as compared to abciximab administration
alone. The same estimates of unit costs were applied as in the previous study. It
was confirmed that stented patients experienced less major adverse cardiac events
than non-stented patients did (6.9% vs. 16.9%, OR= 0.37, p=0.04). Adjustment for
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baseline characteristics yielded similar results, although significance subsided. The
relative risk reduction of 44% that was found closely resembled the 42% that was
found in the EPISTENT trial. The total costs were similar for stented and non-
stented patients (€7,844 vs. € 7,904, p=0.93).
Chapter 6 described our study of the patterns of abciximab prescribing in Dutch
PTCA centres in 1998. All thirteen centres co-operated in the study. The level of
abciximab prescribing varied from 2% to 36% of all PTCAs. The criteria for patient
selection significantly differed between centres. Together, the size of the budget,
participation in clinical trials (investigatorship), size, and type of the institution were
highly associated with the level of abciximab prescribing (R2=0.93, p<0.001). The
more patients doctors had included in clinical trials in the past, the higher was the
likelihood that they prescribed abciximab.
Diffusion of biotech substitutes
Chapter 7 and 8 reported about the introduction of recombinant Factor VIII (rFVIII)
as a substitute for plasma derived Factor VIII (pdFVIII). It was found that its
diffusion was regulated to a great extent by the Dutch Hemophilia Treaters Society,
as they decided upon a gradual introduction of rFVIII. The main reason for this was
that switching all Dutch patients to rFVIII would mean the end of the production of
Dutch pdFVIII. This was considered not to be a desirable situation, as history had
taught that in case of problems with one specific product, it was an advantage to have
several producers at one’s disposal. In addition, the hemophilia physicians agreed to
prescribe rFVIII to all previously untreated patients (PUPs). Both agreements were
largely adhered to, as was demonstrated by the results of our postal surveys among
both patients and physicians.
Both the patients and the physicians agreed that the physician and not the patient
was the most influential in choosing between pdFVIII and rFVIII. Of the responding
physicians, only one doctor would choose to use pdFVIII if he would suffer from
hemophilia A himself, and 74% would choose to use rFVIII. Overall these physicians
prescribed rFVIII to 56% of their patients, however the variation between centers
was wide. The physicians indicated that age was the only factor that influenced their
decision to prescribe either pdFVIII or rFVIII to a patient. In our study among
patients, we found that infection with HIV or hepatitis C, and having family members
who use pdFVIII, were negatively associated with switching from pdFVIII to rFVIII.
Innovativeness, empowerment, high social economic status, and having family
members who use rFVIII were positively associated with switching. This meant that,
although the overall pattern of substitution was largely determined by the Dutch
Hemophilia Treatment Society, patient preferences did have a modest influence in
the diffusion of rFVIII as well.
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In Chapter 9, we studied the diffusion of different gonadotropins preparations,
including the recombinant Follicle Stimulating Hormone (rFSH) preparations that
were introduced since 1996. The diffusion of rFSH was strongly influenced by
reimbursement decisions of the Dutch government. In the reference pricing system
rFSH was first categorised in the same reimbursement cluster with the human
menopausal gonadotropins (hMG) and purified urinary FSH. This meant that a co-
payment of up to € 700 per IVF cycle was required for the use of rFSH, and that its
market share got stuck at 11% only. A report written by representatives of the Patient
Federation for Decreased Fertility and the Dutch Association of Gynaecologists
changed the mind of the Minister of Health and she agreed to fully reimburse rFSH
from 1 February 1999 onwards. Subsequently, the sales of rFSH increased
exponentially to an 80% market share in 2000. As rFSH was three times as
expensive as the former gonadotropin preparations, total FSH expenditures grew
from €5.0 million in 1995, to €26.8 million in 2000. In addition to the government,
the pharmaceutical companies themselves also influenced the diffusion of the
different gonadotropin preparations. They refunded co-payments for some products
and not for others. Moreover, product shortages of one product benefited the
adoption of another. The debate of the relative therapeutic value of rFSH over other
gonadotropins has not been settled yet.
INNOVATION IN MEDICAL TECHNOLOGY
Efficacy and safety are the basic starting points in evaluating the overall utility of new
medicines. Neither the need for a new drug, nor its appropriate use in medical care
can be established without reliable and valid information on efficacy and safety.
However, studies on the development and diffusion of innovations have shown that
safety and efficacy are not the only factors that determine the fate of a new
compound. Other characteristics of an innovation, such as the degree to which the
results of the innovation are visible (observability) or the degree to which the
innovation is perceived as consistent with the existing ideas and past experiences
(compatibility), influence its rate of adoption as well [12]. In addition to
characteristics of the innovation, there are other factors that affect its adoption
process as well. Rogers mentions, for example, the type of innovation decision
(optional, collective or authority), the communication channels, the nature of the
social system and the extent of the promotion efforts [12]. The evolutionary
perspective on innovation and economics is correlated to the concept of adaptation
to local environments. It assumes that the parties involved can never be ‘perfectly
informed’ and that they are bound to rules, norms and institutions. In this
perspective, decision making is, at best, locally good rather than globally optimal
[13].
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Similarly, in the concept of ‘the social construction of technology’ an innovation
becomes a success not necessarily because of the intrinsic nature of the technology
but as a result of social interplay and power politics [14]. Often there is an initial
period of competing technical alternatives and uncertainty, followed by a period in
which one alternative becomes dominant both in the market and in the way scientists
think about the technology.
In Chapter 2 we analysed the cases of three biotechnology drugs in a standardised
way covering: 1) safety, 2) efficacy/effectiveness, 3) economic evaluation, and 4)
ethical, legal and social factors [15]. These are the principle facts with which medical
technology assessment (MTA) is concerned (Figure 1). However, in the light of the
aforementioned theories on the process of innovation, it was not surprising that
decision-makers mentioned not only these factors, but also politics as an important
factor in the assessment of health care technologies. As depicted in Figure 2, there
are different stakeholders that together determine the fate of a biotechnology drug.
Although they will all consider the same facts in the MTA matrix, they inevitably are
influenced by their own political motives, believes and values. All stakeholders are
influenced by values as they act from their own biasing embodiment. Even
researchers, who like to portray themselves as mere observators of reality (‘modest
witnesses’), inevitably are influenced by their own believes and interests.
Randomised controlled clinical trials are widely considered to be the pathway to
objectivity in medical research. However, McCormack and Greenhalgh [16] showed
that even the report of their results might be subject to biases. Prior expectations,
enthusiasm for a positive results, the political need for regular high impact medical
breakthroughs, and the tendency of clinicians to overestimate the benefits and
underestimate the harms of drug treatment, were mentioned as important biases
influencing researchers, authors and editors. The well-known publication bias, i.e.
the fact that negative results tend not to be published, of course strongly relates to
this issue.
The next paragraphs discuss the different stakeholders and the critical issues that we
identified in our studies.
Stakeholders
Patients, physicians, pharmacists, researchers, pharmaceutical companies, health
care insurers, government, the media, and the general public are all stakeholders in
the assessment and diffusion of biotechnology drugs (Figure 2).
On the macro level, government authorities influence the diffusion of biotechnology
drugs as they set the rules for the health care systems in different countries. On a
lower level, they are influential through their decisions about the approval and
reimbursement of drugs. The American Food and Drug Administration (FDA), for
example, sped up the approval of rhGH because of the Creutzfeldt-Jakob crisis [13].
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Figure 1 MTA matrix: principal facts in Medical Technology Asssessment [15]
Safety Efficacy/
Effectiveness
Cost/
Cost-effectiveness
Ethical /legal/
social factors
Due to contamination with the prion causing Creutzfeldt-Jakob disease, pituitary
human growth hormone (pit-hGH) had already been withdrawn from the market
when the first rhGH product filed for approval with the FDA. Most children took pit-
hGH for dwarfism and could forego treatment for a maximum of 6 months without
jeopardising their final height. Remarkably, the FDA approved rhGH almost exactly
six months after the withdrawal of pit-hGH. The approval took 23 months, which
was about half of the normal approval time at that time [13].
The case of the recombinant follitropins (rFSH) clearly demonstrated both the
impact of the pharmaceutical industry and of reimbursement decisions. With the
current trend towards ‘regulated competition’, reimbursement decisions will be
made more and more by health care insurers instead of by governments. As such,
health care insurers will become important stakeholders as well. The influence of the
pharmaceutical companies has also been described for the case of recombinant
human insulin. Recombinant human insulin was introduced in 1982, and by the end
of the 1980s virtually all diabetic patients had switched form animal to recombinant
insulin [17,18]. Since the early 1990s animal derived insulin is not commercially
available anymore in The Netherlands. The pharmaceutical companies played a
major part in bringing about this switch. While the discussion on the equivalence of
recombinant human insulin and porcine insulin was still ongoing, the leading
European manufacturer already announced the withdrawal of the latter human
insulin. This was effected within a few weeks in some countries and over six months
in the United Kingdom [17]. As such, pharmaceutical companies can influence the
diffusion of a biotechnology drug not only through direct promotion efforts, but also
through their manufacturing choices and pricing strategies. This influence is
greatest, of course, when one and the same company markets two competing drugs.
As such, biotech substitutions are a particular example.
As health care professionals, most notably physicians, can be considered as ‘the
customers’ for all prescription drugs (on behalf of their patients), their influence on
the diffusion of biotechnology drugs hardly needs any explanation.
Chapter 10
158
Facts
Insurers
Professionals
A
u
th
o
ri
ti
es Pro
d
u
c
ers
Pr
es
s Public
Pa
tie
nt
sScientists
Values
Figure 2 The different stakeholders look at the facts through their own values
Notwithstanding the current development towards patient empowerment, the Dutch
Hemophilia Treatment Society successfully implemented a policy to restrict the use
of recombinant Factor VIII (rFVIII). Interferon-alfa-2a for the adjuvant treatment of
melanoma presents another example. Shortly after the approval of this compound by
the registration authorities, the Dutch Melanoma Working Group, a multi-
disciplinary group of melanoma treating physicians, stated that in their opinion there
is no place for interferon-alfa in the treatment of melanoma [19]. The case of rFSH
showed the opposite: in this case gynaecologists and patients stood up together for
the reimbursement of rFSH. As such, physicians strongly influence the position of
other stakeholders. It is very unlikely that the patient federation alone could have
achieved the change in reimbursement of rFSH, if the professionals had not
supported them. The media and the public opinion constitute another example. The
variation in the use of taxoids in Dutch hospitals has received broad media coverage
in the Netherlands. This has resulted in a special reimbursement settlement for these
products. The large variation in the use of abciximab, however, has gone largely
unnoticed. One of the reasons for this, can be the opinion of the professionals. They
will only seek publicity when they are strongly convinced of the drug’s benefits, and
of the need for additional funding.
In conclusion, the influence of the different stakeholders illustrates that innovation
in drug therapy requires more than just a new ‘technique’ or compound. The
environment is just as important in the innovation process. For example, the
assembly-conveyer would have been unconceivable without the social, financial and
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economical innovations that took place during the Industrial Revolution [14].
Similarly, scientific advances in biotechnology and life sciences can not be
considered separately from other developments, such as the rise of information
technology and the reorganisation of health care systems. In this regard, Smits has
underlined the importance of ‘co-evolution’ of scientific, technological and societal
systems [20]. Innovation in biotechnology and genomics represents a case par
excellence where the need for ‘co-evolution’ is pertinent. Unmet medical needs,
orphan diseases and other public health interests require constructive strategies to
cope with the fact-value gap.
Critical issues
The studies in this thesis revealed several issues that are critical in the assessment
and diffusion of biotechnology drugs, and that are vulnerable to personal values.
They are discussed below.
Economic evaluation
From the interviews with the decision-makers in Chapter 3 it was concluded that the
attitudes towards cost-effectiveness as a criterion varied, and that the actual use of
economic evaluations in decision-making processes was still limited. This was
confirmed by the studies on Factor VIII, the recombinant follitropins and abciximab.
In all three cases, cost-effectiveness did not seem to be of strong influence on the
diffusion patterns. In case of recombinant Factor VIII this might be explained by the
fact that it is ‘only’ about 10% more expensive than plasma derived Factor VIII. The
recombinant follitropins, however, are three times as expensive as the urinary
gonadotropins. Statements about the cost-effectiveness of rFSH as compared to
uFSH are surrounded by large uncertainties, as the debate about the clinical benefits
is still ongoing. Cost-effectiveness played no part at all in the reimbursement
decision, which was a strong determinant of the diffusion of rFSH.
With regard to abciximab, it was also clear that cost-effectiveness was not an
important factor in the decision-making process. The use of abciximab causes
an initial increase in hospital costs, while subsequent savings may not become
apparent to the hospital management, since the total number of myocardial
infarctions or revascularisation will probably not decrease for various reasons such
as existing waiting lists for interventions. Other factors, such as budget and
investigatorship were identified as important predictors of the level of abciximab
usage within each hospital.
While there is still debate about the cost-effectiveness criterion, all stakeholders
agree that safety and efficacy/effectiveness are the basic facts on which the
assessment of pharmaceuticals is based.
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Risk assessment
This issue is best illustrated by comparing the substitution patterns of three biotech
substitutes: rhGH, rFVIII, and rFSH (see Figure 3).
The switch from pit-hGH to rhGH was the quickest switch possible. Because of the
history of Creutzfeldt-Jakob disease through the use of pit-hGH, rhGH immediately
captured a 100% market share. Plasma derived Factor VIII (pdFVIII) caused many
people to be infected with HIV or hepatitis C. Surprisingly this did not speed up the
diffusion of rFVIII. On the contrary, the diffusion of rFVIII has followed a very slow
and gradual course. The big difference was that one was not able to safeguard pit-
hGH from infectious prions, while in 1995 the viral safety of pdFVIII could to a large
extent be guaranteed. However, in some countries, all patients were switched from
pdFVIII to rFVIII in response to the emergence of Creutzfeldt-Jakob disease as a
potential sequela of the Bovine Spongiform Encephalopathy (BSE) epidemic,
although transmission through clotting factors has never been documented actually.
The issue of infectivity was only a minor theme in the diffusion of rFSH, as
transmission of infectious agents had never been documented for urinary
gonadotropins. Still, advocates of rFSH sometimes use the biological safety of
rFSH as an argument. Fact is, that rFSH did manage to capture a more than 80%
market share, while the relative therapeutic value of rFSH over other gonadotropins
is still debated.
Safety is a relative concept: no drug is ever completely safe. Safety represents a value
judgement of the acceptability of risk. The fact that many people are afraid to travel
by aeroplane, which statistically is the safest way to travel, illustrates that our
attitude towards risk is not purely fact based.
Broadening of indications
Broadening of indications was found in several cases described in this thesis:
filgrastim, growth hormone, abciximab (being used and investigated aside from
PTCA, in unstable angina) and the gonadotropins (first ovarian stimulation, then
also in-vitro fertilisation). It needs no explanation that this issue particularly attracts
the attention of decision-makers that have to pay for the products involved. Once a
product is included in the reimbursement system, in the Netherlands it is reimbursed
for all registered indications. Only in exceptional cases the reimbursement of a drug
is restricted to specific conditions (‘List 2’ of the ‘Regulation on Pharmaceutical
Care’). In general, the payers hardly have any means to control the use of a
pharmaceutical, once it has been approved for reimbursement.
Broadening of indications can be expected for compounds that influence complex
regulating systems within the body, such as the immune system. These compounds
are likely to be useful in a range of diseases.
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Figure 3 Substitution patterns of growth hormone, Factor VIII and follicle
stimulating hormone
Intr. = introduction, pit-hGH = pituitary human growth hormone, rhGH = recombinant
human growth hormone, pfFVIII = plasma derived Factor VIII, rFVIII = recombinant
Factor VIII, Urinary FSH = urinary Follicle Stimulating Hormone, rFSH = recombinant
Follicle Stimulating Hormone
The recently introduced infliximab (Remicade®), which is used for the treatment of
both rheumatoid arthritis and Chrohn’s disease, and the interferons, which are used
for various oncologic indications and in hepatitis treatment, represent good
examples. Many biotechnology drugs, indeed interfere with such complex,
comprehensive physiological systems, and are vulnerable to indication dynamics.
Generalisability and subgroups
The issue of the external validity or generalisability of clinical trial results has often
been discussed [21-23]. Recently Padkin et al. [24] called it one of the key
methodological challenges for achieving a more scientific basis for health care.
Closely related to this issue is the identification of subgroups of patients for whom
the drug might be (most) beneficial or cost-effective. Patient-characteristics, severity
of disease, comorbidity, and compliance are all determinants of the outcome of drug
exposure [25]. Often in a clinical trial population only a selection of the distribution
of determinants in the normal patient population is represented [25,26]. The
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variation in the determinants is kept to a minimum in a clinical trial, in order to be
able to reach sufficient statistical power. As a result, the effectiveness of a drug in
general practice might be different from the efficacy demonstrated in a randomised
controlled trial. One often proposed solution is the conduct of ‘everyday practice
trials’ including a broad range of patients. This, however, goes against the other
issue, namely the definition of subgroups in which the treatment is especially
beneficial. Even within the current ‘homogeneous clinical trials’ there is
heterogeneity. In the cases of filgrastim, growth hormone and abciximab we found
ample debates about this. The topic, of course, closely relates to the question of cost-
effectiveness and cost containment. Sometimes a fine-tuning of indications to start
treatment occurs within professional groups, e.g. the national consensus on the
treatment of hypercholesterolemia [27]. However, these guidelines are not binding to
the professionals. In cases of preventive care where the benefit gradually increases
over subgroups, the issue of broadening of indications is very pronounced.
As we saw in Chapter 6, budgetary constraints urged cardiologists to engage in the
question in which patients abciximab administration is most beneficial. Answers to
this question varied, as there were only limited scientific data available. Full
information on all imaginable subgroups, however, is unobtainable. Kübler [28]
figured out, for example, that it would take more than 450 trials to study all possible
treatment strategies in the postinfarction period.
Outcome measures
The definition of clinically relevant outcome measures was another methodological
issue identified. The paradigm is to use final endpoints, as history has proven that an
improvement of intermediate endpoints does not always result in the expected
improvement of the final endpoint [29]. Theoretically, survival adjusted for quality of
life would embody the ideal endpoint to be considered (apart from the problems
associated with measuring quality of life). As we saw in the cases of growth hormone,
filgrastim and abciximab, this information often is not available. As such,
interpreting the available evidence remains a matter of judgement and of cost-
effectiveness considerations. In case of abciximab for example, some might consider
the prevention of myocardial infarctions a clinically relevant goal in itself, others
might accept it as a predictor of decreased mortality, and yet others are only satisfied
with data on increased survival.
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FINAL CONSIDERATIONS
Although many factors that determine the fate of a biotechnology are similar to those
of ‘classical’ drugs, there is at least one phenomenon that is very specific to
biotechnology drugs, i.e. the phenomenon of biotechnology substitutions. However,
as most compounds that can be replaced have already been replaced by now, this will
not be a big issue in the future.
Future biotech drugs will probably often be new compounds that affect
comprehensive regulatory systems in the body. As such, broadening of the range of
indications is likely. Scientific assessment will rarely provide clear ‘yes/no’ answers.
Seldom will a new biotechnology drug be found to be either worthless or a panacea.
Instead the question is usually one far more difficult to answer: ‘Who should receive
the intervention and under what circumstances?’.
Of course, we need data on safety, efficacy and cost-effectiveness to decide about
this. However, more data does not necessarily lead to better decisions. The paradigm
of statistical significance if p<0.05, is an arbitrary one. As such, further research
on the medical benefits of an intervention is not necessarily cost-effective. Attention
should be paid as well to the mechanisms and incentives that underlie the
decision-making processes.
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In het algemeen varieert de houding ten aanzien van technologische innovatie in
onze samenleving van een omarming van technologie als de oplossing voor alle
problemen enerzijds, tot grote aversie en angst anderzijds. Deze ambivalente
houding bestaat ook ten aanzien van biotechnologie. Het succes van de eerste
biotechnologische geneesmiddelen wekte hoge verwachtingen en vormde een
stimulans voor de jonge biotech industrie. Het eerste biotechnologische
geneesmiddel, recombinant insuline (1982), heeft inmiddels de runder- en
varkensinsuline volledig vervangen. Ook het tweede biotech geneesmiddel betrof een
alternatief voor een reeds bestaand product: recombinant groeihormoon (1985) nam
vrijwel direct de plaats in van hypofysair groeihormoon.
Naast dergelijk substituties zijn er in de afgelopen 20 jaar ook diverse
biotechnologische geneesmiddelen geïntroduceerd met een geheel nieuw werkzaam
bestanddeel. Filgrastim (Neupogen®), bijvoorbeeld, stimuleert de productie en
afgifte van neutrofiele granulocyten door het beenmerg, en kan onder andere worden
toegepast ter preventie van febriele neutropenie bij chemotherapie en beenmerg-
transplantatie. Een ander voorbeeld is abciximab (ReoPro®), een
bloedplaatjesaggregatieremmer, waardoor de kans op complicaties tijdens en na een
dotterprocedure vermindert.
Uiteraard is een kritische evaluatie van nieuwe geneesmiddelen noodzakelijk. Deze
noodzaak wordt nog versterkt door de stijgende kosten voor de gezondheidszorg.
Echter, ook op dit gebied treft men een dualistische houding aan. Enerzijds zijn de
meeste partijen overtuigd van de noodzaak van kostenbeheersing, anderzijds
verwachten patiënten dat veel, zo niet alles in het werk wordt gesteld om hun
gezondheid te verbeteren. Aangezien biotechnologische geneesmiddelen vaak dure
geneesmiddelen zijn die worden toegepast bij ernstige, levensbedreigende ziektes,
kan dit tot spanningen leiden.
Het proces waarin een nieuw geneesmiddel zijn weg vindt in de medische praktijk
wordt ‘diffusie’ genoemd. In dit proefschrift is aandacht besteed aan de beoordeling
en de diffusie van biotechnologische geneesmiddelen. Hierbij is met name aandacht
geschonken aan economische evaluaties en aan het fenomeen dat sommige
biotechnologische geneesmiddelen als alternatief dienden voor vergelijkbare, reeds
bestaande middelen die werden gewonnen uit biologisch materiaal.
In hoofdstuk 2 van dit proefschrift werden de wetenschappelijke discussies rondom
drie biotechnologische geneesmiddelen bestudeerd met betrekking tot: 1) veiligheid,
2) werkzaamheid en effectiviteit, 3) doelmatigheid en 4) sociaal, ethische en
juridische factoren. De drie casussen waren nebacumab, filgrastim and recombinant
groeihormoon.
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Veel factoren die het lot van een biotechnologisch geneesmiddel bepaalden waren
hetzelfde als bij ‘gewone’ geneesmiddelen. Vaak bestond er onzekerheid over de
effectiviteit van het geneesmiddel in de dagelijkse praktijk en over de werkzaamheid
in bepaalde subgroepen. Een belangrijk punt van discussie was de definitie en de
bepaling van klinisch relevante uitkomstmaten. In de bestudeerde casussen werden
vaak intermediaire (‘surrogaat’) eindpunten gebruikt. Een belangrijke limiterende
factor voor klinische evaluatie  was het relatief kleine aantal patiënten. Hierdoor
waren slechts studies van een beperkte omvang mogelijk. Bij bepaalde groepen
geneesmiddelen werd indicatie-uitbreiding geïdentificeerd als een belangrijke
strategie, die de diffusie van de betreffende middelen sterk beïnvloedde. De hoge
prijzen van veel biotech geneesmiddelen trokken aandacht en maakten dat de
bestaande  discussiepunten als het ware werden uitvergroot. Kosten waren een
belangrijke aanjager van het complexe adoptie proces.
In hoofdstuk 3 zijn Nederlandse besluitvormers (artsen, ziekenhuisapothekers,
beleidsmakers en politici) geïnterviewd over dit onderwerp. In het algemeen stonden
zij positief tegenover het idee dat de kosten en de baten van geneesmiddelen met
elkaar in verband worden gebracht, teneinde het beschikbare geld in de
gezondheidszorg zo doelmatig mogelijk in te zetten. Echter, de kennis van de
besluitvormers over de methodologie van economische evaluatie studies was beperkt
en op het moment van de studie (1998/1999) wogen zij informatie over de kosten-
effectiviteit van een geneesmiddel nauwelijks mee in hun beslissingen.
Ziekenhuisapothekers en  beleidsmakers waren meer gericht op de ‘harde feiten’ dan
artsen en politici, die ook meer ‘zachte’ opinies en gevoelens in hun overwegingen
meenamen. De besluitvormers gaven aan dat zij hun eigen afweging van voor- en
nadelen wilden maken, en hun oordeel niet wilden baseren op een enkel getal waarin
alles wordt  samengevat. Zij gaven dan ook aan, met uitzondering van de
ziekenhuisapothekers, weinig te zien in het strikt hanteren van een vast afkappunt
voor kosten-effectiviteit.
In hoofdstuk 4 werd de kosten-effectiviteit berekend van de gecombineerde
toepassing van abciximab en stents bij patiënten die een dotterprocedure
ondergingen. De patiënten uitkomsten na 6 maanden van een grote gerandomiseerde
studie (de EPISTENT studie) werden gecombineerd met Nederlandse kostprijzen.
De daaruit voortvloeiende kosten-effectiviteit ratio was sterk afhankelijk van de
gekozen uitgangsbehandeling (ofwel alleen stents, ofwel alleen abciximab) en van de
gekozen uitkomstmaat (ofwel myocardinfarct-vrije [MI-vrije] overleving, ofwel
ernstige cardiale complicaties-vrije [‘major adverse cardiac event’-vrije = MACE-vrije
overleving]). Vergeleken met uitsluitend abciximab toediening, was de kosten-
effectiviteit ratio €39.000 (95% bovenlimiet [b.l.] €1.400.000) per additionele
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MI-vrije overlevende, en €12.000 (95% b.l €31.000) per additionele MACE-vrije
overlevende. Vergeleken met alleen stenten, was de kosten-effectiviteit ratio €13.000
(95% b.l. €27.000) per additionele MI-vrije overlevende, en €14.000 (95% b.l.
€50.000) per additionele MACE-vrije overlevende. In de subgroep van diabetes
patiënten werden gunstigere kosten-effectiviteit ratios gevonden, met betrouwbaar-
heids intervallen wijzend op mogelijke  kostenbesparingen.
In hoofdstuk 5 werden klinische data uit de dagelijkse praktijk gebruikt om de kosten
en effecten van gecombineerd abciximab en stent gebruik te vergelijken met alleen
abciximab toediening. Dezelfde kostprijzen werden gebruikt als beschreven in
hoofdstuk 4. Het werd bevestigd dat gestente patiënten minder ernstige cardiale
complicaties ervaren dan niet-gestente patiënten (6,9 % versus 16,9 %, OR= 0,37,
p=0,04). Na correctie voor uitgangskarakteristieken bleven de resultaten hetzelfde,
alleen verdween de statistische significantie. De gevonden relatieve risico reductie
was 44% en kwam sterk overeen met de 42% die werd gevonden in de EPISTENT
studie. De totale kosten waren gelijk voor gestente en niet-gestente patiënten
(€7.844 vs. €7.904, p=0,93).
Hoofdstuk 6 beschrijft het patroon van abciximab gebruik door Nederlandse
dottercentra in 1998. Alle 13 dottercentra deden mee aan deze studie. Het percentage
van de dotterprocedures waarbij abciximab werd toegepast varieerde per centrum
van 2% tot 36%. De criteria die werden gebruikt om te beslissen of een patiënt in
aanmerking kwam voor abciximab toediening verschilden sterk tussen de centra.
In multivariate regressie analyse waren vier factoren sterk geassocieerd met de mate
van gebruik van abciximab: het beschikbare budget, participatie in onderzoeken met
abciximab in het verleden, en grootte en karakter (academisch/niet-academisch) van
het ziekenhuis (R2=0,93, p<0,001). Hoe meer patiënten in het verleden waren
geïncludeerd in klinisch onderzoek met abciximab, hoe meer het middel in het
centrum werd gebruikt.
Hoofdstuk 7 en 8 handelen over de introductie van recombinant Factor VIII (rFVIII)
als een alternatief voor uit plasma gewonnen Factor VIII (pFVIII) voor de
behandeling van hemofilie A. We vonden dat het diffusiepatroon voor een groot deel
werd bepaald door de Nederlandse Vereniging van Hemofilie Behandelaren, die had
besloten tot een geleidelijk introductie van rFVIII. Het belangrijkste argumenten
voor dit besluit was dat een radicale switch van pFVIII naar rFVIII het einde zou
betekenen van de productie van pFVIII door Sanquin (‘de Nederlandse Bloedbank’).
Dit werd niet wenselijk geacht aangezien het verleden had geleerd dat het een
voordeel is om met verschillende producenten te werken voor het geval dat zich
problemen voordoen. De hemofiliebehandelaren kwamen tevens overeen dat
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voorheen onbehandelde patiënten bij voorkeur zouden worden behandeld met
rFVIII. Onze enquetes onder patiënten met hemofilie en hemofiliebehandelaren
wezen uit dat beide afspraken grotendeels nageleefd zijn.
Zowel artsen als patiënten gaven aan dat de arts en niet de patiënt de meeste invloed
heeft op de keuze voor een bepaald type FVIII product. Slechts 1 van de
participerende artsen zou kiezen voor pFVIII als hij zelf ernstige hemofilie zou
hebben. In totaal schreven de artsen pFVIII voor aan 56% van hun patiënten. De
variatie in dit percentage per arts was groot. De artsen gaven aan dat leeftijd de enige
factor was die een rol speelde bij de productkeuze voor een bepaalde patiënt.
In onze studie onder patiënten met hemofilie vonden we dat infectie met HIV,
infectie met hepatitis C, en het feit dat iemand familieleden had die pFVIII
gebruikten, negatief gecorreleerd waren met het overstappen van pFVIII naar rFVIII.
Dit betekent dat, ondanks dat het totale substitutiepatroon grotendeels werd bepaald
door de Nederlandse Vereniging van Hemofilie Behandelaren, patiëntenvoorkeuren
toch ook een bescheiden rol spelen in de diffusie van rFVIII.
In hoofdstuk 9 werd de diffusie van de verschillende gonadotrofinen preparaten
geëvalueerd, met inbegrip van de in 1996 geïntroduceerde recombinant Follikel
Stimulerend Hormoon (rFSH) preparaten. De diffusie van rFSH is sterk beïnvloed
door de overheidsbesluiten over het al dan niet opnemen van rFSH in het
verzekeringspakket. Aanvankelijk werd rFSH ingedeeld in het Geneesmiddel
Vergoedings Systeem in hetzelfde cluster als menopauzegonadotrofine (hMG) en
urofollitropine. Dit leidde tot bijbetaling tot €700 per IVF cyclus voor rFSH, en het
marktaandeel bleef dan ook steken op 11%. Een rapport geschreven door vertegen-
woordigers van de Patiëntenvereniging voor Vruchtbaarheidsproblematiek en de
Nederlandse Vereniging voor Obstetrie en Gynaecologie deed de overheid eind jaren
negentig van gedachte veranderen. Besloten werd dat rFSH vanaf 1 februari 1999
toch volledig zou worden vergoed. Direct begon de verkoop van rFSH exponentieel te
stijgen en had rFSH in 2000 een marktaandeel van 80%. Omdat rFSH drie keer zo
duur was als de ‘oude’ gonadotrofinen preparaten, stegen de totale kosten van het
gebruik van gonadotrofinen van €5,0 miljoen in 1995 naar €26,8 miljoen in 2000.
Naast de overheid hadden ook de fabrikanten zelf invloed op de diffusie van de
verschillende gonadotrofinen preparaten. Zij stelden terugbetalingsregelingen in
voor bepaalde producten, en niet voor andere. Bovendien profiteerde sommige
producten van de leveringsproblemen van andere producten. Ondertussen is het
debat over de relatieve therapeutische waarde van rFSH ten opzichte van de anderen
gonadotrofinen nog steeds gaande.
De casussen in dit proefschrift laten zien dat de ‘menselijke’ factor van groot belang
is bij de beoordeling en de diffusie van biotechnologische geneesmiddelen.
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Wetenschappelijke onderzoeken leveren geen dichotome antwoorden op. De manier
waarop de verschillende belanghebbenden wetenschappelijke gegevens (‘facts’)
interpreteren wordt beïnvloed door hun persoonlijk overtuiging, positie, belang en
achtergrond (‘values’).  Zo is er vaak discussie over de externe validiteit van klinische
studies en over de werkzaamheid van het geneesmiddel in specifieke subgroepen.
Een ander discussiepunt is de definitie van een klinisch relevante uitkomstmaat.
De resultaten van dit onderzoek leveren een verbreding op van de kennis van de
beoordeling en diffusie van biotechnologische geneesmiddelen. Bijna nooit zal een
nieuw geneesmiddel in alle opzichten waardeloos zijn of in alle opzichten een
aanwinst. De vraag die overblijft is veel complexer van aard, namelijk: “ Wie moeten
in aanmerking komen voor dit middel en onder welke condities?”. Om deze
besluitvorming te ondersteunen zijn niet alleen klinische data nodig, maar is tevens
inzicht vereist in de mechanismen die ten grondslag liggen aan de diffusie-processen.
De resultaten van dit onderzoek leveren daartoe een bijdrage.
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